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Abstract 
The sinoatrial node (SAN) is the natural pacemaker of the heart and initiates the rhythmic 
contractions of this organ. Its unique genetic profile is mediated by a network of transcriptional 
regulators. Among them is the homeodomain transcription factor SHOX2, which plays a major role 
in maintaining the phenotypic border between the SAN and the surrounding tissue. Mutations in 
this gene have been associated with early-onset and familial forms of Atrial Fibrillation (AF). AF 
is the most common cardiac rhythm disorder, affecting 1-2% of the general population. In the 
clinical context, it often co-exists with malfunctions of the sinus node (sinus node dysfunction, 
SND), however, it is unknown if both diseases interact, perpetuate, or initiate each other. 
In the first part of this project, a candidate gene study was combined with functional analyses to 
identify a causal relationship between novel SHOX2 gene variants and the development of AF and 
SND. Screening 98 SND patients and 450 individuals with AF led to the identification of four 
heterozygous variants in SHOX2 (p.P33R in the SND cohort and p.G77D, p.L129=, p.L130F, 
p.A293= in the AF cohort). We selected mutations based on their in silico predicted pathogenic 
potential and overexpressed them in embryonic zebrafish hearts. A dominant-negative effect 
leading to bradycardia and pericardial edema was detected for p.G77D, while no effect was revealed 
for the p.P33R and p.A293= variants. A significantly impaired transactivation activity for both 
missense variants p.P33R and p.G77D was demonstrated by in vitro reporter assays. Moreover, 
upon overexpression of the p.P33R mutant in zebrafish hearts, a reduced Bmp4 target gene 
expression was revealed. This study demonstrated for the first time a genetic link between SND 
and AF involving SHOX2. 
Patient-specific human induced pluripotent stem cells (iPSCs) harboring putative disease-causing 
variants offer unprecedented opportunities for the investigation of cardiovascular diseases. We 
generated and characterized iPSCs from patients with previously identified heterozygous SHOX2 
mutations (SHOX2 c.849C>A and SHOX2 c.*28T>C). To establish an isogenic control, we 
developed a novel strategy for the scarless correction of heterozygous mutations. Patient-derived 
iPSCs were gene-edited with the CRISPR/Cas system and subdivided into small cell pools (sib-
selection). We quantified wildtype and mutant alleles via digital PCR and next generation 
sequencing to detect shifts in the wildtype/mutant allele ratio that indicated the presence of gene-
corrected cells. Using this method, we managed to enrich our target cells 8-10-fold before 
generating a monoclonal cell population via single-cell cloning.  
The recharacterization of the new lines confirmed a preserved pluripotency and a normal karyotype. 
Future electrophysiological and molecular analysis will give further insights into the contribution 
of SHOX2 to onset and progression of AF. 
  
IV 
Zusammenfassung 
Der sinoatriale Knoten (SAN) ist der natürliche Schrittmacher des Herzens und leitet die 
rhythmischen Kontraktionen dieses Organs ein. Sein einzigartiges genetisches Profil wird durch ein 
Netzwerk von Transkriptionsregulatoren vermittelt. Zu ihnen gehört der Homöodomänen-
Transkriptionsfaktor SHOX2, der eine wichtige Rolle bei der Aufrechterhaltung der phänotypischen 
Grenze zwischen dem SAN und dem umgebenden Gewebe spielt. Mutationen in diesem Gen 
wurden mit früh einsetzenden und familiären Formen des Vorhofflimmerns (AF) in Verbindung 
gebracht. Vorhofflimmern ist die häufigste Herzrhythmusstörung und betrifft 1-2% der 
Allgemeinbevölkerung. Im klinischen Zusammenhang existiert sie häufig zusammen mit 
Fehlfunktionen des Sinusknotens (Sinusknotendysfunktion, SND), es ist jedoch unbekannt, ob 
beide Erkrankungen interagieren, sich gegenseitig aufrechterhalten oder auslösen. 
Im ersten Teil dieses Projekts wurde eine Kandidatengenstudie mit funktionellen Analysen 
kombiniert, um einen kausalen Zusammenhang zwischen neuartigen SHOX2-Genvarianten und der 
Entwicklung von AF und SND zu identifizieren. Bei der Überprüfung von 98 SND Patienten und 
450 Individuen mit VHF wurden vier heterozygote Varianten in SHOX2 detektiert (p.P33R in der 
SND-Kohorte und p.G77D, p. L129=, p.L130F, p.A293= in der Vorhofflimmerkohorte). Wir 
wählten Mutationen basierend auf in silico Vorhersagen über ihr pathogenes Potential aus und 
überexprimierten sie in embryonalen Zebrafischherzen. Ein dominant-negativer Effekt, der zur 
Bradykardie und perikardialen Ödemen führte, wurde für p.G77D gefunden, während p.P33R und 
p.A293= keinen Effekt zeigten. Eine signifikant beeinträchtigte Transaktivierungsaktivität für die 
beiden Missense-Varianten p.P33R und p.G77D wurde durch in vitro Reporter Assays 
nachgewiesen. Darüber hinaus wurde bei Überexpression der p.P33R-Mutante in Zebrafischherzen 
eine reduzierte Expression des Bmp4 Zielgens festgestellt. Diese Studie zeigt zum ersten Mal eine 
genetische Verbindung zwischen SND und AF unter Beteiligung von SHOX2. 
Patientenspezifische humane induzierte pluripotente Stammzellen (iPSCs), die potenziell 
krankheitsverursachende Varianten besitzen, bieten unzählige Möglichkeiten für die Untersuchung 
von Herz-Kreislauf-Erkrankungen. Wir generierten und charakterisierten iPSCs von Patienten mit 
zuvor identifizierten heterozygoten SHOX2-Mutationen (SHOX2 c.849C>A und SHOX2 
c.*28T>C). Um eine isogene Kontrolle zu etablieren, entwickelten wir eine neuartige Strategie zur 
narbenlosen Korrektur heterozygoter Mutationen. Von Patienten stammende iPSCs wurden mit 
dem CRISPR/Cas-System geneditiert und in kleine Zellpools unterteilt (Sib-Selektion). Wir 
quantifizierten Wildtyp- und mutierte Allele mittels digitaler PCR und Next-Generation-
Sequenzierung, um Verschiebungen im Wildtyp/Mutanten-Allel-Verhältnis zu erkennen, die auf 
das Vorhandensein von genkorrigierten Zellen hindeuteten. Mit dieser Methode gelang es uns, 
 
V 
unsere Zielzellen 8- bis 10-fach anzureichern, bevor wir durch Einzelzellklonierung eine 
monoklonale Zellpopulation erzeugten.  
Die Re-Charakterisierung der neuen Linien bestätigte eine erhaltene Pluripotenz und einen 
normalen Karyotyp. Zukünftige elektrophysiologische und molekulare Analysen werden weitere 
Einblicke in den Beitrag von SHOX2 zur Entstehung und Progression von Vorhofflimmern geben. 
  
VI 
Graphical abstract 
Sumer et al. (under revision) 
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1 
Introduction 
1.1. The heart – setting the pace of life 
The heart is a story of evolutionary success. From the most primitive tubular structures to the 
sophisticated four-chambered mammalian and avian organs, the rhythmic contractions of the heart 
ensure the transport of nutrients, metabolites, and oxygen throughout the body.2 The complete 
separation of oxygenated and deoxygenated blood circulations in birds and mammals enable high 
metabolic turnovers 3 and might well have laid the foundation for the development of higher 
cognitive processes that are made possible by a large, energy-demanding brain. Interestingly, the 
cephalopods (e.g. octopuses and squids), being the only invertebrates known to have evolved some 
form of higher intelligence, rely on three hearts and high cardiac outputs to meet their metabolic 
rates.4 
In literature and culture, the heart is often depicted as the seat of emotions, passion, and love. While 
this has been debunked as a myth by our modern understanding of neurobiology, love might indeed 
be the last chapter of cardiac evolution: An anatomical feature specific for mammals is the 
development of a myelinated vagus nerve that connects the heart to medullary cranial nerves. The 
heart rate can be rapidly slowed and sped up by changes in the vagal tone. In the brain, input from 
the frontal cortex allows the vagal tone to be influenced by perceptions signaling safety or by 
recognition of situations that require calm and prosocial behavior. The ability to slow down the 
heart rate enables human behavior critical for courtship and long-lasting bonding, giving the 
original idea of a love-heart relationship a surprisingly profound biological base.5,6 
Anatomically, the inhibitory vagus nerves innervate the cardiac atria. A substantial part of them 
ends in a specialized tissue in the right atrium, the so-called ‘sinoatrial node’ (SAN). The SAN is 
the re-entry point for contractions in the healthy heart and therefore sets the pace. Its role is 
established during early embryonic development, when the heart forms as the first organ and stays 
active for a lifetime until its ceased activity is associated with the final stage of life – death. 
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1.2. The mammalian heart 
1.2.1. The cardiac conduction system (CCS) 
The sequential contraction of different parts in the heart is essential for ensuring an adequate blood 
circulation. It is orchestrated by the depolarization of specialized cardiomyocytes in the atria and 
ventricles. These cells are organized in electrically coupled clusters, which together form the CCS. 
A distinct feature of CCS components are their different conduction velocities. In a healthy heart, 
the SAN is the dominant pacemaker controlling the rate of contraction. It is located at the junction 
of the superior caval vein and the right atrium. Automatically generated electrical impulses are 
rapidly propagated through the atria, leading to their synchronized contraction. The signal arrives 
at the atrioventricular node (AVN), which is positioned dorsally at the base of the interatrial septum, 
where it is delayed due to the slow conduction velocity within the tissue. This ensures the complete 
blood flow into the ventricles. The impulse then rapidly propagates through the atrioventricular 
bundle (or bundle of His, AVB) into the right and left bundle branches (BBs) in the ventricular 
septum. The bundle of His and the BBs are the only electrical connection between atria and 
ventricles, which are insulated from each other by the annulus fibrosus. Once the propagation of 
action potentials reaches the Purkinje fiber network, it is rapidly distributed throughout the 
ventricles, causing them to contract and pump the blood into the vascular system.7 
Different features of the CCS components, like the rate of spontaneous differentiation, the degree 
of intercellular coupling and action potential morphology suggest multiple CCS lineages.8 During 
heart development, atrial and ventricular chambers are formed from fast-conducting myocardium, 
which differentiates within the primitive heart tube. Most of the CCS develops from areas in 
between these regions that maintain embryonic, slow-conducting properties (Figure 1A). On the 
molecular level, the distinct electrophysiological differences are mediated by transcriptional 
regulators specific for their respective CCS component (Figure 1B).7 
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Figure 1 Mammalian heart development and electrocard iogram  
Figure 1 Mammalian heart development and electrocardiogram. (A) “From E9.5 onwards, atrioventricular canal (AVC) precursors 
(green) located in the IFT of the early heart tube begin to develop into the atrioventricular node (AVN, shown in parts d and e) and left 
and right atrioventricular ring bundles (LAVRB and RAVRB, shown in parts d and e). The sinus venosus (SV, blue) is added to the 
heart tube from the caudal second heart field pool of progenitors. c| From E10.5 onwards, the sinoatrial node (SAN) develops in the right 
sinus horn. From the outer curvatures of the heart tube, the myocardium expands, yielding the four heart chambers: left atrium (LA), 
right atrium (RA), left ventricle (LV), and right ventricle (RV). The septal part of the interventricular ring (yellow) begins to form the 
atrioventricular bundle (AVB). From early fetal stages onwards, compact working myocardium (grey) forms at the epicardial side of the 
ventricles. d| From E14.5 onwards, the septal trabeculations form the left and right bundle branches (LBB and RBB, yellow). The 
Purkinje fiber network (PFN, red) is derived from early ventricular chamber myocardium. e| The cardiac conduction system in the adult 
heart. Action potentials are initiated in the SAN and propagate (grey arrows) to the atria, AVN, AVB, BBs, PFN, and the ventricular 
cardiomyocytes. The LAVRB and RAVRB prevent direct action potential propagation from the atria to the ventricles.“ Figure and legend 
taken from van Eif et al., Cardiac Development 2018. (B) Schematic drawing showing the different CCS components and their respective 
key transcription factors that play a role in the development, specification, and function of the tissue. A combination of general and 
tissue-specific transcription factors mediates the distinct electrophysiological properties. Picture based on licensed stock photo 
AdobeStock_163503654 (C) Example of a normal electrocardiogram. Abnormalities in electrocardiogram traces can be indicative of 
cardiac conduction system (CCS) disorders. For example, an increased PP interval but normal PR interval indicates sinus bradycardia 
(sinoatrial node dysfunction). Progressive lengthening of the PR interval followed by a QRS indicates a first-degree atrioventricular 
block. 
 
The sequential impulse propagation in the heart can be visualized in an electrocardiogram (ECG) 
(Figure 1C). It plots electrical activity in the heart in a graph of voltage versus time. The signaling 
propagation from the SAN through the atria causes cardiomyocytes to depolarize resulting in the P 
wave. In contrast, the ventricular depolarization is reflected by the QRS complex, and the T wave 
represents ventricular repolarization. The PR interval, defined as the time from the onset of the P 
wave to the beginning of the QRS complex indicates the time that the impulse requires to travel 
through the atria, the AVN and AVBs. The ventricular conduction system is assessed by the 
duration of the QRS complex and the QT interval measures the duration of ventricular 
depolarization and repolarization. 
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Abnormalities in the ECG, such as prolonged intervals and segment durations can be indicative of 
CCS disorders and are associated with cardiac arrhythmias.7,9 Due to the non-invasiveness of 
electrodes that are planted on a patient’s chest and limbs, electrocardiography is a routinely used 
examination method for assessing the cardiac function in the clinical context. 
 
1.2.2. The sinoatrial node 
The SAN is a heterogenous tissue that 
comprises different cell populations, 
including fibroblasts endothelial cells, 
connective tissue, and specialized 
cardiomyocytes. These pacemaker 
cells are capable of spontaneous 
depolarization without external 
stimulation and thereby initiate the 
cardiac cycle. Compared to 
cardiomyocytes of the working 
myocard, they contain poorly 
developed sarcomeres and different 
electrical activity. In the center of the 
SAN, cardiac cells are connected by 
slow conducting connexins, such as 
Cx30.2 (Gjd3) and Cx45 (Gjc1), which 
prevent them from being externally stimulated.10 The automatic electrical activity is mediated by 
an interplaying combination of membrane ion channels, (‘membrane clock’) and intracellular Ca2+ 
handling mechanisms (‘Ca2+ clock’), causing a non-stable membrane potential.11 The SAN is 
innervated by the autonomic nervous system enabling a regulation of the heart beat to change 
cardiac output and metabolic demand.7 
During early mouse embryogenesis (~E8), the heart tube is formed by the fusion of two heart-
forming regions in the lateral plate mesoderm. At this point, all myocardial cells are slow-
conducting and automatic, however dominant automaticity is already located caudally at the inflow 
tract. The addition of cardiomyocytes derived from the second heart field elongates the primitive 
heart tube at both poles (Figure 1A b). This gives rise to the sinus venosus (SV), which becomes 
the dominant re-entry point for contractions. From E10.5 onwards, the SAN develops from the right 
sinus horn (Figure 1A c-e), to which the pacemaker activity finally gets restricted.7,9,12 
The genetic network which regulates SAN development and mediates its unique properties is highly 
conserved.2 The Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4 
Figure 2 The genetic network of the SAN 
Figure 2 The genetic network of the SAN. SHOX2 maintains the phenotypic 
border between working myocard and SAN tissue by antagonizing NKX2.5 to 
prevent the expression of fast-conducting connexins and atrial ion channels. It 
synergizes with TBX5 and TBX18 to induce the SAN genetic program by 
activating the expression of ISL1, BMP4 and TBX3. This ultimately leads in the 
activation of genes, such as CACNA1g and HCN4, which mediate the unique 
pacemaker properties. Outside of the SAN, SHOX2 is repressed by PITX2. 
Figure and legend adapted from van Eif et al., Cardiac development 2018. 
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(Hcn4), is crucial for pacemaker activity. Its expression is initially global, but ultimately only 
maintained in pacemaker cells of the SAN and AVN.13 In contrast, the expression of Nkx2.5 remains 
high in cells of the working myocard but is downregulated in pacemaker cells which express Tbx18 
instead.14,15 In the atria, Nkx2.5 initiates the expression of chamber-specific genes, such as fast-
conducting connexins Cx40 (Gja5) and Cx43 (Gja1) or ion channels (e.g. Scn5a).16 The 
asymmetrical formation of the SAN is ensured by Pitx2, which represses left-sided pacemaker 
development. This is achieved by inhibition of the Short Stature homeobox 2 transcription factor 
(Shox2), T-Box Transcription Factor 3 (Tbx3) and presumably other mechanisms.7,17,18 T-Box 
Transcription Factor 5 (Tbx5), which is expressed in the SV and precursor tissues, activates the 
pacemaker genes Bmp4, Shox2 and Tbx3.19,20 Shox2 maintains the phenotypic border between SAN 
and working myocard by a common antagonistic mechanisms with Nkx2.5.21 Additionally, it 
activates the SAN genetic program including Hcn4, Tbx3 and its direct targets Isl1 and Bmp4.19,22 
Tbx3 supports the activation of pacemaker genes and suppresses the expression of atrial genes such 
as Gja1, Gja5 and Scn5a (Figure 2).23 Disturbances in this fine-tuned network of transcriptional 
regulators can lead to the expression of “pacemaker genes” outside the SAN or genes of the working 
myocard on the inside. This can affect the electrophysiological properties of the different tissues 
resulting in impaired electrical transmission or altered sequential contractions, which clinically 
manifest as arrhythmias. 
 
1.3. Disturbances in the CCS 
1.3.1. Atrial fibrillation (AF) 
AF is the most common cardiac arrhythmia with a worldwide prevalence of 37 million cases (0.51% 
of the world population). With an ageing population, the substantial socioeconomic burden and 
incidence are expected to further increase.24 The hallmark of AF is the rapid and disorganized 
electrical activation of the atria, leading to uncoordinated contractions. This is caused by ectopic 
re-entry points that reside outside of the SAN. Structural changes such as fibrosis and tissue scarring 
upon heart strokes or congenital abnormalities in Ca2+ handling (early afterdepolarizations and 
delayed afterdepolarizations) are the underlying mechanisms for the initial formation of this ectopic 
activity. This results in a progressive electrical and structural remodeling of the atrial tissue which 
sustains the ectopic re-entry and ultimately stabilizes it (Figure 3). In the clinical context, the atrial 
flattering is initially self-terminating (paroxysmal) but progresses to a persistent and ultimately to 
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a permanent type with no spontaneous termination if not treated correctly.25 The loss of a 
synchronized electrical conduction leads to blood stasis in the atria and predisposes patients to the 
development of atrial thrombi and stroke.26 AF is epidemiologically associated with other 
conditions such as coronary artery disease, cardiomyopathies, hyperthyroidism, arterial 
hypertension, obesity and diabetes mellitus.24 The lack of a risk factor in some cases and the often 
observed familial aggregation, however, suggests underlying genetic predispositions to develop the 
disease. Large genome-wide association studies (GWAS) and meta-analyses have identified more 
than hundred loci that are significantly associated with AF.27 Additionally, rare variants identified 
in AF patients were analyzed in both cell and animal models.26 The majority of risk genes encode 
ion channels, but structural proteins, signaling molecules and transcription factors have been linked 
to this disease as well.26 Among the transcription factors are the SHOX2-inducing T-Box 
Transcription Factor 5, the SHOX2 antagonist NKX2.5, the SHOX2 repressor PITX2 and SHOX2 
itself.26,28-30 
 
 
Figure 3 Key features of  atr ial fibri llat ion 
Figure 3 Key mechanisms of atrial fibrillation. Rapid/Sustained ectopic or re-entrant activity can maintain AF. An ectopic beat acting 
on vulnerable substrate functions as a trigger and leads to the development of a re-entry point. Atrial ectopy is rare in healthy hearts with 
atrial electrical properties being unsuitable for maintenances of AF. However, atrial remodeling by altering ion-channel function or 
inducing tissue fibrosis creates a substrate for re-entrant AF. Remodeling can also produce changes in cell Ca2+-handling, thus making 
ectopic activity more likely. Legend and figure concept are based on Dobrev D, Mattel S, Lancet 2010 
Abbreviations: EADs=early afterdepolarizations. DADs=delayed afterdepolarizations. 
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1.3.2. Sinus node dysfunction (SND) 
SND, also referred to as sick sinus syndrome, includes a spectrum of symptoms and heart rhythm 
dysfunctions caused by an abnormal sinus impulse formation and/or propagation. This 
heterogenous clinical entity presents in different electrocardiographic manifestations, such as sinus 
arrest (no electric impulse generation for >2 s), sinoatrial exit block (sinus impulse is 
delayed/blocked in atria) and bradycardia (<60 heart beats per minute).31 Electrophysiological 
characteristics of SND are an increased sinus node recovery time (time until first automated impulse 
after stimulation), a delayed conduction along the crista terminalis and areas of low voltage within 
the right atrium.11,32 The disease is often asymptomatic in early phases; in progressed stages, 
symptoms can include fatigue and dizziness due to reduced cerebral perfusion, effort dyspnea, 
syncope and presyncope. Patients are at risk of developing major cardiovascular events, including 
chronotropic incompetence (inadequate leading pacemaker response to exercise/stress) and 
thromboembolism. Depending on how SND manifests clinically, it is treated by the administration 
of antiarrhythmic drugs (AADs) and pacemaker implantation.31 Currently 30-50% of pacemaker 
implantations in the US are primarily due to SND and the incidence of the disease is projected to 
double until 2060.33 
The etiology of the disease can be extrinsic, intrinsic or a mixture of the two. In a retrospective 
study of patients presenting with bradycardia, half of the cases were attributable to a treatable 
extrinsic cause such as electrolyte imbalance (e.g. Hyperkalemia, hypocalcemia), adverse drug 
reaction or acute myocardial infarction while the other half were assumed to be 
intrinsic/idiopathic.11 The pathophysiology of idiopathic SND or ‘primary SND’ is still not fully 
understood. Idiopathic SND generally occurs in the elderly population, but familial forms have also 
been reported at earlier stages.11 
 
1.3.3. SND and arrhythmias 
Atrial arrhythmias and SND frequently coexist in 40-70% of patients suffering from AF at the time 
of diagnosis of SND. The combination of SND with AF is the basis of the ‘tachycardia-bradycardia 
syndrome’, where atrial flutter or fibrillation episodes alternate with sinus pauses at their 
termination.34 Both disorders interact to initiate and perpetuate each other, yet, their complex 
relationship remains elusive.35 The connecting paradigm between the two clinical entities is likely 
the anatomical and electrophysiological remodeling of the atria that is visible on the structural, 
cellular and genomic levels.35 SND and AF are associated with senescence. Age-induced 
degenerative fibrosis leads to slower intrinsic heart rates and increased sinus node conduction time, 
both of which favor the manifestation of SND and AF.31 The declined sinus node impulse formation 
can allow ectopic atrial foci to mature and fire. The stabilization of such re-entry points outside the 
SAN ultimately results in AF. In turn, AF can shut down the sinus node activity by overdrive 
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suppression.34 Persistent atrial arrhythmias result in cardiomyocyte apoptosis, electric decoupling, 
progressive fibrosis and dilatation of the atrial and SAN tissue.36,37 It manifests on the molecular 
level in the downregulation of ion channels and connexins.35 
Under these aspects it might not be surprising that most SND-related genes are also associated with 
AF. For example, several mutations and deletions within the HCN4 gene were found in patients 
suffering from paroxysmal AF or bradycardia.38-40 HCN genes encode hyperpolarization-activated 
cyclic nucleotide-gated channels, which are highly expressed in the CCS, where they are 
responsible for the automated generation of action potential. SCN5A is expressed in the atria but 
absent in the SAN.11 Mutations in this gene result in highly variable clinical presentations, including 
AF, Brugada syndrome, long-QT syndrome but also SND, which especially manifests as sinus exit 
block.41,42 
Medical treatment of AF in the presence of SND and reverse is challenging. Application of rate 
control agents and AADs can worsen SND-related bradycardia leading to life-threatening 
symptoms such as long sinus pauses. On the other hand, treating one condition can ameliorate the 
symptoms of the other, for example by reverting detrimental tissue remodeling.43 
 
1.4. SHOX2 gene, expression, and function 
1.4.1. SHOX2 gene 
During embryogenesis, the homeobox gene family controls many developmental processes that are 
highly conserved among species.44 Mutations in several members have been described in human 
diseases including Léri-Weill dyschondrosteosis (SHOX) and Rieger syndrome (PITX2).45,46 The 
short-stature homeobox containing gene family comprises SHOX and its related homologue 
SHOX2. The encoded amino acid sequence and common homology domains share 99% and 83% 
similarity, respectively.47 SHOX2 is localized on 3q25.32 (chr3:157,813,800-157,824,292, minus 
strand (GRCh37/hg19)) and consists of 6 exons. Nucleic acid sequencing revealed two isoforms, 
SHOX2a and SHOX2b. Both isoforms contain the homeodomain, the SH3 domain and an OAR 
domain. It is expressed in developing limbs, the nasal cavity, branchial arches, embryonic 
reproductive nodules, the central nervous system, and the heart. In the latter, Shox2 expression is 
restricted to the CCS, especially the SAN and AVN and the adjacent venus valves.48 Its central role 
in heart development (as described above) was confirmed in various animal models. Reduced 
pacemaker proliferation induces lethal SV and SAN hypoplasia and bradycardia in Shox2-/- mice 
between E11.5 and E17.5. In the SAN region, a switch to the genetic program of the working 
myocard can be observed with an ectopic expression of Nkx2.5, Nppa and Cx40 and a 
downregulation of Tbx3, Hcn4 and Isl1.48,49 In zebrafish, the morpholino-mediated knockdown of 
endogenous zShox2 leads to severe bradycardia and pericardial edema, which can be rescued by the 
overexpression of its direct target Isl1.22 
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1.4.2. SHOX2 and AF  
The first heterozygous missense mutations were identified in a cohort of 378 patients with early-
onset AF.28 From these, a coding variant (SHOX2 c.849C>A, SHOX2 p.H283Q) and a 3’ 
untranslated region (3’UTR) variant (SHOX2 c.*28T>C) were shown to affect the regulation and 
function of SHOX2. Mechanistically, the coding variant impeded the transactivational activity of 
the SHOX2 protein, as seen in reporter assays where it failed to activate both BMP4 and ISL1 target 
genes. Furthermore, if endogenous Shox2 was substituted for mutated Shox2 in embryonic zebrafish 
hearts via morpholino injection, it could not rescue the pericardial edema and bradycardia 
phenotype that is observed upon loss of Shox2 via MO-mediated knockdown (Figure 4A). The 
3’UTR variant was present in the general population without known AF, but significantly enriched 
in AF patients compared to control cohorts. The base substitution led to a novel miR-92b-5p binding 
site that was shown to be functional in in vitro reporter assays. This miRNA was also significantly 
lower expressed in carrier AF patients when compared to affected non-carriers; with a more 
pronounced effect, when a subset of carrier patients with a PR interval >200 ms was compared to 
non-carriers with a PR interval of <200 ms (Figure 4B).28 The association of SHOX2 with AF was 
further confirmed by the identification of a heterozygous nonsense mutation (p.R194X) in a cohort 
of unrelated patients with familial AF that was absent in the control group. This variant co-
segregated with the disease phenotype in the patient’s family as well as in all affected members 
with complete penetrance. The nonsense mutation resulted in a premature stop codon, truncating 
the homeodomain of SHOX2 and therefore leading to a complete loss of function as a transcriptional 
activator (Figure 4C).50 
  
Introduction 
10 
  
Figure 4 SHOX2 and atrial fibrillation 
Figure 4 SHOX2 and atrial fibrillation. (A) Three mutations (p.G81E, p.H283Qand c.*28T>C) were found in a cohort of patients with 
an early onset of atrial fibrillation (<65 years). zShox2 p.H277Q was overexpressed in embryonic zebrafish hearts (72 hpf) after pLNA-
mediated knockdown of endogenouszShox2. It failed to rescue the bradycardia and pericardial edema phenotype that is observed after 
the loss of Shox2. An impaired transactivational activity was shown for SHOX2 p.H283Q but not SHOX2 p.H81E in a Dual-Luciferase 
Reporter Assay. (B) SHOX2 c.*28T>C generates a novel miR-92b-5p binding site that was shown to be functional in a Luciferase 
Reporter Assay. AF patients carrying the heterozygous SHOX2 c.*28T>C mutation had significantly reduced miR-92b-5p plasma levels 
when compared to AF non-carriers. AF patients in general showed a reduced SHOX2 expression in right atrium tissue. (C) The SHOX2 
p.R194X (SHOX2 c.580C>T) mutation was associated with a familial form of AF. The nonsense mutation co-segregated with AF in the 
family with complete penetrance. SHOX2 p.R194X is a truncated protein lacking the homeodomain that is crucial for its function as a 
transcription factor. A severely reduced transactivational activity was shown for SHOX2p.R194X in a Dual-Luciferase Reporter Assay.  
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1.5. The induced pluripotent stem cell (iPSC) model 
 
1.5.1. iPSCs in cardiac disease models 
Research on the genetic basis of human cardiovascular disease has mainly relied on animal models 
in the past due to the limited access of human primary cardiac tissue. However, species-specific 
electrophysiological and transcriptional differences in cardiomyocytes can confound the translation 
of these findings to clinical relevance.51,52 iPSCs help to overcome these limitations, as they provide 
an unlimited source of cardiomyocytes that allow for close genotype-phenotype associations if they 
originate from patients. This forms the basis for the investigation of underlying pathogenic 
mechanisms and the discovery of promising therapeutic targets.53 In addition, they offer a 
personalized drug-screening platform for precision medicine and individualized therapy.54 
In the last decade after the first description of the methods to reprogram human somatic cells into a 
pluripotent state55, iPSC models for several classes of cardiac disorders have been developed. 
Primary arrhythmic diseases caused by mutations in ion channels and characterized by abnormal 
ECG, have been extensively studied in iPSCs. For example, iPSC-derived cardiomyocytes (iPSC-
CMs) with mutations in KCNQ1, KCNH2 or SCNA5, modelling 3 subtypes of Long-QT syndrome, 
recapitulated the electrophysiological phenotypes observed in patients and responded to anti-
arrhythmic or proarrhythmic drugs in a comparable manner. Molecular analysis of these cells 
provided insights into pathological mechanisms, such as aberrant protein trafficking, abnormal ion 
currents or altered channel activation.56-58 
Cardiomyopathies, such as dilated (DCM), hypertrophic (HCM) and arrhythmogenic (ACM) 
cardiomyopathies were mimicked in iPSCs harboring mutations in risk genes like TNNT2, LMNA 
and TTN (DCM), MYH7 (HCM) or PKP2 (ACM). These models often showed structural 
disorganizations including sarcomeric disarray and abnormal cell size as well as reduced 
contractility and aberrant Ca2+ handling.59-61 The cardiovascular effects of metabolic and other 
disorders, for example Barth syndrome (BTHS) or Duchenne muscle dystrophy, were also analyzed 
in iPSC models. BTHS iPSC-CMs with mutations in the TAZ gene exhibited mitochondrial 
dysfunction and sarcomeric disorganization.62 Patient-specific iPSC-CMs harboring deletions in the 
DMD gene, show abnormal Ca2+ handling and arrhythmogenic susceptibility, which can be 
ameliorated with somatic gene editing.63 
AF has been mimicked in human embryonic stem cells (hESCs). Artificial tissue consisting of 
atrial-like CMs was generated, in which stable re-entrant rotor patterns could be induced. These 
rotors are typical for AF, however, treatment with flecainide (class Ic anti-arrhythmic drug) did not 
influence their pattern or occurence.64 The first iPSC-based model for AF, in which the triggering 
cellular mechanisms of a familial form of AF were investigated, was recently described. Longer 
action potential durations, aberrant Ca2+ streams and enhanced pacemaker currents If were described 
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in iPSC-CMs with the common patient genetic background.65 Several limitations of this study 
remain with a missing defined genetic causality and the lack of a state-of-the-art differentiation to 
atrial-like iPSC-CMs. Yet, these results are encouraging that iPSC-CMs can be used to identify AF 
mechanisms, to screen for therapeutic targets or to predict responses of AF patients to certain 
medication. 
 
1.5.2. Genome-editing in iPSCs 
The applicability and versatility of iPSCs has been further potentiated by recent advances in gene 
transduction and editing technologies.66 Genome-targeting is feasible due to the development of 
site-specific nucleases, such as zinc finger nucleases (ZFNs), transcription activator-like effector 
nucleases (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 
as these enzymes helped to overcome the low frequency of random homology mediated gene 
targeting in stem cells.67-70 
Following a DNA double-strand break (DSB), endogenous repair mechanisms through non-
homologous end joining (NHEJ) or homology-directed repair (HDR) are activated by the cell. 
NHEJ does not require a homologous template for repair but often leads to the insertion or deletion 
of nucleotides (Indels), potentially resulting in the disruption of the gene function due to frameshift 
or loss-of-function mutations. This mechanism can be utilized if the loss of one or two gene copies 
is desired, as in the generation of knockout cell lines or animals. In contrast, during HDR a sequence 
of (partially) homologous DNA, naturally the undamaged sister chromosome, serves as a repair 
template. This normally leads to a complete restoration of the DNA sequence.71 In the presence of 
an exogenously introduced template, the alteration or insertion of specific DNA sequences, ranging 
from single nucleotide exchanges to whole transgenes, can be achieved.72 
While the sequence specificity of ZFNs is mediated by a sequential fusion of several zinc finger 
domains binding to defined base pair triplets, TALENs are recruited to their target loci by their 
TALE DNA-binding domain, which consists of modularly assembled amino acids recognizing 
dinucleotide sequences.68,73-77 Despite concerns regarding undesired DNA cleavage at other 
genomic sites than the target locus (off-targets), ZFNs and TALENs have been successfully used 
in genome-editing of iPSCs.78-81 However, additional technical aspects, such as restrictions in 
targetable DNA sequences, laborious cloning efforts and the complex protein engineering further 
limit a broader application of ZFNs and TALENs.82-85 
The field of genome editing has been revolutionized by the CRISPR/Cas9 system. Originally a 
component of the adaptive immune response in Streptococcus pyogenes, the CRISPR-Cas9 
nuclease has been repurposed for simple and versatile gene engineering.86,87 The targeting of 
specific genomic loci is mediated by single-guide RNA (gRNA), which consists of an RNA scaffold 
enabling the formation of Cas9 ribonucleoprotein (RNP)/gRNA complexes and a ~20 nt 
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“protospacer” complementary to a genomic sequence that is adjacent to a three base pair NGG motif 
(PAM motif).88-90 A significant technical advantage of CRISPR/Cas9 over TALENS and ZFNs is 
that this protospacer sequence can be easily exchanged to target any part of the genome. Yet, off-
targeting also remains a safety issue with this method.91 
Utilizing DSBs to introduce sequence alteration by error-prone NHEJ-mediated DNA repair has 
led to numerous knockout models in iPSCs.90 However, even though the disruption of genes is a 
practical tool for basic research and might even be a feasible therapeutic option in certain cases, the 
true potential of genome engineering lies within precise modifications.92,93 A plethora of 
possibilities results from wanted sequence alterations including the generation of gene knock-ins, 
reporter cell lines and the insertion or correction of patient-specific mutations: Knock-in and 
reporter cell lines can facilitate the monitoring of gene expression in vitro and tracing of 
transplanted cells in vivo or enable the selection and purification of certain subtypes in mixed 
populations of differentiated cells.94-97 Insertion of disease-linked variants into a wildtype 
background helps to interrogate the influence of these mutations on the onset and progression of a 
disease by direct comparison of mutated cells to their isogenic counterpart. Yet, this approach is 
limited to monogenic diseases or variances with a high impact on the phenotype. In sporadic or 
idiopathic diseases, a combination of multiple risk alleles with low effect size is thought to be the 
genetic basis. Individual risk variants might not be sufficient to cause a disease-associated 
phenotype. Fortunately, optimizations in iPSC technology and commercially available tools have 
streamlined iPSC derivation, so that the generation of patient-specific iPSCs harboring all risk 
alleles has become broadly accessible.67 The correction of putative disease-contributing variants in 
these cells could also unravel subtle phenotypic changes when comparing patient cells to their 
isogenic controls, even if the disease phenotype overall persists. Gene correction also holds 
potential for human gene therapy approaches, in which somatic cells are reprogrammed to iPSCs 
and the detrimental mutation is corrected before the cells are differentiated to the desired cell type 
and re-transplanted into the patient for a beneficial effect.98 
However, a key limitation in precise genome editing remains indicating that mammalian cells 
preferentially choose the error-prone NHEJ pathway rather than a homology-directed approach 
using exogenous templates to repair DSBs.99 Under normal circumstances, frequencies of ~1% for 
single-base substitutions or deletions are often reported.90,100-102 In recent years, substantial effort 
has been undertaken to develop strategies for improved HDR efficiency: 
Culturing iPSCs at 32°C for 24-48h after Cas9 transfection, was reported to increase the efficiency 
of single nucleotide exchanges.99 Selection genes are often used to enrich for successfully edited 
cells. However, these genes sometimes need to be incorporated into the genome and either remain 
or must be removed in a second step, eventually leaving a genomic ‘scar’ in the process. Other 
approaches were based on enhancing either the NHEJ or the HDR pathway via the application of 
small molecules.103 Similarly, it was shown that the inhibition of NHEJ key molecules via gene 
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silencing improved HDR efficiency and abolished NHEJ activity.104 Cells preferentially choose 
NHEJ or HDR dependent on the cell cycle with HDR being restricted to the late S and G2 phases 
while NHEJ pathway is dominating during G1, S and G2 phases.105 On this base, strategies were 
developed to increase HDR by fusing Cas9 to Geminin which resulted in a cell-cycle-tailored 
expression or by arresting cells in S phase before delivery of Cas9.106,107 The HDR templates were 
optimized in regard to design (single-stranded vs double-stranded), homology arm length and 
symmetry around Cas9 cut site for improved incorporation of sequence changes.108-110 Also the 
Cas9 enzyme itself was extensively modified to improve its specificity and efficiency: By 
catalytical inactivation of one of the nuclease domains, a Cas9 nickase was generated which led to 
single-strand DNA breaks that were preferentially repaired via HDR if provided with the right 
template.111 Recent approaches focus on avoiding DSBs by coupling catalytically inactive, 
‘deactivated’ Cas9 (dCas9) with enzymes: In base-editing, dCas9 linked with deaminases is used 
to achieve transition mutations (purine to pyrimidine and reverse) in a narrow window of DNA base 
pairs.112 Prime-editing fuses dCas9 to a reverse transcriptase that is capable of achieving transition 
and transversion mutations as well as insertions and deletions.113 
An alternative approach was used for detection of rare single-base editing events in iPSCs: Here, 
iPSCs were subcloned in small cell pools (termed ‘sib-selection’) to randomly enrich cells of 
interest. Subsequently digital PCR was applied to detect the correctly edited cell subpopulations in 
these pools. With subsequent subcloning rounds, always using the sib-selection with the highest 
percentage of cells of interest, the target population was enriched until single cell-cloning and 
screening of correctly edited clones could be performed with relative ease.102 
 
1.6. Aim of the thesis 
SHOX2 is a key regulator in cardiac development and specifically the SAN as shown in various 
animal models. Mutations in this gene have been identified in patients with early-onset and familial 
AF. However, the molecular mechanisms that involve SHOX2 and lead to the onset and the 
progression of the disease in humans have not been fully elucidated yet. In addition, SHOX2 has 
not been linked to SND despite the high gene expression in this tissue and the close relationship 
between this disease and AF. 
The aim of the first part of this PhD thesis was to find a causal relationship between novel SHOX2 
variants and the development of SND and AF. For this, cohorts of AF and SND patients should be 
screened and newly identified mutations analyzed in vivo and in vitro. 
In the second part, an in vitro AF model should be established based on patient-specific iPSCs. 
Cells harboring heterozygous SHOX2 mutations have been previously described. Two patients were 
planned to be recruited and clinically examined. A reprogramming of somatic cells and 
characterization of several iPSC lines per patient was planned. To generate a suitable control for 
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these lines, the heterozygous SHOX2 mutations needed to be precisely corrected and novel methods 
developed along the way, to allow for an easier and scarless correction of heterozygous mutations 
with a gene-editing tool of choice. 
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2. Material and Methods 
1.1. Materials 
1.1.1. Cell culture reagents 
Basal media  
Dulbecco’s Phosphate Buffered Saline (DPBS) w/o Ca2+/Mg2+ Thermo Fisher Scientific 
DPBS /w Ca2+/Mg2+ Thermo Fisher Scientific 
Dulbecco’s Modified Eagle’s Medium (DMEM)/F12 (1:1) Thermo Fisher Scientific 
DMEM (1x), high glucose Thermo Fisher Scientific 
Distilled water Thermo Fisher Scientific 
  
Stem cell media  
mTeSR™1 STEMCELL Technologies 
Essential 8™ Thermo Fisher Scientific 
StemFit® Basic02 Nippon Genetics 
  
Media supplements  
Non-essential Amino Acid Supplement (‘NEAA’) (100x) Thermo Fisher Scientific 
GlutaMAX™ Supplement (100x) Thermo Fisher Scientific 
Penicillin-Streptomycin (P/S) 10.000 U (100x) Thermo Fisher Scientific 
Normocin™ (used 1:1000) InvivoGen 
Plasmocin™ (used 1:1000) InvivoGen 
Fetal bovine serum (FBS) Thermo Fisher Scientific 
Fetal bovine serum (LOT# 044M3395) Sigma-Aldrich  
2-Mercaptoethanol Sigma-Aldrich 
Recombinant Human FGF-basic (154 a.a.) PeproTech 
L-Ascorbic acid Sigma-Aldrich 
Y-27632 hydrochloride (ROCK inhibitor) Cayman Chemicals 
  
Cell dissociation reagents  
0.05% Trypsin-EDTA (1x), phenol red Thermo Fisher Scientific 
TrypLE™ Express Thermo Fisher Scientific 
Accumax™ Merck Millipore 
Dispase (1 U/ml) in DMEM/F12 STEMCELL Technologies 
  
Freezing media  
mFreSR™ STEMCELL Technologies 
Bambanker™ Nippon Genetics 
  
Coating reagents  
Geltrex™ LDEV-Free, hESC-Qualified, Reduced Growth Factor 
Basement Membrane Matrix 
Thermo Fisher Scientific 
Fibronectin bovine plasma Sigma-Aldrich 
Gelatin from porcine skin Sigma-Aldrich 
  
Transfection reagents  
Polyethyleneimine (PEI) Sigma-Aldrich 
Lipofectamine® 2000 Transfection Reagent Thermo Fisher Scientific 
FuGENE® HD Promega 
P3 Primary Cell 4D-Nucleofector™ X Kit S Lonza 
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Luciferase assay  
Dual-Luciferase® Reporter Assay System Promega 
  
Other reagents  
KaryoMAX™ Colcemid™ Solution in PBS Thermo Fisher Scientific 
Paraformaldehyde (PFA) Sigma-Aldrich 
Dimethyl sulfoxide (DMSO Sigma-Aldrich 
UltraPure™ Ethylenediaminetetraacetic acid (EDTA), 0.5M, pH 
8.0 
Thermo Fisher Scientific 
Poly(2-hydroxyethyl methacrylate) (Poly-HEMA) Sigma-Aldrich 
 
HEK293TN medium DMEM (high glucose) 
 10% FBS 
 1% P/S 
  
EB-20 medium DMEM/F12 
 20% FBS (LOT# 044M3395) 
 1% GlutaMAX™ Supplement 
 1% NEAA Supplement 
 0.1 mM 2-Mercaptoethanol 
 0.5% P/S 
  
EB-2 medium DMEM/F12 
 2% FBS (LOT# 044M3395) 
 1% GlutaMAX™ Supplement 
 1% NEAA Supplement 
 0.1 mM 2-Mercaptoethanol 
 0.5% P/S 
 
1.1.2. Bacteriological Media and Supplements 
Reagents  
Ampicillin Roth 
Bacto™ Agar BD 
Bacto™ Tryptone BD 
Chloramphenicol Sigma-Aldrich 
Glucose Merck 
Glycerol Sigma-Aldrich 
Kanamycin Roth 
Magnesium chloride (MgCl2) Merck 
Magnesium sulfate (MgSO4) Merck 
Potassium chloride (KCl) Merck 
Sodium chloride (NaCl) Sigma-Aldrich 
Yeast extract BD 
 
Media for bacterial 
cultures 
 
LB medium 1% Bacto™ Tryptone 
 0.5% Yeast Extract 
 1% NaCl 
 ddH2O ad 1L 
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LB agar 1.5% Bacto™ Agar 
 LB medium ad 1L 
  
SOB medium 2% Bacto™ Tryptone 
 0.5% yeast extract 
 10 mM NaCl 
 10 mM MgCl2 
 10 mM MgSO4 
 ddH2O ad 1L 
  
SOC medium 1L SOB medium 
 20% glucose 
  
Ampicillin 50 mg/ml in 70% ethanol, diluted 1:1000 in LB medium/agar 
  
Kanamycin 30 mg/ml in ddH2O, diluted 1:1000 in LB medium/agar 
 
1.1.3. Vector constructs 
Vectors  
pDestTol2CG2 Provided by Prof. Steffen 
Just 
p5Ecmlc Provided by Prof. Steffen 
Just 
p3EpolyA Provided by Prof. Steffen 
Just 
pDONR™221 Thermo Fisher Scientific 
pDest27 Thermo Fisher Scientific 
pGL3basic Promega 
pRL-TK Promega 
 
1.1.4. Reagents and buffers for molecular analyses 
Reagents  
Acetic acid Merck 
LE Agarose Biozym 
Chloroform Sigma-Aldrich 
Distilled Water Thermo Fisher Scientific 
Ethanol (EtOH) Sigma-Aldrich 
EDTA Sigma-Aldrich 
GeneRuler DNA Ladder (100 bp+ /1 kb+) Thermo Fisher Scientific 
Glycine Sigma-Aldrich 
Isopropanol Sigma-Aldrich 
Midori Green DNA stain Nippon Genetics 
KCl Merck 
Sodium citrate (Na Citrate) AppliChem 
TRIS-(hydroxyl methyl)-aminomethane (Tris) Carl Roth 
 
50x TRIS-Acetate-EDTA (TAE) buffer 2 M TRIS 
 1 M acetic acid 
 50 mM EDTA 
 H2O ad 10 l 
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1% NaCl (w/v) 5 g NaCl 
 ddH2O ad 500 ml 
  
0.55% KCl (w/v) 2.75 g KCl 
 ddH2O ad 500 ml 
  
 
1.1.5. Kits 
DNA and RNA extraction, purification & quantification  
QIAquick® PCR & Gel Cleanup Kit Qiagen 
GeneJET Plasmid Miniprep Kit Thermo Fisher Scientific 
ZymoPURE™ II Plasmid Midiprep Kit Zymo Research 
Quick-DNA™ Miniprep Plus Kit Zymo Research 
Quick-DNA™ 96 Plus Kit Zymo Research 
GeneElute™ 96 Well Tissue Genomic DNA Purification Kit Merck 
Qubit™ dsDNA BR Assay Kit Thermo Fisher Scientific 
Qubit™ RNA BR Assay Kit Thermo Fisher Scientific 
directPCR® lysis reagent PEQLAB 
TRIzol™ Reagent Thermo Fisher Scientific 
Direct-zol RNA Microprep Zymo Research 
  
Conventional PCR  
HotStarTaq DNA Polymerase Qiagen 
Q5® High-Fidelity DNA Polymerase New England Biolabs 
Deoxynucleotide triphosphate  
(dNTP) Set 100 mM Solutions 
Thermo Fisher Scientific 
  
Cloning  
FastDigest™ Restriction Enzymes Thermo Fisher Scientific 
FastAP Thermosensitive Alkaline Phosphatase Thermo Fisher Scientific 
T4 DNA Ligase Thermo Fisher Scientific 
Gateway® Gene Cloning Thermo Fisher Scientific 
  
In vitro RNA synthesis  
Precision gRNA Synthesis Kit Thermo Fisher Scientific 
  
Droplet Digital™ PCR (ddPCR™) or digital PCR (dPCR)  
Pierceable Foil Heat Seal Bio-Rad 
ddPCR™ 96-Well Plates Bio-Rad 
Droplet Generation Oil for Probes Bio-Rad 
DG8™ Cartridges for QX100/QX200 Droplet Generator Bio-Rad 
DG8™ Gaskets for QX100/QX200 Droplet Generator Bio-Rad 
ddPCR™ Buffer control kit Bio-Rad 
ddPCR™ Supermix for probes (no dUTP) Bio-Rad 
ddPCR™ Droplet Reader Oil Bio-Rad 
  
cDNA synthesis and qRT-PCR  
SuperScript™ III First-Strand Synthesis System Thermo Fisher Scientific 
qPCRBIO SyGreen Mix Lo-ROX Nippon Genetics 
  
Cloning & Mutagenesis  
FastDigest™ Restriction enzymes Thermo Fisher Scientific 
T4 DNA Ligase Thermo Fisher Scientific 
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Mix & Go E.coli Transformation Kit and Buffer Set Zymo Research 
QuikChange™ Lightning Site-Directed Mutagenesis Kit Agilent 
  
Other  
TaqPath™ ProAmp™ Master Mix Thermo Fisher Scientific 
GeneArt™ Platinum™ Cas9 Nuclease Thermo Fisher Scientific 
TrueCut™ Cas9 Protein v2 Thermo Fisher Scientific 
Venor®GeM Classic Mycoplasma Detection Kit Minerva Biolabs 
 
1.1.6. Bacteria strains and cell lines 
Bacterial strains  
DH5α fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 
Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 
hsdr17 
XL10-Gold® Ultracompetent Cells TetrΔ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac 
Hte [F  ́ proAB lacIq ZΔM15 Tn10 (Tetr) Amy 
Camr] 
One Shot™ ccdB Survival™ 2 T1R Competent 
Cells 
F-mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 araΔ139 
Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 
nupG fhuA::IS2 
 
Cell lines  
HEK293TN BioCat 
SHOX2.2.6 (= SHOX2 c.849C>A_1) Reprogrammed somatic cells to iPSCs from 
Patient I in collaboration 
SHOX2.2.10 (= SHOX2 c.849C>A_2) Reprogrammed somatic cells to iPSCs from 
Patient I in collaboration 
SHOX2 B7 (= SHOX2 c.28*T>C_1) Reprogrammed somatic cells to iPSCs from 
Patient II in collaboration 
SHOX2 Klon 2 (= SHOX2 c.28*T>C_2) Reprogrammed somatic cells to iPSCs from 
Patient II in collaboration 
SHOX2 Klon Z (= SHOX2 c.28*T>C_3) Reprogrammed somatic cells to iPSCs from 
Patient II in collaboration 
SHOX2.2.6-1D6-1H10 
(= SHOX2_c849C>A_isoWT_1) 
isogenic control line from SHOX2.2.6 with 
corrected mutation 
SHOX2 B7-2F4-2D2 
(= SHOX2_c.*28T>C_isoWT_1) 
isogenic control line from SHOX2 B7 with 
corrected mutation 
HANS6 (= control_1) control iPSC clone derived from an individual 
with no known cardiovascular diseases 
 
1.1.7. Oligonucleotides 
Oligonucleotides (Primers) for cloning, sequencing and expression analysis were designed with 
Primer3, Primer3plus114,115 and tested for specificity with UCSC in silico PCR. TaqMan probes for 
dPCR and genotyping were designed with Primer3plus and OligoAnalyzer 3.1. By default, primers 
were designed for an annealing temperature of 60°C and TaqMan probes for 65°C. For quantitative 
PCR, primers were designed with the Universal ProbeLibrary Assay Design Center (Roche). 
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Primers for mutagenesis were designed according to the recommendations in the manual 
QuikChange Lightning Site-directed Mutagenesis Kit. 
 
Mutagenesis Primers 
Name Sequence (5' to 3') Purpose 
SHOX2_98_C_to_G CGTACCGGGAGGTGCTGGAGAGCGGGCGGCTGCGCGGGGCCAAGGAGCCG 
introducing the mutation 
c.98C>G into SHOX2 
SHOX2_230_G_to_A CGGAGGCGGCGGCGGAGGAGGCGGAGGAGATGTAGGAGGAGGAGGAGCAG 
introducing the mutation 
c.230G>A into SHOX2 
SHOX2_879_C_to_T ACGAAAGCTGAGGTCCAGGCTACGCTGTTTCTCCCGGGCGAGGCGTTTCG 
introducing the mutation 
c.879C>T into SHOX2 
 
Sequencing primers 
Primer name Sequence (5' to 3') Purpose 
SHOX2 Ex1.1 for TGTAAAACGACGGCCAGTAGAGGTTGAGCGCCGGGCTGACGT 
Sequencing 
SHOX2 Ex1.1 rev GGATAACAATTTCACACAGGCCTACACCTCCTCCGCCTCCTCCG 
SHOX2 Ex 1.2 for TGTAAAACGACGGCCAGTCGCAGCAGCCCGGCAGTCCGGGC 
SHOX2 Ex 1.2 rev GGATAACAATTTCACACAGGCTGCCGGGGGTCAGTCAGGTCGT 
SHOX2 Ex2+ for CCGAGTACTGGGTGATTG 
SHOX2 Ex2+ rev GCCAAGACCCCTCGAACT 
SHOX2 Ex2 for TCCACGAGGGGGAAGGATTC 
SHOX2 Ex2 rev CACCAGACACTAGAAGCACCA 
SHOX2 Ex3 for TGTAAAACGACGGCCAGTTTGCTTGCTGTATCTCCCAAT 
SHOX2 Ex3 rev GGATAACAATTTCACACAGGTTTGCTCAGACTATCAAATGTTCC 
SHOX2 Ex4 for TGTAAAACGACGGCCAGTTTTGGAACCCTGAAAAATGC 
SHOX2 Ex4 rev GGATAACAATTTCACACAGGGGCTCAGAGACAGGTGATG 
SHOX2 Ex5 for TGTAAAACGACGGCCAGTCCCAAACACAACCCAACTCT 
SHOX2 Ex5 rev GGATAACAATTTCACACAGGGCTGGGAACATCATGTAGGG 
SHOX2 Ex6 for AGGATAGTCATTGCAACGTGA 
SHOX2 Ex6 rev TCTCAAAGGGGTAACGGAGA 
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nCounter probes for Zebrafish gene expression analysis 
Probe name Sequence (5' to 3') Purpose 
actb1 
GTGCTTCTAAACAGAACTGTTGCCACCTTAAATG
GCCTAGCAATGAGATTCAAACGAACGACCAACC
TAAACTCTCGAACAGAACAAGATGACATCAGCA 
nCounter Control 
probe 
eef1a1l1 
GAAGGCTGCCAAGACCAAGTGAATTTCCCTCAA
TCACACCGTTCCAAAGGTTGCGGCGTGTTCTTCC
CAACCTCTTGGAATTTCTCTAAACCTGGGCACT 
nCounter Control 
probe 
rpl13a 
AAGAGAAAGGAAAAGGCCAAGCTGCGCTATTCC
AAGAAGAAAGTTGAGATGAAGCTGACTAAGCAG
GCTGAAAAGAACGTTGAGAGCAAGATCGCAGTA
T 
nCounter Control 
probe 
rps18 
GTACAAAATCCCAGACTGGTTCCTGAACAGACA
GAAGGACATAAAAGATGGGAAATACAGCCAGGT
CCTTGCTAATGGTCTGGACAATAAACTGAGAGA
A 
nCounter Control 
probe 
b2m 
TACTTTCGATATCAACTGCTGTTGTCCTGAATGC
TGAAGGATTGTCTGCTTGGCTCTCTCGAATAAAA
CGGCCACAATGAGAGCACTCATCACTTTTGCA 
nCounter Control 
probe 
hsp90ab1 
CTCACAGTCCGGCGACGAGATGACCTCCCTCAC
AGAATACGTCAGCCGTATGAAGGAGAACCAAAA
GTCCATCTATTACATCACTGGTGAGAGCAAAGA
C 
nCounter Control 
probe 
bmp4 
GAGCCAACACCGTGAGAGGATTCCATCATGAAG
AGCACCTGGAGGAGCTGCAGTCAGACGGCTCCC
AGGAGACGCCTCTGCGATTCGTTTTTAATCTCAG 
nCounter Shox2 
target gene probe 
 
Primers for genome-editing methods 
Primer name Sequence (5' to 3') Purpose 
SHOX2_C849A_gRNA_1_fw TAATACGACTCACTATAGCTGCAGCTGGACAGCG in vitro synthesis 
SHOX2 c.849C>A 
gRNA-1 SHOX2_C849A_gRNA_1_rev TTCTAGCTCTAAAACCAGCGCTGTCCAGCTGCAG 
SHOX2_C849A_gRNA_2_fw TAATACGACTCACTATAGCCAGGTGCGGATGCAG 
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SHOX2_C849A_gRNA_2_rev TTCTAGCTCTAAAACCCACCTGCATCCGCACCTG 
in vitro synthesis 
SHOX2 c.849C>A 
gRNA-2 
SHOX2_C28T_gRNA_1_fw TAATACGACTCACTATAGCGTGCAGGCTGAGTGC in vitro synthesis 
SHOX2 c.*28T>C 
gRNA-1 SHOX2_C28T_gRNA_1_rev TTCTAGCTCTAAAACGCGGCACTCAGCCTGCACGC 
SHOX2_C28T_gRNA_2_fw TAATACGACTCACTATAGGCGTGCAGGCTGAGTG in vitro synthesis 
SHOX2 c.*28T>C 
gRNA-2 SHOX2_C28T_gRNA_2_rev TTCTAGCTCTAAAACCGGCACTCAGCCTGCACGCG 
SHOX2_C849A_ddPCR_fw CTTGTCCTTTCAGGTTCAGG 
dPCR primer 
SHOX2_C849A_ddPCR_rev GCGGATGCAGGTGGT 
SHOX2_T28C_ddPCR_fw TGAAAGCCAAAAAGCACGCC 
dPCR primer 
SHOX2_T28C_ddPCR_rev GGCGTGCAGGCTGAGTG 
SHOX2_849A_ddPCR_FAM [FAM]TGTGGCGCAAGCGCAC[BHQ1] 
SHOX2 c.849A 
detection 
SHOX2_849C_ddPCR_HEX 
[HEX]TGTGGCGCACGCGCAC[BH
Q1] 
SHOX2 c.849C 
detection 
SHOX2_28C_ddPCR_FAM [6FAM]CCAATGTCGCGCCCGTCC
CGC[BHQ1] 
SHOX2 c.*28C 
detection 
SHOX2_28T_ddPCR_HEX [HEX]CACCAATGTCGCGCCTGTC
CCGC[BHQ1] 
SHOX2 c.*28T 
detection 
SHOX2_C849A_NGS_fw AACCCAACTCTCTCTCTGGC Primer for SHOX2 
c.849C>A NGS 
amplicon SHOX2_C849A_NGS_rev GTTCTTGCTGGTGGTCTTGG 
SHOX2_T28C_NGS_fw GACCACCAGCAAGAACTCCA Primer for SHOX2 
c.*28T>C NGS 
amplicon SHOX2_T28C_NGS_rev GTCTGGCTTTCCGAGTCCAA 
SHOX2_C849A_T7_fw ATTTCAGCCCAGTTCCCAGG Sanger sequencing 
SHOX2 c.849C>A 
region SHOX2_C849A_T7_rev AGAGTCCATCGTTGCAGCTT 
SHOX2_C28T_Ex6_fw AGGATAGTCATTGCAACGTGA Sanger sequencing 
SHOX2 c.*28T>C 
region SHOX2_C28T_Ex6_rev TCTCAAAGGGGTAACGGAGA 
 
Primers for gRNA off-target sequencing 
Primer name Sequence (5' to 3') Purpose 
KCNMA1_fw AATGCCACAATCACGGATGC SHOX2 c.849C>A 
gRNA-1 off-target 1 KCNMA1_rev GATTTCCTGACCCCTGACCC 
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RNA5SP462_fw GAATGTTCTCTCCGGCTCCC SHOX2 c.849C>A 
gRNA-1 off-target 2 RNA5SP462_rev GAGAGCCATGAGACTGGAGC 
LINC00315_fw GTGAGAGGTGAGGGTCAAGC SHOX2 c.849C>A 
gRNA-1 off-target 3 LINC00315_rev AGGGTGGTGTTGAGCTAACG 
RP11-422N16.3_fw GGGTTCCGGGATCTGAAAGG SHOX2 c.849C>A 
gRNA-1 off-target 4 RP11-422N16.3_rev CCTCACCTAACCCTCACAGC 
RAB10_fw AAGCAGGTTCTCTGAGCACC SHOX2 c.849C>A 
gRNA-1 off-target 5 RAB10_rev AATGCTCCTGTCTCCAAGCC 
SUN5_fw AGGCGTCAGATACAAGCAGG SHOX2 c.849C>A 
gRNA-1 off-target 6 SUN5_rev TTACCTGTCCAACCTCACGC 
ING5_fw GACCTGAAGTGATCCACCCG SHOX2 c.849C>A 
gRNA-1 off-target 7 ING5_rev TTGGGTCCAAACTACAGCCC 
LINGO4_fw ATTGTTAGCAGTGTGGGGGC SHOX2 c.849C>A 
gRNA-1 off-target 8 LINGO4_rev TGCTATTGCATGACCCCTCC 
SYNDIG1_fw TTCACCAAGGCCTTTCCAGG SHOX2 c.849C>A 
gRNA-1 off-target 9 SYNDIG1_rev TACAGGAAGAGGGAGAGGCC 
FCN2_fw CCTGGAGATGATCTCGCACC SHOX2 c.849C>A 
gRNA-1 off-target 10 FCN2_rev GCTTATCCCCACCTCACACC 
CPSF2_fw CATGTGGAGTCTCAGGTCCC SHOX2 c.849C>A 
gRNA-1 off-target 11 CPSF2_rev GTAGGACATAGCCCCACTGC 
POLR1A_fw GGCCAAGAAGTGAATGCTGC SHOX2 c.849C>A 
gRNA-1 off-target 12 POLR1A_rev ATTGAGACCAGGCCTGTTGG 
TSHZ3_fw AATGCTGGGCTGAGAAGTCC  SHOX2 c.*28T>C 
gRNA-1 off-target 1 TSHZ3_rev CCTTTGTTCCTTCAAGCAGGC  
ABCF1_fw CTGTTCTCTCCTGGCAGTGG SHOX2 c.*28T>C 
gRNA-1 off-target 2 ABCF1_rev CAGGTGGTCAAAGAGGTCCC 
UPK2_fw AGGCAGAGGAAATTCCAGGC SHOX2 c.*28T>C 
gRNA-1 off-target 3 UPK2_rev CTTGGGTGCTGAGAGTGAGG 
TEF_fw CTTGCTTTAGGGGAGCCTCC SHOX2 c.*28T>C 
gRNA-1 off-target 4 TEF_rev TTTCGCTTTTGTTGCCCAGG 
TRIM71_fw GTTCTGTGCCTCCAGAGTCC SHOX2 c.*28T>C 
gRNA-1 off-target 5 TRIM71_rev GGCGGGCTACAATGTTTTCC 
TMEM121_fw CCGTTCCGTTTCCTTCCTGG SHOX2 c.*28T>C 
gRNA-1 off-target 6 TMEM121_rev AGAGCTTGATCTCCAGCACG 
LANCL2_fw GGGCGTTCGGTTTTCTTTGG SHOX2 c.*28T>C 
gRNA-1 off-target 7 LANCL2_rev AACACAGCCTGTCTCTTCGG 
SAMD4A_fw GCAGGAGTAGGAAAGGCTGG SHOX2 c.*28T>C 
gRNA-1 off-target 8 SAMD4A_rev CACTTGCTGGGATGGGTTCC 
POU5F1P2_fw TTGGAAACCACAGGCAGAGG SHOX2 c.*28T>C 
gRNA-1 off-target 9 POU5F1P2_rev TCTCAGTGACACACCACACG 
TPRN_fw CTCCATAACTGGCTTGGGGG SHOX2 c.*28T>C 
gRNA-1 off-target 10 TPRN_rev CGTCCTCATCATCGAGACGG 
PLCH2_fw ATTCAGGCTGAGCTGTCACG SHOX2 c.*28T>C 
gRNA-1 off-target 11 PLCH2_rev TCCCATCCCCACCAGATAGG 
KRT16_fw GTGAAGCTTGCAGTGAACCG SHOX2 c.*28T>C 
gRNA-1 off-target 12 KRT16_rev CCTCACACCCCATCAACTCC 
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Primers for iPSC (re-)characterization 
Primer name Sequence (5' to 3') Purpose 
SEV_transgene_fw GGATCACTAGGTGATATCGAGC RT-PCR, Sendai 
virus transgene 
expression SEV_ transgene_rev ACCAGACAAGAGTTTAAGAGATATGTATC 
SOX2 trans_fw ATGCACCGCTACGACGTGAGCGC RT-PCR, Sendai 
virus transgene 
expression SOX2 trans_rev AATGTATCGAAGGTGCTCAA 
KLF4 trans_fw TTCCTGCATGCCAGAGGAGCCC RT-PCR, Sendai 
virus transgene 
expression KLF4 trans_rev AATGTATCGAAGGTGCTCAA 
cMYC trans_fw TAACTGACTAGCAGGCTTGTCG RT-PCR, Sendai 
virus transgene 
expression cMYC trans_rev AATGTATCGAAGGTGCTCAA 
OCT3/4 trans_fw CCCGAAAGAGAAAGCGAACCAG RT-PCR, Sendai 
virus transgene 
expression OCT3/4 trans_rev AATGTATCGAAGGTGCTCAA 
OCT3/4_fw GACAGGGGGAGGGGAGGAGCTAGG qRT-PCR, iPSC 
characterization OCT3/4_rev CTTCCCTCCAACCAGTTGCCCCAAAC 
SOX2_fw GGGAAATGGGAGGGGTGCAAAAGAGG qRT-PCR, iPSC 
characterization SOX2_rev TTGCGTGAGTGTGGATGGGATTGGTG 
NANOG_fw TGCAAGAACTCTCCAACATCCT qRT-PCR, iPSC 
characterization NANOG_rev ATTGCTATTCTTCGGCCAGTT 
REX1_fw ACCAGCACACTAGGCAAACC qRT-PCR, iPSC 
characterization REX1_rev TTCTGTTCACACAGGCTCCA 
TDGF1_fw CCCAAGAAGTGTTCCCTGTG qRT-PCR, iPSC 
characterization TDGF1_rev ACGTGCAGACGGTGGTAGTT 
PDX1_fw AAGCTCACGCGTGGAAAG qRT-PCR, iPSC 
characterization PDX1_rev GGCCGTGAGATGTACTTGTTG 
SOX7_fw TGAACGCCTTCATGGTTTG qRT-PCR, iPSC 
characterization SOX7_rev AGCGCCTTCCACGACTTT 
AFP_fw GTGCCAAGCTCAGGGTGTAG qRT-PCR, iPSC 
characterization AFP_rev CAGCCTCAAGTTGTTCCTCTG 
CD31_fw ATGCCGTGGAAAGCAGATAC qRT-PCR, iPSC 
characterization CD31_rev CTGTTCTTCTCGGAACATGGA 
DESMIN_fw GTGAAGATGGCCCTGGATGT qRT-PCR, iPSC 
characterization DESMIN_rev TGGTTTCTCGGAAGTTGAGG 
ACTA2_fw GTGATCACCATCGGAAATGAA qRT-PCR, iPSC 
characterization ACTA2_rev TCATGATGCTGTTGTAGGTGGT 
SCL_fw CCAACAATCGAGTGAAGAGGA qRT-PCR, iPSC 
characterization SCL_rev CCGGCTGTTGGTGAAGATAC 
MYL2_fw TACGTTCGGGAAATGCTGAC qRT-PCR, iPSC 
characterization MYL2_rev TTCTCCGTGGGTGATGATG 
KRT14_fw CACCTCTCCTCCTCCCAGTT qRT-PCR, iPSC 
characterization KRT14_rev ATGACCTTGGTGCGGATTT 
NCAM1_fw CAGATGGGAGAGGATGGAAA qRT-PCR, iPSC 
characterization NCAM1_rev CAGACGGGAGCCTGATCTCT 
TH_fw TGTACTGGTTCACGGTGGAGT qRT-PCR, iPSC 
characterization TH_rev TCTCAGGCTCCTCAGACAGG 
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GABRR2_fw CTGTGCCTGCCAGAGTTTCA qRT-PCR, iPSC 
characterization GABRR2_rev ACGGCCTTGACGTAGGAGA 
SOX17_fw ACGCCGAGTTGAGCAAGA qRT-PCR, iPSC 
characterization SOX17_rev TCTGCCTCCTCCACGAAG 
GATA6_fw ACCACCTTATGGCGCAGAAA qRT-PCR, iPSC 
characterization GATA6_rev ATAGCAAGTGGTCTGGGCAC 
CDH5_fw TGTCCTTGTCTATTGCGGAGA qRT-PCR, iPSC 
characterization CDH5_rev CCTACCAGCCCAAAGTGTGT 
DES_fw GTGAAGATGGCCCTGGATGT qRT-PCR, iPSC 
characterization DES_rev GGGCTGGTTTCTCGGAAGTT 
TH_fw GCCCTACCAAGACCAGACGTA qRT-PCR, iPSC 
characterization TH_rev CGTGAGGCATAGCTCCTGA 
GABRR2_fw TCACTGGGTATCACGACGGTG qRT-PCR, iPSC 
characterization GABRR2_rev CAGCACCGAGAGGAACACGA 
KRT14_fw CCATTGAGGACCTGAGGAAC qRT-PCR, iPSC 
characterization KRT14_rev CAATCTGCAGAAGGACATTGG 
hPAX6_fw TCAGAGCCCCATATTCGAGC qRT-PCR, iPSC 
characterization hPAX6_rev CAAAGACACCACCGAGCTGA 
NESTIN_fw GAGGTGGCCACGTACAGG qRT-PCR, iPSC 
characterization NESTIN_rev AAGCTGAGGGAAGTCTTGGA 
hWNT3_fw ATCTACGACGTGCACACCTG qRT-PCR, iPSC 
characterization hWNT3_rev TGCTTCCCATGAGACTTCGC 
 
Single-stranded oligodeoxynucleotides (ssODNs) 
ssODN name Sequence (5' to 3') Purpose 
SHOX2_C28T
_ssODN 
ATCGCCGATCTCAGACTGAAAGCCAAAAAGCAC
GCCGCAGCCCTGGGTCTGTGACGCCAACGCCAG
CACCAATGTCGCGCCTGTCCCGCGGCACTCAGCC
TGCACGCCCTCCGCGCCCCGCTGCTTC 
ssODN to correct 
SHOX2 c.*28T>C 
SHOX2_T28C
_ssODN 
ATCGCCGATCTCAGACTGAAAGCCAAAAAGCAC
GCCGCAGCCCTGGGTCTGTGACGCCAACGCCAG
CACCAATGTCGCGCCCGTCCCGCGGCACTCAGCC
TGCACGCCCTCCGCGCCCCGCTGCTTC 
ssODN to insert 
SHOX2 c.*28T>C 
SHOX2_A849
C_ssODN 
CACCCTAGGATAGTCATTGCAACGTGACGCCCTT
GTCCTTTCAGGTTCAGGCGCAGCTGCAGCTGGAC
AGCGCTGTGGCGCACGCGCACCACCACCTGCAT
CCGCACCTGGCCGCGCA 
ssODN to correct 
SHOX2 c.849C>A 
SHOX2_C849
A_ssODN 
CACCCTAGGATAGTCATTGCAACGTGACGCCCTT
GTCCTTTCAGGTTCAGGCGCAGCTGCAGCTGGAC
AGCGCTGTGGCGCAAGCGCACCACCACCTGCAT
CCGCACCTGGCCGCGCA 
ssODN to insert 
SHOX2 c.849C>A 
 
Antibodies 
Target Host Source Catalog number Dilution 
anti-rabbit IgG-
AlexaFluor488 goat Thermo Fisher Scientific A32731 1:500 
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anti-rabbit IgG-
AlexaFluor594 goat Thermo Fisher Scientific A32740 1:500 
NANOG rabbit  Abcam ab21624 1:500 
OCT4 rabbit  Abcam ab19857 1:500 
SOX2 rabbit  Abcam ab137385 1:200 
TRA1-81-
AlexaFluor488 mouse BD Pharmingen 560174 1:20 
 
1.1.8. Databases 
Database name  
1000 genomes http://www.1000genomes.org 
CCTop CRISPR/Cas9 target online 
predictor 
http://crispr.cos.uni-heidelberg.de/ 
Cas-Analyzer http://www.rgenome.net/cas-analyzer/#! 
CHOPCHOP http://chopchop.cbu.uib.no/ 
Heart, Lung, and Blood Institute 
Trans-Omics for Precision Medicine 
program 
https://www.nhlbiwgs.org/ 
Ensembl Genome Browser http://ensembl.org/index.html 
Genecards https://www.genecards.org/ 
gnomAD https://gnomad.broadinstitute.org/ 
GTEx portal: https://gtexportal.org/home/index.html 
GWAS Catalog https://www.ebi.ac.uk/gwas/ 
NCBI http://www.ncbi.nlm.nih.gov/ 
OligoAnalyzer 3.1 https://www.idtdna.com/pages/tools/oligoanalyzer 
Primer3 http://primer3.ut.ee/ 
Primer3plus https://primer3plus.com/ 
QuikChange Primer Design https://www.agilent.com/store/primerDesignProgram.jsp 
SNV lookup https://cadd.gs.washington.edu/snv 
The Human Protein Atlas https://www.proteinatlas.org/ 
UCSC http://genome.ucsc.edu/ 
UCSC in silico PCR http://rohsdb.cmb.usc.edu/GBshape/cgi-bin/hgPcr 
Universal Probe Library Assay 
Design Center 
https://lifescience.roche.com/en_de/brands/universal-
probe-library.html 
Pixabay https://pixabay.com/de/ 
 
1.1.9. Instruments 
Instrument Company 
Automated Inverted Microscope DMI4000B Leica 
DS-11 FX spectrophotometer DeNovix 
Maxisafe 2020 Laminar flow hood Thermo Fisher Scientific 
Microbiological incubator WTB Binder 
QuantStudio3 Applied Biosystems 
QUANTUM Gel Documentation System Peqlab 
QX200 Droplet Generator Bio-Rad 
QX200 Droplet Reader Bio-Rad 
Steri Cult CO2 incubator Thermo Fisher Scientific 
Thermal Cycler Mastercycler pro-vapo protect Eppendorf 
Thermomixer Eppendorf 
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1.2. Zebrafish-based Methods 
Zebrafish experiments were performed in collaboration with AG Just by Dr. Christoph Paone and 
Sabrina Diebold (Department of Internal Medicine II, University of Ulm, Ulm, Germany). 
Care and breeding of zebrafish, Danio rerio, was done as described previously.116 The TE4/6 
wildtype strain was used for all injection procedures. 20 ng/μl of pDestTol2CG2-empty, 
pDestTol2CG2-SHOX2 wildtype, or pDestTol2CG2-SHOX2 mutant was microinjected into one-
cell-stage embryos for overexpression experiments as previously described.22,28 Morphological 
analysis and heart rates were determined 72 hours post fertilization (hpf). For target gene expression 
using nCounter technology, hearts were isolated 72 hpf as well.1  
 
1.3. DNA-based Methods 
1.3.1. Polymerase chain reaction (PCR) 
For subsequent applications such as cloning, sequencing and expression analysis, DNA 
amplification was performed with PCR according to manufacturer’s instructions. See Table A and 
Table B for reaction composition. 
 
Component Final concentration   Program   
10x PCR Buffer 1x         
dNTP mix (10 mM each) 200 µM of each dNTP  95°C 15 min   
Fw+rev Primer (10 µM each) 0.1-0.5 µM  94°C 30 s x30 
HotStarTaq DNA Polymerase 2.5 units/reaction  60°C 30 s   
Template DNA 50-200 ng  72°C 1 min   
H2O ad total volume variable  72°C 10 min   
Total volume Variable (25 or 100 µl)         
Table A: standard reaction composition using the HotStarTaq DNA Polymerase according to the HotStarTaq® PCR 
Handbook (10/2010 ©2007-2010 QIAGEN) 
 
Component Final concentration   Program   
5x Q5 Reaction Buffer 1x         
dNTP mix (10 mM each) 200 µM of each dNTP  98°C 30 sec   
Fw+rev Primer (10 µM each) 0.5 µM  98°C 10 s x30 
Q5 High-Fidelity DNA Polymerase 0.02 U/µl  60°C 30 s   
Template DNA 50-200 ng  72°C 30 s/kb   
H2O ad total volume variable  72°C 2 min   
Total volume Variable (25 or 50 µl)         
Table B: standard reaction composition using the Q5® High-Fidelity Polymerase according to the Datasheet for Q5® 
High-Fidelity DNA Polymerase (M0491) 
 
1.3.2. Agarose gel electrophoresis 
Agarose gels were run for size separation and gel extraction of PCR product and digested DNA 
vectors. Depending on the expected fragment sizes, 1-2% agarose gels were run at 80-120 V for 
30-120 min. For size comparison, GeneRuler™ 100 bp or 1 kb Plus DNA Ladders were loaded on 
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the gel in addition to the samples. DNA was stained with Midori Green advanced or ethidium 
bromide and visualized under UV light. 
 
1.3.3. Plasmid DNA and PCR fragment purification 
PCR fragments were purified with the QIAquick® PCR Purification Kit as described in the 
QIAquick® Spin Handbook 03/2008. Small scale extraction of plasmid DNA was performed from 
5 ml bacteria LB culture using the GeneJET Plasmid Miniprep Kit (for details see Thermo Scientific 
GeneJET Plasmid Miniprep Kit Quick protocol, ©2012 Thermo Fisher Scientific Inc.). Large scale 
extraction of plasmid DNA was performed from 50 ml bacteria LB culture using the ZymoPURE™ 
II Plasmid Midiprep Kit with the vacuum protocol (for details see Instruction Manual 
ZymoPURE™ II Plasmid Midiprep Kit, version 1.2.0). The DNA was eluted in H2O or the included 
elution buffer and subsequently stored at -20°C. 
 
1.3.4. Restriction digestion 
DNA vectors and PCR fragments were digested with FastDigest® restriction enzymes according to 
the recommendations. 
 
1.3.5. Dephosphorylation 
Digested DNA vectors were dephosphorylated with FastAP Thermosensitive Alkaline Phosphatase 
to prevent re-ligation according to manufacturer’s instruction (for details see manual Thermo 
Scientific FastAP Thermosensitive Alkaline Phosphatase, MAN0012876, Rev. B.00). 
 
1.3.6. Ligation 
Purified inserts and vectors were mixed in a molar ratio of 1:3 and ligated using T4 DNA Ligase 
according to manufacturer’s instructions (for details see manual DNA Insert Ligation (sticky-end 
and blunt-end) into Vector DNA, Thermo Fisher Scientific). 
 
1.3.7. Gateway® gene cloning 
Cloning of SHOX2 into the pDONR™221 vector and subsequent generation of SHOX2 
overexpression constructs for zebrafish was done by Sandra Hoffmann (Department of Human 
Molecular Genetics, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany) 
using the Gateway® cloning system. For details to reaction setups, transformation and clone 
selection see User Guide Gateway® pDONR™ vectors, MAN0000291, Publication Part number 
25-0531, Rev 29 March 2012. 
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1.3.8. Site-directed mutagenesis 
Patient-specific mutations were introduced in a pDest27 or pDestTol2CG2 vector containing the 
SHOX2 wildtype sequence with the QuikChange Lightning Site-Directed Mutagenesis Kit. Primer 
design and reaction setup were carried out following the manufacturer’s manual (for details see 
QuikChange Lightning Site-Directed Mutagenesis Kit, Instruction Manual 210518-12 Revision 
F.0). 
 
1.3.9. Transformation 
Chemically competent cells were prepared with the Mix & Go E.coli Transformation Kit and Buffer 
Set following the provided protocol (for details see Mix & Go E.coli Transformation Kit and Buffer 
Set, Instruction Manual, Ver. 1.0.7). E. coli were transformed with plasmids and ligations mixes: 
• Add 1-2 μl ligation or <1 ng plasmid DNA to 100 µl of thawed cells 
• Mix carefully and incubate 5-10 min on ice 
• Add 500 μl of pre-warmed SOC medium 
• Incubate cells 30-60 min at 37°C in a bench shaker at 300 rpm 
• Distribute 10-100 µl of bacteria on pre-warmed LB-agar plates with glass beads containing 
appropriate selection antibiotics and grow overnight at 37°C. 
 
1.3.10. Genomic DNA (gDNA) extraction and purification 
Genomic DNA was extracted from pelleted cells either directly after centrifugation or from snap-
frozen cell pellets using the Quick-DNA™ Miniprep Plus Kit according to manufacturer’s 
instructions (for details see Instruction Manual Quick-DNA™ Miniprep Plus Kit, version 1.2.1). 
For high throughput (96-well) DNA purification from iPSC sib-selections (see chapter 1.3.10), the 
Quick-DNA™ 96 Plus Kit was used (for details see Instruction Manual Quick-DNA™ 96 Plus Kit, 
version 1.1.0). The purified DNA was eluted in TE buffer or H2O and stored at -20°C. 
 
1.3.11. DNA quantification 
Double-stranded DNA was quantified and tested for purity with the NanoDrop 1000 system or the 
DeNovix system according to manufacturer’s instructions. For precise measurements, DNA was 
analyzed with the Qubit™ dsDNA BR Assay Kit according to manufacturer’s instructions (see 
Qubit® dsDNA BR Assay Kits, MAN0002325, Revision A.0) on the Qubit® 2.0 Fluorometer using 
1 µl DNA solution as input. 
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1.3.12. Digital PCR (dPCR) 
Relative allele quantification in sib-selections was performed with dPCR, here ddPCR™. Allele-
specific TaqMan probes were used to discriminate wildtype from mutant alleles in SHOX2 
c.*28T>C and SHOX2 c.849C>A iPSC clones. SHOX2 c.*28T and SHOX2 c.849C alleles were 
referred to as “WT alleles” and SHOX2 c.*28C and SHOX2 c.849A as “Mut alleles”, respectively. 
The dPCR reaction was prepared with the ddPCR™ Supermix for probes as described in the official 
protocol in PCR 8-tube strips (for details see ddPCR™ Supermix for Probes, 10026235 Rev C). 1 
µl FastDigest HindIII enzyme was included in the PCR reaction to improve droplet generation. The 
composition of the Primer/Probe mix and the dPCR reaction is listed in Table C and Table D 
respectively. 
 
Component Volume per reaction [µl] Final concentration 
dPCR primer fw [100 µM] 18 18 µM 
dPCR primer rev [100 µM] 18 18 µM 
FAM TaqMan probe [100 µM] 5 5 µM 
HEX TaqMan probe [100 µM] 5 5 µM 
H2O ad total volume 54 - 
Total volume 100 - 
Table C: Primer/Probe mix for 100 µl dPCR reactions 
 
Component Volume per reaction [µl] 
Final 
concentration   
Program 
  
2x ddPCR™ Supermix for probes 11 1x     
20x target primer/probe mix 
(FAM/HEX) 1.1 
900 nM/250 
nM  
95°C 10 min   
FastDigest HindIII 1.1 1x  94°C 30 sec x40 
Template DNA (50-150 ng/reaction) 1.1 - 8.8 2.5 - 7.5 ng/µl  65°C 1 min 
H2O ad total volume variable variable  98°C 10 min   
Total volume 22 -         
Table D: standard dPCR reaction composition. The final volume of 22 µl includes 10% excess. 20 µl of the PCR mix 
are used for the droplet generation. A ramp rate of 2°C/sec was set for the PCR program. 
 
The dPCR reaction was pipetted under sterile conditions in a PCR UV cabinet. The preparation of 
PCR samples for droplet generation took place at the QX200™ Droplet Generator. The dPCR 
droplet generation was performed at the Dept. of Infectious Diseases, Virology, Heidelberg 
University Hospital (under supervision of Dr. Kathleen Börner and Prof. Dirk Grimm). Rainin LTS 
pipets and tips were used during this process exclusively in accordance with manufacturer’s 
recommendations. The dPCR setup in detail: 
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• Mount DG8™ cartridge in DG8™ cartridge holder 
• Pipet 70 µl of droplet generation oil for probes in the respective wells of the DG8™ 
cartridge 
• Vortex and spin down prepared dPCR samples in PCR 8-tube strips 
• Pipet 20 µl of each dPCR sample in the respective wells of the DG8™ cartridge 
• Span DG8™ gasket over DG8™ cartridge and load into QX200™ Droplet generator 
• After droplet generation, load 42 µl of droplet suspension into dPCR 96-well plate 
• Seal plate with pierceable foil heat seal for 5 sec at 180°C in PX1™ PCR plate sealer 
• Immediately load plate into C1000 Touch™ Thermal Cycler and run PCR program 
• After end-point PCR, span the dPCR 96-well plate into QX200™ Droplet Reader and load 
prepared template into QuantaSoft™ Software (version 1.7.4.0917) 
• Start dPCR Droplet Readout 
For details to dPCR template generation and analysis of the results see chapter 1.6.1 
 
1.3.13. Sanger Sequencing 
Sanger Sequencing of cloning constructs and PCR products was carried out by GATC (Ebersberg), 
EUROFINS (Ebersberg) and GENEWIZ (Leipzig). Samples were prepared according to company’s 
guidelines. 
 
1.3.14. Next generation sequencing (NGS) (sample preparation of sib-
selections 
The sib-selections with the highest abundance of WT alleles, as detected by dPCR, were analyzed 
in depth via next generation sequencing. DNA was extracted from thawed sib-selections. A PCR 
was done in duplicates using the Q5® high fidelity DNA Polymerase with 100-200 ng gDNA input 
and 30 reaction cycles. The PCR products were pooled, purified with the QIAquick® PCR 
Purification Kit and sent for NGS to GENEWIZ (Leipzig). 
 
1.3.15. directPCR® lysis and genotyping 
iPSC colonies derived from single cell-cloning were screened for SHOX2 c.*28T homozygosity 
with a TaqMan probe-based genotyping assay. The protocol was adapted from the TaqPath™ 
ProAmp™ Master Mixes User Guide. 50% iPSCs of a 96-well were lysed in 70 µl of directPCR® 
lysis reagent and with 0.2 mg/ml Proteinase K at 55°C for 16h. The Proteinase K was subsequently 
inactivated at 85°C for 45 min. The cell lysate was used directly for genotyping without further 
dilution. The 20x target primers/probes mix was generated as described in Table 1.3. The 
genotyping reaction composition is listed in Table E. Samples were run in duplicates; gDNA from 
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homozygous wildtype iPSC clones (control clones) and heterozygous SHOX2 c.*28T>C iPSC and 
SHOX2 c.849C>A clones (patient-specific clones) were used as positive and negative control, 
respectively. 
 
Component Volume per reaction [µl] 
Final 
concentration   Program   
2x TaqPath™ ProAmp™ Master 
Mix 5 1x 
 60°C 30 sec   
20x target primers/probes 
(FAM/HEX) 0.5 900 nM/250 nM 
 95°C 5 min   
directPCR® cell lysate 2.5 ≤25%  95°C 5 sec 
x40 
H2O ad total volume 2 -  60°C 30 sec 
Total volume 10 -   60°C 30 sec   
Table E: standard genotyping reaction composition for the 96-well format. 
 
1.3.16. The Multiplex Human Cell Line Authentication Testing 
To exclude cross contaminations with other cell lines and to verify a common origin of all patient-
specific iPSC clones and their respective isogenic controls, cell lines were authenticated using 
Multiplex Cell Authentication (MCA) by Multiplexion (Heidelberg, Germany) as previously 
described.117 15 µl of genomic DNA with a concentration of 15-30 ng/µl was provided as requested 
by the company. Single Nucleotide Polymorphism (SNP) genotyping was performed on 48 loci and 
the resulting SNP profile compared to the company’s reference database. 
 
1.4. RNA-based methods 
1.4.1. In vitro gRNA synthesis 
The gRNAs for the electroporation of Cas9 RNP/gRNA complexes was synthesized in vitro with 
the GeneArt™ Precision gRNA Synthesis Kit according to the manufacturer’s manual (for details 
see GeneArt™ Precision gRNA Synthesis Kit user guide). Primers were designed as described. The 
lyophilized and desalted Primers were diluted in Nuclease-free water. The purified gRNA was 
diluted in nuclease-free water to a concentration of 500-1000 ng/µl and measured with the Qubit™ 
RNA BR Assay Kit on the Qubit™ 2.0 Fluorometer using a 1 µl of a 1:100 diluted gRNA as input 
(for details see Qubit® dsDNA BR Assay Kits, MAN0002325, Revision A.0). 
 
1.4.2. RNA isolation from zebrafish hearts 
Total RNA from Zebrafish hearts 72 hpf was isolated with the Direct-zol™ RNA Microprep Kit 
(Zymo Research) according to manufacturer’s instructions (for details see instruction manual 
Direct-zol™ RNA MicroPrep Ver.1.0.0).1 
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1.4.3. RNA isolation from iPSCs 
For RNA extraction from cultured iPSCs, cells were pelleted, resuspended in TRIzol™ and either 
stored at -80°C or immediately processed. After adding 200 µl of chloroform per 1 ml TRIzol™, 
samples were vortexed thoroughly and incubated at RT for 5 min. The aqueous phase containing 
RNA was separated from the organic phase by centrifugation for 5 min and 12,000 g at 4°C and 
transferred into a new 1.5 ml tube. 10 µg of glycogen and 500 µl of isopropanol per 1 ml TRIzol™ 
were added and the solution was mixed by inversion. The samples were incubated for 60 min at RT 
and centrifuged for 10 min and 12,000 g at 4°C. After removal of the supernatant, the RNA pellet 
was washed twice by addition of 1 ml 75% EtOH (-20°C), vortexing and subsequent centrifugation 
for 5 min and 7,500 g at 4°C. The pellet was air-dried for 10 min and resuspended in 20 µl RNAse-
free water. RNA concentration and purity were determined on a DeNovix DS-11 
spectrophotometer. 
For the characterization of patient-specific iPSC lines, the RNA was extracted with TRIzol™ 
reagent or Absolutely RNA Miniprep Kit in collaboration with Dr. Svenja Laue, Birgit Campbell, 
Dr. Tatjana Dorn and Alessandra Moretti (First Department of Medicine, Cardiology, Klinikum 
rechts der Isar – Technical University of Munich, 81675 Munich, Bavaria, Germany). 
 
1.4.4. qRT-PCR 
cDNA reverse transcription was performed using the SuperScript III First-Strand Synthesis Kit 
(Invitrogen) with 1 μg of RNA as input. For semi-quantitative analysis, 1 µl cDNA was subjected 
to PCR reaction using Taq polymerase (Thermo Fisher Scientific). For qRT-PCR analysis, 1-2 μl 
cDNA and the Power SYBR Green PCR Master Mix (Applied Biosystems) or the qPCRBIO 
SyGreen Mix (Nippon Genetics) were used. Real-time quantitative PCR (qPCR) was conducted on 
a QuantStudio3 System (Thermo Fisher Scientific). All samples were measured in duplicates and 
the relative gene expression levels were normalized to the reference genes SDHA and HPRT1 or 
GAPDH using the Relative Standard Curve Method or semi-quantitively. 
 
1.4.5. nCounter expression analysis 
For Bmp4 expression analysis in zebrafish, 40 hearts from two independent experiments were 
pooled per condition to obtain 50 ng of input material. The procedure was performed by the 
nCounter Core Facility Heidelberg using the nCounter SPRINT Profiler. The workflow is described 
in detail at http://www.nanostring.com/elements/workflow. Background correction and 
normalization of data was performed using the nSolver Analysis Software 4.0 (NanoString 
Technologies). The most stable expressed genes were chosen for normalization based on the 
geNorm method.1 
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1.5. Cell-based Methods 
1.5.1. Cultivation and passaging of HEK293T cells 
HEK293TN cells (BioCat) were maintained in DMEM high glucose medium supplemented with 
10% FCS and 100 U/ml Pen-Strep at 37°C, 5% CO2 in a humidified atmosphere. Cells were 
passaged every 3-4 days by aspiration of culturing medium, washing cells once in pre-warmed PBS 
and adding 0.05% Trypsin-EDTA. Cells were incubated until detachment from the culturing flask. 
Trypsinization was stopped by addition of pre-warmed culturing medium and a fraction of the cell 
suspension was seeded on new flasks. 
 
1.5.2. PEI transfection for luciferase assays 
HEK293TN cells were co-transfected with the BMP4 pGL3-basic reporter construct (1 µg) together 
with SHOX2 WT or mutant expression constructs (1 µg) and TK-Renilla Firefly (500 ng) using 
PEI at a DNA:volume ratio of [1µg]:[3µl]. Transfections were performed in the 6-well format. Cells 
were subjected to passive cell lysis 24h after transfection.19 
 
1.5.3. Luciferase Assay 
Luciferase reporter assays were performed with the Dual-Luciferase® Reporter Assay System 
(Promega) according to the manufacturer’s protocol (for details see Technical Manual, TM040, 
Revised 06/15). In brief: 24h after transfection, cells were washed twice with PBS and lysed with 
150 µl (6-well format) of Passive Lysis Buffer per well. For lysis, cells were incubated for 15 min 
at RT and subjected to one freeze/thaw cycle at -80°C before analysis. Cell lysates were scraped 
off the culturing plate with a pipette tip and aliquoted in white 96-well polypropylene flat bottom 
plates (Greiner Bio-Rad). Luciferase activity was measured in a Berthold Centro LB 960 
Luminometer. Experiments were performed independently four times with technical triplicates for 
each sample. 
 
1.5.4. Generation of patient-specific iPSC lines 
AF patients carrying the SHOX2 mutations were recruited by Prof. Stefan Kääb and Dr. Sebastian 
Clauss (First Department of Medicine, Cardiology, Klinikum rechts der Isar – Technical University 
of Munich, 81675 Munich, Bavaria, Germany). Peripheral blood mononuclear cells (PBMCs) were 
isolated and reprogrammed into iPSCs in collaboration with Dr. Svenja Laue, Dr. Tatjana Dorn, 
Birgit Campbell, Prof. Alessandra Moretti and Prof. Karl-Ludwig Laugwitz (First Department of 
Medicine, Cardiology, Klinikum rechts der Isar – Technical University of Munich, 81675 Munich, 
Bavaria, Germany) using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Life Technologies), 
as previously described.56  
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1.5.5. Conditions for standard iPSC cultivation and differentiation 
Standard cultivation of iPSCs was performed with 5% CO2 at 37°C in a humidified atmosphere. 
Cells were regularly tested for mycoplasma contamination by colleagues using the Venor®GeM 
Classic Kit according to manufacturer’s instructions (for details see Venor®GeM Classic 
Instructions for Use, Document Version 32). Contaminated cell lines were treated with 
Plasmocin™ (1:1,000) in culturing medium for 2-3 weeks and re-tested before usage in 
differentiation and gene editing. 
 
1.5.6. Colony-based cultivation and small clump-passaging of iPSCs with Essential 
8™ and EDTA 
Colony-based cultivation of iPSCs in Essential 8™ on Geltrex™ LDEV-free, hESC-qualified, 
Reduced Growth Factor Basement Membrane matrix (1:100) was done following manufacturer’s 
recommendations (for details see Essential 8™ Medium, Publication Number MAN0007569, 
Revision 3.0). Every 3-4 days or upon 70-80% confluency, cells were washed twice with pre-
warmed DPBS and incubated in 0.5 mM UltraPure™ EDTA at room temperature (RT) for 7-10 
min. After aspiration of EDTA, cells were resuspended with a 5 ml Stripette™ in 1 ml Essential 
8™ supplemented with 10 μM Y-27632 and split 1:6-1:20 into new 3.5 cm dishes. Y-27632 was 
removed 24h after splitting. 
 
1.5.7. Single cell-based cultivation and passaging of iPSCs with StemFit® 
Cells were grown in StemFit® supplemented with 100ng/ml bFGF on Geltrex™ LDEV-free, hESC-
qualified, Reduced Growth Factor Basement Membrane matrix (1:100) according to manufacturer’s 
instructions. After reaching 70-85% confluency, cells were passaged following this protocol: 
• Wash 2x with pre-warmed DPBS 
• Add pre-warmed TrypLE™ Express 
• Incubate at 37°C, 5% CO2 for 5-10 min 
• Resuspend cells in TrypLE™ Express and transfer to 50 ml conical Falcon™ 
• Dilute cell suspension 1:10 with pre-warmed DMEM/F12(1:1) 
• Centrifuge at 200 g for 5 min in swing-bucket rotor centrifuge 
• Remove supernatant and resuspend cells in pre-warmed StemFit® supplemented with 100 
ng/ml bFGF and 10 µM Y-27632 
• Count cells in Neubauer counting chamber and seed 1,000-2,000 cells/cm2 on a new 
Geltrex™-coated dish 
• Cultivate cells for ≥24h in StemFit® 100 ng/ml bFGF and 10 µM Y-27632 before removing 
the ROCK inhibitor 
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1.5.8. Freezing of iPSCs  
iPSCs were frozen at 70-85% confluency. The standard splitting protocol was used to generate the 
cell suspension. After centrifugation, the supernatant was removed, and the cell pellet was 
resuspended in 1 ml of Bambanker™ (single cell suspensions) or mFreSR™ (colony fragment 
suspensions). The freezing suspension was transferred to a 1.5 ml cryogenic vial and gradually 
frozen (-1 °C/min) in a Nalgene freezing container at -80°C. 24-48h after freezing, the vial was 
transferred to liquid nitrogen tanks. 
 
1.5.9. Thawing of iPSCs 
For thawing of iPSCs, cryogenic vials were taken from the liquid nitrogen tank and thawed in a 
37°C water bath until only small ice crystals remained. The cell suspension was transferred to a 50 
ml conical Falcon™. 5 ml of DMEM/F12(1:1) supplemented with 100 ng/ml bFGF and 10 µM Y-
27632 was added dropwise to the suspension while gently shaking the tube. After centrifugation at 
200g for 5 min, the supernatant was removed, and the cell pellet was resuspended in in culturing 
medium and 10 µM Y-27632. For cultivation in Essential 8™, all cells were seeded on a Geltrex™-
coated dish. For cultivation in StemFit®, cells were counted and three times the number of cells that 
are used for routine splitting (3,000-18,000 cells/cm2) were seeded on a Geltrex™-coated dish. 
 
1.1.1. Spontaneous differentiation of iPSCs 
Spontaneous differentiation of iPSCs into cells of all three germ layers was induced by embryoid 
body (EB) formation, as previously reported.56 In brief: Cells were washed twice with pre-warmed 
DPBS and incubated with 0.6 ml/plate Dispase (1 U/ml) for 5 min at 37°C. Upon removal of the 
enzyme, cells ware washed with 3 ml/plate DMEM/F12 (1:1). Cells were detached from the plate 
in 2 ml DMEM/F12 (1:1) with cell scrapers, transferred to a Falcon™ tube and centrifuged at 200 
g for 5 min. The colony fragments were resuspended using 5 ml Stripette™ tips in Essential 8™ 
containing 10 μM Y-27632 and transferred to a Poly-HEMA-coated dish to prevent adherence (day 
0 of differentiation). Floating EBs were incubated for 72h under standard conditions. On day 3 of 
differentiation, medium was changed to EB-20 medium containing 50 µg/ml L-ascorbic acid. For 
this, EBs were pelleted by gravity in a Falcon™ tube and washed in 2 ml EB-20 medium. The 
washing medium was removed after cell clumps had sunk to the bottom and replaced by fresh EB-
20 for continued cultivation in the Poly-HEMA-coated dishes. The medium was changed on day 5. 
On day 7, floating embryoid bodies were plated on gelatin-coated 4-well plates at densities 15-25 
EBs per well in EB-20 supplemented with 50 µg/ml L-ascorbic acid (for coating purposes, plates 
were incubated with 0.5 ml/well 0.1 % gelatin in DPBS for ≥30 min). From day 12 onwards, 
differentiations were screened for the appearance of spontaneously beating cardiomyocyte clusters 
that were manually excised using fine cannulas. For RNA extraction and qPCR analysis of germ 
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layer markers during the (re-)characterization of iPSC lines, cells were harvested on day 21 in 
TRIzol™ Reagent (See Master Thesis Viktoria Frajs, SHOX2 in atrial fibrillation disease 
modelling using induced pluripotent stem cells) 
 
1.5.10. Transfection of iPSCs 
iPSCs were transfected with plasmid DNA, gRNA, RNPs and ssODNs with the 4D-Nucleofector™ 
System according to Lonza’s official guidelines, as described in the 4D-Nucleofector™ System 
Manual (CD-MN025 04/16, ©Lonza 2016) and the Genome Editing using Nucleofector™ 
Technology Technical Reference Guide (CD-DS021 02/15, ©Lonza 2015). In detail, the following 
protocol was used: 
 
GFP Control Cas9 (plasmids) Cas9 (RNP/gRNA) 
500 ng of pmaxGFP® 500 ng Cas9/gRNA vector 1 µg of Platinum™ Cas9 RNP 
(provided in the kit) + 50-200 pmol ssODN + 250 ng synthesized gRNA 
  + 50-200 pmol ssODN  
 
• Treat cells ≥1h before transfection with 10 µM Y-27632  
• Wash 2x with pre-warmed DPBS 
• Add pre-warmed TrypLE™ Express 
• Incubate at 37°C, 5% CO2 for 5-10 min 
• Resuspend cells carefully in TrypLE™ Express (check complete dissociation to single cells 
under microscope) and transfer to 50 ml Falcon™ 
• Dilute cell suspension 1:10 with pre-warmed DMEM/F12(1:1) 
• Centrifuge at 200 g for 5 min in swing-bucket rotor centrifuge 
• In case of RNP/RNA transfection: Meanwhile prepare Cas9 RNP/gRNA complexes by 
mixing 1 µg of GeneArt™ Platinum™ Cas9 Protein with 250 ng of synthesized gRNA in 
5 µl of P3 transfection buffer in 1.5 ml Eppendorf tubes (complexes are formed after 5 min 
and stable for 30 min). For the transfection control condition prepare 500ng of pmaxGFP® 
vector in 5 µl of P3 transfection buffer in a 1.5 ml Eppendorf tube. 
• Remove supernatant and resuspend cells in pre-warmed StemFit supplemented with 100 
ng/ml bFGF and 10 µM Y-27632 
• Count cells in Neubauer counting chamber and transfer 2.0-5.0*105 cells per condition to 
15 ml Falcon™ 
• Centrifuge at 200 g for 5 min in swing-bucket rotor centrifuge 
• Remove supernatant completely and resuspend cells in 15 µl P3 transfection buffer per 
condition 
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• Mix 15 µl of cell suspension with prepared Cas9 RNP/gRNA complexes or plasmid DNA 
and immediately transfer to one well of a 16-stripe (avoid air bubbles!) 
• Transfer cells into the 4D-Nucleofector™ X Unit and start program DN-100 
• Add StemFit® supplemented with 100 ng/ml bFGF and 10 µM Y-27632 and transfer whole 
cell suspension into one well of a 24-well plate coated with Geltrex™ (1:100) 
• Check for transfection rate 24-48h after transfection 
 
1.5.11. Sib-selection of transfected iPSCs 
Transfected iPSCs were seeded in small pools of 200 cells per well (sib-selection) on 96-well plates 
48h after transfection with Cas9 RNP/gRNA complexes, as previously described102. The standard 
splitting protocol was used to generate a cell suspension of 4000 cells/ml in bFGF containing 100 
ng/ml bFGF and 10 µM Y-27632. 50 µl cell suspension per well (200 cells/well) were plated with 
a multichannel pipet on a Geltrex™-coated 96-well plate already containing 50 µl culturing media. 
The first medium change without Y-27632 was carried out after 2 days. Subsequently, the cells 
were fed every 2-3 days until they reached the desired confluency. 
 
1.5.12. Freezing/DNA extraction of sib-selections 
After reaching 70-90% confluency (~7-9 days after seeding), sib-selections were further processed. 
Multichannel pipets were used for the pipetting steps. Cells were washed 2x with 100 µl/well DPBS 
and treated with 30 µl/well TrypLE™ Express. After incubation for 5-10 min at 37°C and 5% CO2, 
15 µl of TrypLE™ cell suspension was mixed with 35µl of DPBS and then used for DNA extraction 
with the Quick-DNA™ 96 Plus Kit (see chapter 1.3.10), while the remaining half of the cell 
suspension was mixed with 85 µl Bambanker™ in the original plate and frozen at -80°C in a 
Styrofoam container. 
 
1.5.13. Thawing of sib-selections 
Upon identification of sib-selections with a high abundance of WT alleles via dPCR, frozen cells 
in 96-well plates were thawed in the incubator at 37°C, 5% CO2 for 10-15 min. The 100 µl cell 
suspensions were transferred to a 15 ml conical Falcon™ and diluted with 1 ml of DMEM/F12(1:1) 
containing 10 µM Y-27632. After centrifugation (200 g, 5 min), the cell pellets were resuspended 
in 100 µl StemFit supplemented with 100 ng/ml bFGF and 10 µM Y-27632 and completely 
transferred to a Geltrex™-coated 96-well plate. 
 
1.5.14. Single cell-cloning of iPSCs 
iPSC sib-selections, in which a subpopulation of isogenic WT cells (homozygous for SHOX2 
c.*28T or SHOX2 c.849C)) was identified via NGS and dPCR, were used for single cell-cloning. 
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The protocol was modified from the manufacturer’s StemFit® Technical tips manual. The method 
is based on limited dilution. In detail: 
• Thaw 200 µl Geltrex™ per 96-well plate to be seeded on ice 
• Wash 2x with pre-warmed DPBS 
• Add pre-warmed TrypLE™ Express 
• Incubate at 37°C, 5% CO2 for 5-10 min 
• Resuspend cells carefully in TrypLE™ Express (check complete dissociation to single cells 
under microscope) and transfer to 50 ml Falcon™ 
• Dilute cell suspension 1:10 with pre-warmed DMEM/F12(1:1) 
• Centrifuge at 200 g for 5 min in swing-bucket rotor centrifuge 
• Remove supernatant and resuspend cells in pre-warmed StemFit® supplemented with 100 
ng/ml bFGF and 10 µM Y-27632 
• Prepare 10 ml of a 10 cells/ml cell suspension by serial dilution with StemFit® 
supplemented with 100 ng/ml bFGF and 10 µM Y-27632 
• Pipet 200 µl ice-cold Geltrex™ to cell suspension and immediately transfer whole mixture 
into pipetting reservoir (Geltrex™ polymerizes within 5 min at ≥15°C) 
• Plate 100 µl (= 1 cell/well) into each well of an uncoated 96-well plate 
• Change medium after 72h for the first time and subsequently every other day until cells are 
ready for passaging 
• Split cells 1:1 into a new Geltrex™-coated 96-well after 7-8 days 
• After reaching 70-85% confluency, 50% of the cells were split onto a Geltrex™-coated 24-
well plate while the other 50% was subjected to directPCR lysis and subsequent genotyping 
(see chapter 1.3.15) 
 
1.5.15. Karyotyping 
For karyotyping of the patient-derived iPSC lines, cells were arrested in metaphase with N-
desacetyl-N-methylocolchicine (KaryoMAX™ Colcemid™ solution). The metaphase preparation 
was provided to Brigitte Schoell (Department of Human Genetics, Institute of Human Genetics, 
University of Heidelberg, 69120 Heidelberg, Baden-Wuerttemberg, Germany) for multiplex in situ 
hybridization (M-FISH) and imaging. Ten metaphases were analyzed, and representative pictures 
were prepared by Prof. Anna Jauch (Department of Human Genetics, Institute of Human Genetics, 
University of Heidelberg, 69120 Heidelberg, Baden-Wuerttemberg, Germany). The protocol for 
chromosomal preparation in detail: 
 
• Culture iPSCs in 3-4 wells of a 6-well plate for each metaphase preparation 
• Change culturing medium 24h before starting Colcemid™ treatment 
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• Treat cells with 0.08 µg/ml Colcemid™ (1:125 dilution of 10 µg/ml stock) for 17h 
• Remove medium and wash cells 1x in prewarmed DPBS (collect DPBS afterwards in 15 
ml Falcon™) 
• Add 1 ml of Accumax™ per well and incubate cells at 37°C for 5 min 
• Collect Accumax™ solution in the 15 ml Falcon™ 
• Wash wells with 2 ml DPBS each and add to the 15 ml Falcon™ 
• Centrifuge cell suspension at 300 g for 10 min, RT 
• remove supernatant, leaving about 0.5 ml above the cell pellet, re-suspend cell pellet by 
tapping the tube 
• Add 10 ml of hypotonic solution (1:1 mixture of 0.55% KCL and 1% Na Citrate) slowly 
while vortexing carefully and mix by inverting the tube 
• Incubate at 37°C for 20 min 
• Add 2 ml of fixative (methanol / glacial acetic acid, 3:1 v:v, precooled at -20°C) to 
hypotonic solution 
• Centrifuge at 300 g for 10 min, RT 
• Remove supernatant down to 3-5 ml, and resuspend cell pellet 
• Add 10 ml of fixative slowly while vortexing carefully and mix by inverting the tube 
• Centrifuge at 300 g for 10 min, RT 
• Repeat fixation procedure 3 times using the same volume fixative 
• Transfer suspension to a new 15 ml Falcon™ tube 
• Store cells in fixative at -20°C 
 
For karyotyping by G banding, chromosomes were obtained according to routine procedures and 
based on previously published protocols by Karin Hüllen and Alexandra Köppel (Department of 
Human Genetics, Institute of Human Genetics, University of Heidelberg, 69120 Heidelberg, Baden-
Wuerttemberg, Germany). Karyograms were made of trypsin giemsa-stained metaphases and 
analyzed by Prof. Hans Janssen (Department of Human Genetics, Institute of Human Genetics, 
University of Heidelberg, 69120 Heidelberg, Baden-Wuerttemberg, Germany). 
 
1.5.16. Immunofluorescence staining 
For the expression analysis of pluripotency markers during iPSC line (re-)characterization, cells 
were grown on Geltrex™-coated coverslips. Upon colony forming, they were fixed with 4% PFA 
for 15 min at RT and washed 3 times shortly in DPBS afterwards. 
For the initial characterization, cells were subjected to simultaneous permeabilization and blocking 
with 10% normal goat serum in DPBS/0.1% Triton-X-100 for 1 h at 37°C. Cells were stained with 
Material and Methods 
42 
primary antibodies for NANOG, TRA1-81, OCT4 and SOX2 in PBS/0.1% Triton-X-100 
containing 1% goat serum overnight at 4°C. After 5 washes in DPBS (3x 3 min, 2x shortly), 
incubation with AlexaFluor488- and AlexaFluor-594-conjugated secondary antibodies (Thermo 
Fisher Scientific) specific to the appropriate species was done in PBS/0.1% Triton-X-100 
containing 1% goat serum for 1 h at 37°C. Nuclei were detected with 1 μg/ml Hoechst 33258. 
For the re-characterization of isogenic clones, cells were permeabilized for 10 min at 4°C with 0.1% 
Triton X-100 in DPBS. Subsequently, they were blocked in 1% BSA in DPBS for 1 h at RT and 
incubated with primary antibodies in blocking solution for 1 h at RT. After 3 washes in DPBS for 
5 min each, cells were incubated with respective secondary antibodies in blocking solutions for 1 h 
at RT. Nuclei were counterstained with Hoechst 33342 (1:5000). 
The Immunofluorescence staining for the initial characterization was done in collaboration with 
AG Moretti by Dr. Svenja Laue, Dr. Tatjana Dorn and Birgit Campbell (First Department of 
Medicine, Cardiology, Klinikum rechts der Isar – Technical University of Munich, 81675 Munich, 
Bavaria, Germany). The immunofluorescence staining for the re-characterization was done by 
Viktoria Frajs under supervision (See Master Thesis Viktoria Frajs, SHOX2 in atrial fibrillation 
disease modelling using induced pluripotent stem cells). Images were taken on a Leica DMI4000 
B fluorescence microscope with a Leica DFC3000 G camera system using 10x, 20x and 40x 
objectives. 
 
1.5.17. Alkaline Phosphatase (ALP) staining 
The newly generated iPSC lines were stained for alkaline phosphatase activity using the NBT/BCIP 
alkaline phosphatase blue substrate according to manufacturer’s instructions in collaboration with 
AG Moretti by Dr. Svenja Laue, Dr. Tatjana Dorn and Birgit Campbell (First Department of 
Medicine, Cardiology, Klinikum rechts der Isar – Technical University of Munich, 81675 Munich, 
Bavaria, Germany). 
For the re-characterization of the isogenic lines, iPSCs were cultured in StemFit® until reaching 
about 40% confluency. Cells were washed once in DPBS and fixed with 4% PFA for 20 min at RT 
followed by 3 washes with DPBS for 10 min each. Fixed colonies were stained with 3 ml/3.5 cm 
plate of ALP staining solution for 20 min at room temperature and washed twice in DPBS before 
imaging on a stereomicroscope. The ALP staining was done by Viktoria Frajs under supervision 
(See Master Thesis Viktoria Frajs, SHOX2 in atrial fibrillation disease modelling using induced 
pluripotent stem cells). 
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1.6. In silico methods, bioinformatics, and ethical statements 
1.6.1. dPCR template generation and analysis 
All dPCR experiments were run using QuantaSoft (version 1.7.4.0917). Templates were generated 
with the following settings: ABS (experiment), ddPCR™ Supermix for probes (supermix), Mut 
(Ch1, FAM) and WT (Ch2, HEX). For analysis, automatically set thresholds were used to define 
positive/negative droplets whenever applicable or set manually with the lasso function. 
 
1.6.2. gRNA design 
gRNA design was performed with the CCTop - CRISPR/Cas9 target online predictor.118 As input, 
the genomic DNA sequence ~200bp up- and downstream of the mutation of interest (SHOX2 
c.849C>A or SHOX2 c.*28T>C) was used. The PAM type was set to NGG (Streptococcus 
pyogenes). For target selection, the target site length was set to 20 nt and the target site 5’ or 3’ 
limitations were set to NN (standard settings). For off-target prediction, the maximum of total 
mismatches was set to 4 nt, the core length was set to 12 nt with a maximum of total mismatches 
of 2 (standard settings). As a reference genome, the human genome (assembly homo sapiens 
GRCh37/hg19) was used. The three gRNAs closest to the mutation were selected. The chosen 
gRNAs were re-evaluated with the CHOPCHOP web tool with regard to efficiency and off-
targets.119 
 
1.6.3. Off-target analysis 
The top 20 off-target sites predicted by CCTop were further evaluated. Exonic off-target sites were 
automatically included into downstream analysis. For intronic and intergenic off-target sites, the 
target sequence coordinates were analyzed in the UCSC Genome Browser. The inclusion criteria 
for downstream analysis were: Conservation among species, DNase clustering, expressed sequence 
tags and active chromatin marks. If a combination of these criteria indicated a potential regulatory 
relevance of this DNA segment, the off-target site was sequenced. 
 
1.6.4. ssODN design 
ssODNs were designed as previously described109: The template spanned the Cas9 cut site 
asymmetrically, reaching from -82 nt to +35 nt for gRNAs targeting the SHOX2 c.849C>A locus 
and -81 nt to +45 nt for gRNAs targeting the SHOX2 c.*28T>C locus. The DNA oligo was 
synthesized and purified via desaltation by Integrated DNA Technologies (IDT). 
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1.6.5. Analysis of iPSC sib-selections via NGS 
The raw files generated after NGS (Gzipped .fastq files read 1 and read 2) were uploaded to the 
CRISPR RGEN Tool Cas-Analyzer120 for the detection of potential isogenic subpopulations within 
the sib-selections. The following settings were used for the analysis: 
Full reference sequence (5’ to 
3’) 
The full sequence of the PCR product without NGS-specific 
tags 
Nuclease Type Single nuclease 
Selected Nuclease SpCas9 from Streptococcus pyogenes: 5’-NGG-3’ 
Target DNA sequence The 20 nt of DNA targeted by the respective gRNA 
Donor DNA sequence for HDR [no donor sequence] 
Comparison range (R) 100 nt 
Minimum frequency (n) Variable, 0.00025%-0.25% of the total reads with indicator 
sequences 
WT marker (r) [no WT marker] 
  
The minimum frequency of alleles to be considered in the analysis was calculated from the total 
amount of reads that contained both indicator sequences (the first and last 12 nt of the comparison 
range). The threshold was set to 0.25*10-3 % of total reads for cell pools or 0.25% of total reads for 
sib-selections (minimum allele frequency in 200*103 or 200 cells, respectively). The frequency of 
WT alleles was calculated as a range (from minimum to maximum) with the following formulas: 
 
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 % 𝑜𝑜𝑜𝑜 𝑊𝑊𝑊𝑊 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 =
#[𝑊𝑊𝑊𝑊 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎,𝑚𝑚𝑚𝑚𝑎𝑎𝑢𝑢𝑚𝑚𝑢𝑢𝑎𝑎𝑢𝑢] + #[𝑊𝑊𝑊𝑊 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎, 𝑎𝑎𝑢𝑢𝑚𝑚𝑢𝑢𝑎𝑎𝑢𝑢]
#[𝑢𝑢𝑜𝑜𝑢𝑢𝑎𝑎𝑎𝑎 𝑟𝑟𝑎𝑎𝑎𝑎𝑢𝑢𝑎𝑎]
∗ 100 
𝑚𝑚𝑎𝑎𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 % 𝑜𝑜𝑜𝑜 𝑊𝑊𝑊𝑊 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 =
#[𝑊𝑊𝑊𝑊 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎,𝑚𝑚𝑚𝑚𝑎𝑎𝑢𝑢𝑚𝑚𝑢𝑢𝑎𝑎𝑢𝑢] + #[𝑊𝑊𝑊𝑊 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎, 𝑎𝑎𝑢𝑢𝑚𝑚𝑢𝑢𝑎𝑎𝑢𝑢] + #[𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎, ? ]
#[𝑢𝑢𝑜𝑜𝑢𝑢𝑎𝑎𝑎𝑎 𝑟𝑟𝑎𝑎𝑎𝑎𝑢𝑢𝑎𝑎]
∗ 100 
Definitions:  
#[WT alleles, unedited] Sum of all alleles with a detectable WT base with no 
additional mutations within the comparison range 
#[WT alleles, edited] Sum of all WT alleles with a detectable WT base with 
additional mutations within the comparison range (point 
mutations, insertions, or deletions) 
#[alleles,?] Sum of all alleles without a detectable SHOX2 c.849C>A 
or SHOX2 c.*28T>C base due to a base-spanning deletion 
#[total reads] Number of reads containing left and right indicator 
sequences 
 
The percentage of isogenic cells in the sib-selection was calculated from these results with the 
following formulas: 
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 % 𝑜𝑜𝑜𝑜 𝑚𝑚𝑎𝑎𝑜𝑜𝑖𝑖𝑎𝑎𝑚𝑚𝑚𝑚𝑖𝑖 𝑖𝑖𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 =  ([𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 % 𝑜𝑜𝑜𝑜 𝑊𝑊𝑊𝑊 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎] − 50%) ∗ 2 
𝑚𝑚𝑎𝑎𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 % 𝑜𝑜𝑜𝑜 𝑚𝑚𝑎𝑎𝑜𝑜𝑖𝑖𝑎𝑎𝑚𝑚𝑚𝑚𝑖𝑖 𝑖𝑖𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 =  ([𝑚𝑚𝑎𝑎𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 % 𝑜𝑜𝑜𝑜 𝑊𝑊𝑊𝑊 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎] − 50%) ∗ 2 
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The average of the minimum and maximum percentage of isogenic cells was then used to calculate 
how many single cell clones would need to be screened to find at least one isogenic clone with a 
self-chosen probability P. 
𝑚𝑚 =  
log (1 − 𝑃𝑃)
log 𝑞𝑞
 
Definitions:  
n Number of cells that need to be screened to find 
at least one isogenic clone with the probability P 
P Probability to find at least one isogenic clone. 
Value can be chosen arbitrarily (e.g. 95%) 
q Probability that analyzed clone is not isogenic. 
Value is calculated by subtracting the percentage 
of isogenic cells in the sib-selection from 1 
 
From the calculated number of cells x, the amount of 96-well plates that needed to be used for single 
cell-cloning was determined: 
#[96 𝑤𝑤𝑎𝑎𝑎𝑎𝑎𝑎 𝑝𝑝𝑎𝑎𝑎𝑎𝑢𝑢𝑎𝑎𝑎𝑎] =  
𝑚𝑚
𝑖𝑖𝑎𝑎𝑜𝑜𝑚𝑚𝑎𝑎𝑐𝑐𝑚𝑚𝑎𝑎𝑚𝑚𝑢𝑢𝑐𝑐[%] ∗ 96
 
The clonability was defined as the percentage of wells on a 96-well plate from which an iPSC clone 
could be derived (survived the first split and did not differentiate). This was empirically determined 
in pilot experiments and found to be 10-20%. 
 
1.6.6. Illustrations 
Figures were prepared using Adobe Illustrator and Photoshop 2020. DNA schemes were drawn 
using Illustrator of Biological Sequences.121 Some figure elements were taken from Pixabay 
(www.pixabay.com) and modified (citation or permission required). 
 
1.7. Patient information and study design 
 
1.7.1. Ethics statement for the genetic analysis of AF and SND patients 
All patients recruited for this study were German individuals. The AF patient cohort (n = 450) 
consisted of participants from the Gutenberg Health Study 122 enrolled in the period from 2007 to 
2012 at the University Medical Center of the Johannes Gutenberg University Mainz, Germany. The 
SND patient cohort (n = 98) was recruited from the Department of Medicine I of the Ludwig 
Maximilians University Hospital Grosshadern, Munich, from 2013 to 2014. For at least 95% of all 
cases, clinical parameters were available. The study was approved by the ethical commission of the 
Medical Faculty, University of Heidelberg, Heidelberg, Germany (S-104/2010 “Molekulare 
Grundlagen SHOX2-bedingter Herzfehlbildungen” 17.03.2010) and was performed in accordance 
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with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. 
A written informed consent was given by every participant prior to the inclusion in the study, 
including the consent to use their DNA for genetic analyses.1 
 
1.7.2. Ethics Statement for the generation of iPSCs 
The study was approved by the ethical commission of the Medical Faculty, Technical University 
of Munich, Munich, Germany (“Induzierbare pluripotente Stammzellen als innovatives Patienten-
basiertes in vitro Modell für Vorhofflimmern” als Teilprojekt 5 des Hauptprojekts “Erzeugung und 
Charakterisierung patientenspezifischer induzierter, pluripotenter Stammzellen” 2109/08) and was 
performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki 
and its later amendments. Every participant gave written informed consent including the consent to 
use their blood samples prior to the inclusion in the study. 
 
1.8. Statistics 
Statistics were performed using GraphPad Prism version 8 for Windows (Prism 8 for Windows, 
Software MacKiev, LLC, USA). 
 
1.8.1. Analysis of heart rate and luciferase activity 
Differences in zebrafish embryonic heart rates were tested for their significance with a one-way 
ANOVA combined with Tukey’s honestly significant difference post hoc test for multiple 
comparisons. Differences in luciferase activities were tested by a one-way ANOVA followed by 
uncorrected Fisher’s least significant difference test.1 
 
1.8.2. Expression analysis 
Differences in expression were tested by a ratio t-test.1 
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2. Results 
2.1. Functional characterization of rare variants in the SHOX2 gene 
identified in SND and AF 
 
Mutations in SHOX2 have been found in patients with early-onset and familiar forms of AF.28,50 To 
identify novel variants in SHOX2 and elucidate the causal relationship between them and the 
development of AF and SND, a candidate gene study was combined with functional analyses. The 
AF cohort included 450 participants from the Gutenberg Health Study enrolled in the period from 
2007 to 2012 at the University Medical Center of the Johannes Gutenberg University Mainz, 
Germany.122 The SND cohort comprised 98 individuals recruited from the Department of Medicine 
I of the Ludwig Maximilians University Hospital Grosshadern, Munich between 2013 and 2014. 
Patient characteristics and clinical parameters were available for more than 95% of the candidates 
(See Table S1-4 in Appendix). Recruitment was done in collaboration with Dr. Sebastian Clauss, 
Dr. Tina Klier, Prof. Stefan Kääb (Department of Medicine I, Klinikum Grosshadern, University of 
Munich (LMU), 81675 Munich, Bavaria, Germany), Tanja Zeller and Renate B. Schnabel 
(Department of General and Interventional Cardiology, University Heart Center Hamburg (UHZ), 
University Hospital Hamburg/Eppendorf, Hamburg, Germany). 
 
2.1.1. Identification and evaluation of SHOX2 variants in AF and SND cohorts 
The six coding exons of the longest SHOX2 isoform (NM_003030.4), including the primate specific 
exon 2+, were screened for variants via Sanger Sequencing in a joint effort with Birgit Weiss and 
Sandra Hoffmann (Department of Human Molecular Genetics, Institute of Human Genetics, 
University of Heidelberg, Heidelberg, Germany). Values and allele frequencies are reported from 
the given databases as of March 2020. In total, four heterozygous synonymous and non-
synonymous variants (c.230G>A/p.G77D, c.387G>A/p.L129=, c.388C>T/p.L130F, and 
c.879C>T/p.A293=) were identified in patients suffering from AF (4/450) and one heterozygous 
missense mutation (c.98C>G/p.P33R) was identified in an individual from the SND cohort (1/98). 
The SND patient carrying this variant also presented with AF. In silico prediction based on 
“combined annotation dependent depletion” (C-scores or CADD) 123,124 was used to predict the 
pathogenic potential of these variants and to select all variants with C-scores ≥20 for functional 
analyses. This included p.G77D (C-score = 22.2) and p.A293= (C-score = 20.6) from the AF study 
cohort and the SND variant p.P33R (C-score = 25.8). The in silico analysis was expanded using a 
set of publicly accessible prediction tools that are based on deep-neural network classification or 
machine learning approaches (DANN, FATHM-MKL, GWAVA), empirical scoring systems 
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(FunSeq2), or a tool that combines these classifications (PredictSNP2). Except for p.G77D, the all 
variants with a CADD score ≥20 were predicted to be deleterious by a majority of the tools, while 
the rest was mainly classified as neutral. 
None of the variants were present in the European Non-Finnish population of the 1,000 genomes 
project.125 From the AF variants, p.A293= was reported with an allele frequency of 0.0004578% 
(58/126696) in the European Non-Finnish population of genome Aggregation Database (gnomAD), 
while p.G77D was not present. For p.P33R, gnomAD reported an allele frequency of 
0.000009694% (1/103152) (Table 1). In addition, the recently released DZHKomics database 
which comprises approximately 1,150 genomes from unrelated healthy individuals of 6 German 
population cohorts (GHS, Gutenberg-Gesundheitsstudie; HCHS, Hamburg City Health Study; 
NOKO, Heidelberg Normal Kontrollen; IKMB, Institut für Klinische Molekularbiologie Kiel; 
KORA, Kooperative Gesundheitsforschung in der Region Augsburg; SHIP, Study of Health in 
Pomerania) were included in the analysis (unpublished data, https://ihg4.helmholtz-
muenchen.de/cgi-bin/DZHKomics/search.pl). Only the AF variant c.387G>A was present in this 
cohort with an allele frequency of 0.00433526 (9/1150). 
In summary, this data expands the list of SHOX2 variants associated with AF, confirms previous 
findings 28,50 and indicates a novel association of SHOX2 with SND. 
 
 
Figure 5 Identi fied SHOX2  varian ts in  pat ients with sinus node dysfunction (SND) and atrial f ibri lla tion (AF)  
Figure 5 Identified SHOX2 variants in patients with sinus node dysfunction (SND) and atrial fibrillation (AF). Schematic drawing 
showing all identified variants within the SHOX2 gene in patients with AF and SND. The novel identified variants and the respective 
cohorts are highlighted in green. The previously published variants are greyed out. Figure and legend based on Hoffmann S, [...], Sumer 
SA et al. 2019 
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Table 1 Overview o f SHOX2 varian ts  
Patient cohort AF (n = 450) SND (n = 98) 
Genomic position 
(GRCh37) 
3:157823584 
C>T 
3:157822878 
C>T 
3:157822877 
G>A 
3:157816005 
G>A 
3:157823716 
G>C 
Reference 
number N/A rs753047735 N/A rs150931445 rs768138092 
Transcript 
consequence c.230G>A c.387G>A c.388C>T c.879C>T c.98C>G 
Protein 
consequence p.G77D p.L129= p.L130F p.A293= p.P33R 
Patient cohort 
allele frequency 
0.0011111 
(1/450) 
0.0033333 
(3/450) 
0.0011111 
(1/450) 
0.0011111 
(1/450) 
0.0051020 
(1/98) 
TGP allele 
frequency - - - - - 
gnomAD v2.1.1 
(non-TOPMed) 
allele frequency 
- 0.0003456 (25/72338) 
0.00001750 
(1/57154) 
0.0004578 
(58/126696) 
0.000009694 
(1/103152) 
DZHKomics 
allele frequency - 
0.00433526 
(9/1150) - - - 
CADD Score 22.2 10.68 9.02 20.6 25.8 
PredictSNP2 Neutral Neutral Neutral Deleterious Deleterious 
DANN Neutral Neutral Neutral Deleterious Deleterious 
FATHMM Neutral Neutral Neutral Deleterious Deleterious 
FunSeq2 Deleterious Neutral Deleterious Neutral Deleterious 
GWAVA Deleterious Neutral Deleterious Neutral N/A 
Table 1. Overview of SHOX2 variants identified in AF and SND patients and control databases: 1000 gnomes project (TGP) and the 
genome Aggregation Database (gnomAD); only the European Non-Finnish populations were considered. Novel variants were selected 
for further functional studies based on the predicted pathological potential via Combined Annotation Dependent Depletion (CADD). 
Table and legend modified from Hoffmann, […], Sumer et al., 2019.1 
 
2.1.2. Functional characterization of SHOX2 p.P33R, p.PG77D and p.A293= in 
vivo and in vitro 
The functional relevance of the three selected variants was tested by investigating their pathogenic 
potential in the zebrafish as a model system in collaboration with Christoph Paone, Sabrina Diebold 
and Steffen Just (Department of Internal Medicine II, University of Ulm, Ulm, Germany). As shown 
before, a morpholino-mediated knockdown of endogenous Shox2 in zebrafish embryos leads to 
pericardial edema and severe bradycardia.22,48 The phenotype can be rescued by the ectopic 
expression of (human) Shox2. The missense mutation p.H283Q, identified in a previous study, 
affects a highly conserved amino acid, also present in the zebrafish genome (corresponding 
mutation Shox2 p.H277Q). Upon expression in Shox2-depleted embryo hearts, the mutated version 
failed to restore a normal heart rate and was therefore demonstrated to affect the pacemaker function 
of the gene.28 Here, the SHOX2 p.H283Q was used as a positive control in a modified experiment, 
where this variant or the newly identified variants were overexpressed in a cardiac-specific manner. 
A dominant-negative effect could be observed upon overexpression of SHOX2 p.H283Q that 
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resulted in pericardial edema and significantly reduced heart rates, similar to what was previously 
found for the corresponding zebrafish variant (Figure 5A).28 Similarly, the missense variant 
SHOX2 p.G77D, identified in the AF cohort, also revealed pericardial edema upon overexpression 
(Figure 5A). In addition, a bradycardia phenotype (significantly reduced heart rate) could be 
observed for p.G77D, while the synonymous AF variant p.A293= and the SND variant p.P33R 
showed no difference (Figure 5B). To investigate if the identified missense variants impede the 
transactivation activity of SHOX2, in vitro dual luciferase reporter assays were performed by 
Sandra Hoffmann (Department of Human Molecular Genetics, Institute of Human Genetics, 
University of Heidelberg, Heidelberg, Germany). The reporter gene under the control of the BMP4 
promotor, a direct SHOX2 target, can be activated by the WT protein, while p.H283Q severely 
affects this ability.19,28 In the current study, both missense variants p.P33R and p.G77D were found 
to be unable to activate the BMP4 promotor when compared with WT SHOX2 (Figure 5C). These 
results were in accordance with the in vivo phenotypic changes for P.G77D and further indicated a 
functional consequence of this AF-associated mutation. However, as this was the first time that an 
observable phenotype for the p.P33R SND mutation could be shown, the target gene expression 
was tested in vivo. WT and p.P33R SHOX2 were overexpressed in the hearts of zebrafish embryos. 
Cardiac RNA was isolated 72 h post fertilization and subjected to comparative gene expression 
analysis in collaboration with Ralph Roeth (Department of Human Molecular Genetics, Institute of 
Human Genetics, University of Heidelberg, Heidelberg, Germany). Bmp4 RNA levels were 
significantly downregulated upon overexpression of the p.P33R mutant (Figure 5D), confirming 
the impaired Bmp4 reporter activation that had been observed in the luciferase assay. 
Thus, the functional investigations in zebrafish and the in vitro studies demonstrated a pathological 
potential for two of the three novel identified SHOX2 variants.1 
In vitro analysis and assays as well as the use of model organisms are valuable tools to investigate 
the pathogenic influence of mutations on gene function and expression. A lot of the current 
knowledge on the molecular pathways in the heart relies on heterologous expression systems, such 
as mouse and zebrafish. However, distinct species-specific electrophysiological and transcriptional 
properties do exist, resulting in considerable functional differences. This includes features like a 
different resting heart rate or the sheer physiological size of the heart leading to different signal 
transduction times. On the other hand, access to primary human tissue, especially from disease-
bearing patients, is limited in quantity and in time due to the difficulties to propagate these cells in 
culture.51 These limitations can be overcome by iPSC-based disease models that offer an unlimited 
source of patient-specific cardiomyocytes with putative disease-causing mutations. Therefore, two 
patients harboring SHOX2 variants with a functional impact on the gene’s function were recruited. 
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Figure 6 Functiona l characterization of SHOX2 variants in vivo and in vitro  
Figure 6 Functional characterization of SHOX2 variants in vivo and in vitro. (A) Cardiac-specific overexpression of SHOX2 mutants 
compared with SHOX2 WT (wild-type) leads to pericardial edema (arrow) for p.G77D and p.H283Q but not for p.P33R and p.A293= 
in zebrafish 72hpf. (B) The heart rate of zebrafish embryos was significantly reduced upon overexpression of p.G77D and p.H283Q but 
normal for p.P33R and p.A293= 72hpf compared with empty vector-injected embryos. SHOX2 WT overexpression showed no effect. 
Data are expressed as mean ± SD of three to six independent experiments. All P-values were determined by one-way ANOVA with 
Tukey’s multiple comparison test (*P < 0.05; ***P < 0.001; ns: not significant). (C) Luciferase activity of BMP4 reporter construct co-
expressed withSHOX2 wild-type (WT) or SHOX2 mutants (p.H283Q, p.G77D, p.P33R) in HEK293T cells 24 h after transfection. All 
values are normalized to the empty pGL3 basic vector co-transfected with the respective expression constructs. Data are expressed as 
mean ± SEM of four independent experiments performed in triplicate. All P-values were determined by one-way ANOVA followed by 
uncorrected Fisher’s least significant difference test (*P < 0.05). (D) nCounter analysis revealed downregulation of Bmp4 expression in 
zebrafish hearts (72 hpf) overexpressing the mutant p.P33R compared with wild-type SHOX2 (n = 40 hearts per condition from two 
independent experiments). Statistical differences were determined by a ratio paired t-test (**P < 0.01). Figure and legend taken from 
Hofmann S, [...], Sumer SA et al. Front. Genet. 2019.{Hoffmann, 2019 #230} 
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2.2. Clinical analysis of patients recruited for iPSC reprogramming 
 
Two AF patients harboring the previously described heterozygous SHOX2 mutations (SHOX2 
c.849C>A and SHOX2 c.*28T>C) 28 were recruited for the reprogramming of PBMCs to iPSCs by 
Prof. Stefan Kääb and Dr. med. Sebastian Clauss (Department of Medicine I, Klinikum 
Grosshadern, University of Munich (LMU), Munich, Germany). A blood sample was provided for 
the extraction of PBMCs. The cardiological conditions of the two patients were analyzed based on 
available information from clinical records. 
 
2.2.1. Patient I (SHOX2 c.849C>A, SHOX2 p.H283Q) 
The male patient with the SHOX2 c.849C>A mutation was born in 1949 and developed AF at the 
age of 56 years. When he was recruited for study enrollment in 2009 at the age of 62, his AF had 
become persistent. An echocardiography at that time revealed a slightly enlarged left atrium (LA 
diameter = 43 mm) and a reduced EF of 43 %. In addition, the patient was diagnosed with arterial 
hypertension. The patient’s ECG showed a sinus rhythm with normal heartbeat rate and 
unremarkable P-, PR-, QRS- and QT-durations (Figure 6A). No other family member had 
developed AF (parents, one brother, one sister, one son) (Figure 6A). Except for hypertension in 
the patient’s brother and mother no other cardiovascular disease was present within the family 
(including coronary artery disease, stroke, (dilated/hypertrophic/restrictive/arrhythmogenic) 
cardiomyopathy, other forms of arrhythmias, or sudden (cardiac) death) and no other family 
member had or has an implanted cardioverter defibrillator/pacemaker. The patient himself had no 
pacemaker or cardioverter/defibrillator implanted (Patient’s characteristics are summarized in 
Table 2). In March 2016, at the patient’s age of 66, blood samples were obtained for iPSC 
reprogramming purposes during a regular clinical follow-up visit. 
 
2.2.2. Patient II (SHOX2 c.*28T>C) 
The male patient harboring the SHOX2 c.*28T>C mutation was born in 1970 and developed AF at 
the age of 37 years. At the time of study enrollment in early 2011, his ECG showed a prolonged PR 
interval (first-degree atrioventricular block), a clinically unremarkable QRS duration (no bundle 
branch block) and normal QT durations (Figure 6B). He was further diagnosed with DCM (left 
ventricular end diastolic diameter of 67 mm in February 2011). For primary prevention purposes, a 
single chamber cardioverter-defibrillator had been implanted. The cardiovascular risk factors of this 
patient included: Diabetes mellitus type II, hypercholesterolemia, ex-smoker status. Additionally, 
the patient suffered from chronic kidney disease and Crohn’s disease. No other family member 
developed AF (both parents, six brothers and sisters of the patient’s father, six brothers and sisters 
of the patient, three children of the patient). The patient’s father who had a known dilated 
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cardiomyopathy died from myocardial infarction at the age of 46 and one of the father’s brothers 
suffers from coronary artery disease and received surgical revascularization (coronary artery 
bypass). Another brother of the patient’s father died from cardiac arrest at the age of 59. Several 
relatives (both parents, one brother of the patient’s father, two brothers and one sister of the patient) 
suffer from hypertension. Besides that, no other cardiovascular disease was present within the 
family (including stroke, (hypertrophic/restrictive/arrhythmogenic) cardiomyopathy, or other forms 
of arrhythmias) (Figure 6B) and no other family member had or has an implanted cardioverter 
defibrillator/pacemaker. In March 2011, the patient suffered from progressive congestive heart 
failure with an ejection fraction (EF) of 25% presumably due to the patient’s DCM and the AF that 
progressed to a persistent type. Consequently, the patient received a heart transplant in October 
2011. At that time, the patient was treated with Amiodarone (class III anti-arrhythmic drug) and 
Dobutamine (emergency medication for decompensated heart failure) besides the standard 
treatment with diuretics, while beta-blockers (class II anti-arrhythmic drug) and ACE inhibitors 
were stopped (Patient’s characteristics are summarized in Table 2). In January 2015, at the patient’s 
age of 45, blood samples were obtained for iPSC reprogramming purposes during a routine follow-
up visit after heart transplantation. 
 
Table 2 P atient characteris tics  
    
AF patient I 
(SHOX2 
c.849C>A) 
AF patient II 
(SHOX2 c.*28T>C) 
 age at disease onset 
[years] 56 37 
  age at recruitment [years] 66 41 
 AF disease progression 
(at time of enrollment) persistent persistent 
  heart transplantation no yes 
Echocardiography 
(at time of 
enrollment) 
ejection fraction 43% 25% 
structural LA diameter = 43 mm LVEED = 67 mm 
  medication Pantozol, Marcumar 
Amiodarone, Dobutamine, 
β-blockers (paused), 
ACE inhibitors (paused)  
 cardioverter-
defibrillator [yes/no] Yes No 
  
additional 
cardiovascular 
diseases 
arterial 
hypertension dilated cardiomyopathy 
 cardiovascular risk 
factors N/A 
Diabetes mellitus II, 
hypercholesterolemia 
ex-smoker 
  secondary diagnosis N/A renal insufficiency, Morbus Crohn 
Table 2: Patient characteristics 
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Figure 7 Pa tients' E CG and  family pedigree with card iovascula r diseases 
Figure 7 Patients’ ECG and family pedigree with cardiovascular diseases. (A) Patient I (SHOX2 c.849C>A) suffered from HT and 
AF but showed an unremarkable ECG. Except for HT in the mother and the patient‘s brother, no other cardiovascular disease* was 
present. (B) Patient II (SHOX2 c.*28T>C) suffered from AF and DCM. His ECG revealed a slightly prolonged PR interval (first degree 
atrioventricular block). A substantial amount of cardiovascular diseases was present in family members, including HT in both parents, 
two of the father‘s brothers and three siblings. Like the patient, the father suffered from DCM and died from MI at the age of 46 years. 
One of the father‘s brothers suffered from CAD and another brother died from SCD, when he was 59 years old. Other cardiovascular 
diseases* were excluded. (Sumer et al., for revision only) 
*cardiovascular diseases: Stroke, coronary artery disease, (dilated/hypertrophic/restrictive/arrhythmogenic) cardiomyopathy, other 
forms of arrhythmias, or sudden (cardiac) death 
Abbreviations: ECG = electrocardiogram, HT = Hypertension, AF = Atrial fibrillation, DCM = Dilated cardiomyopathy, MI = 
Myocardial infarction, CAD = Coronary artery disease, SCD = sudden cardiac death 
arrow = index patient, black = atrial fibrillation, grey = other cardiovascular diseases, white = no known cardiovascular diseases 
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2.3. Generation and characterization of SHOX2 c.849C>A and 
SHOX2 C.*28T>C iPSC lines 
 
PBMCs were reprogrammed to iPSCs by Dr. Svenja Laue, Birgit Campbell and Dr. Tatjana Dorn 
(First Department of Medicine, Cardiology, Klinikum rechts der Isar – Technical University of 
Munich, 81675 Munich, Bavaria, Germany) with non-integrating Sendai viruses coding KLF4, 
OCT3/4, SOX2, c-MYC as previously described (Figure 7A).56 
Two iPSC clones generated from Patient I (SHOX2 c.849C>A) and three iPSC clones generated 
from patient II (SHOX2 c.*28T>C) were selected for detailed characterization by me and in 
collaboration with AG Moretti and AG Jauch (Department of Human Genetics, Institute of Human 
Genetics, University of Heidelberg, 69120 Heidelberg, Baden-Wuerttemberg, Germany): The 
presence of the patient-specific heterozygous mutations was confirmed by Sanger Sequencing 
(Figure 7B). All clones displayed stem cell-like colony-forming properties and high alkaline 
phosphatase activity (Figure 7C). The loss of viral transgene expression after 10 to 20 passages 
was confirmed via RT-PCR (Figure 7D). All lines expressed the pluripotency markers NANOG 
and TRA1-81 on protein level, as detected by immunofluorescence staining (Figure 7E). In 
addition, qRT-PCR analysis of OCT3/4, SOX2, REX1, NANOG and TDGF1 indicated that these 
iPSCs had reactivated their endogenous pluripotency genes (Figure 7F). Furthermore, the capacity 
to generate derivates of all three germ layers in vitro was demonstrated by spontaneous 
differentiation as EBs (Figure 7G). Metaphase analysis by M-FISH revealed no chromosomal 
aberrations and a normal karyotype for all 5 clones (Figure 7H). MCA testing confirmed a shared 
origin for all SHOX2 c.849C>A and SHOX2 c.*28T>C clones, respectively, which also differed 
from the control line that was cultured in parallel (Figure 7I). 
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Figure 8 Generation and characterization of patien t-specific iPSCs from pa tient I (SHOX2  c.849C>A) and  patient II (SHOX2 c.*28T>C)  
Figure 8 Generation and characterization of patient-specific iPSCs from patient I (SHOX2 c.849C>A) and patient II (SHOX2 
c.*28T>C). iPSCs were generated by reprogramming peripheral blood mononuclear cells (PBMCs) using the CytoTune-iPSC 2.0 Sendai 
Reprogramming Kit (Life Technologies). (A) Integration-free reprogramming scheme with Sendai viruses, leading to the generation of 
two iPSC clones from patient I and three iPSC clones from patient II. (B) Sequencing of SHOX2 c.849C>A (= SHOX2 p.H283Q) and 
SHOX2 c.*28T>C mutations in patient-derived iPSC clones. (C) Detection of alkaline phosphatase activity as a pluripotency marker, 
representative bright field image of an iPSC colony stained for alkaline phosphatase. (D) Confirmation of loss of Sendai viral transgenes 
after reprogramming by RT-PCR, a = uninfected PBMCs (negative control), b = infected PBMCs (positive control), c-e = iPSC clones 
from patient I and patient II. (E) Immunofluorescence detection of the endogenous pluripotency markers NANOG and TRA-1-81 in 
patient-specific iPSCs at passage 17 or 18 after reprogramming; scale bar, 50 μm. (F) Analysis of expression profile of endogenous 
pluripotency genes in patient-specific iPSCs by qRT-PCR. Values are normalized to GAPDH and relative to uninfected parental patient 
PBMCs. (G) Schematic of the spontaneous differentiation of iPSCs into EBs. qRT-PCR analysis of lineage markers specific for each of 
the three embryonic germ layers after 21 days of spontaneous EB differentiation in patient-specific iPSCs. Values are normalized to 
GAPDH and relative to iPSCs harvested at day 0. (H) M-FISH analysis of the two SHOX2 c.849C>A clones and three SHOX2 c.*28T>C 
clones showing no chromosomal abnormalities. (I) Multiplex Human Cell Line Authentication Testing confirmed a shared origin for all 
SHOX2 2 c.849C>A and SHOX2 c.*28T>C clones, respectively, and excluded cross contaminations with other known cell lines. In 
addition, the origin from the healthy donor control line (Control_1) used in the lab was excluded. (Sumer et al., under revision)  
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2.4. Generation of isogenic controls for SHOX2 c.849C>A and 
SHOX2 c.*28T>C iPSC lines 
 
Many iPSC models use cells generated from age-matched healthy donors or unaffected family 
members as controls.56,57,60 Late age-onset diseases, such as AF, are characterized by long latency 
and slow progression, often resulting in subtle phenotypes in vitro.101 To avoid that observable 
differences between patient-specific and control lines were masked by a variable genetic 
background or disease confounding factors, isogenic iPSC lines were generated for one of the 
SHOX2 c.849C>A and SHOX2 c.*28T>C clones, respectively. In these control clones the putative 
disease-causing mutation was corrected to the WT sequence using the CRISPR/Cas system. This 
genome-editing was performed in a scarless manner to exclude any potential impact on an 
observable phenotype.126 Consequently, the insertion of selection markers or silent mutations to 
prevent re-cutting by the Cas9 enzyme was avoided. A novel method for enriching gene-corrected 
iPSCs prior to single-cell cloning was developed based on a previously reported strategy, which 
proposed the use of sib-selection to capture rare editing events.102 
 
2.4.1. gRNA design and validation 
To target the heterozygous SHOX2 c.849C>A and SHOX2 c.*28T>C mutations, gRNAs with 
cutting sites close to the mutation of interest were selected using CCTop - CRISPR/Cas9 target 
online predictor.118 The gRNAs were predicted to range from moderately to highly efficient with a 
substantial number of off-targets. However, as gene conversion tracks are relatively short in 
mammalian cells,127 the distance between Cas9 cut site and targeted DNA sequence had to be 
minimized for high HDR efficiency. One of the gRNAs targeting the SHOX2 c.*28T>C region 
(gRNA-3) utilized the PAM site created by the T>C mutation and was therefore presumed to bind 
in an allele-specific manner. 
Cells were transfected with Cas9 ribonucleoprotein RNP/gRNA complexes and a ssODN as HDR 
template (Figure 8A). After 48h, genome-targeting efficiency of each gRNA was determined by 
NGS for a precise estimation of indel size, frequency and sequence identity.128 For the SHOX2 
c.849C>A locus, the two selected gRNAs were moderately effective, producing indel frequencies 
of 36% and 21%, respectively. For SHOX2 c.*28T>C, gRNA-1 and gRNA-2 were less effective, 
producing indel frequencies of 17% in iPSCs, while the amount of detectable indels in gRNA-3-
transfected cells barely exceeded the negative control (Figure 8B). gRNA-3 was therefore deemed 
to be non-functional and was excluded from further applications. Due to the heterozygous nature 
of the SHOX2 mutations, the frequency of HDR events in these large cell pools could not be 
determined precisely. 
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Figure 9 gR NA design and va lida tion for the SHOX2 c.849C>A  and the SHOX2 c.*28T>C locus  
Figure 9 gRNA design and validation for the SHOX2 c.849C>A and the SHOX2 c.*28T>C locus. (A) Experimental overview for 
gRNA validation. hiPSCs were transfected with Cas9 RNP/gRNA complexes and ssODNs. After 48h, the Cas9-targeted region was 
amplified and analyzed via NGS. (B) Box, upper half: The SHOX2 c.849C>A and SHOX2 c.*28T>C locus with selected gRNA binding 
sites. PAM sequences are depicted in blue, the mutated base pair in red. Box, lower half: Indel frequency for each gRNA in hiPSCs 48h 
after transfection. The targeted region is centered. The cumulative frequency of deletions (blue) and insertions (green) at each position 
is depicted in percentage of reads (% Reads). (Sumer et al., under revision) 
Abbreviations: RNP = ribonucleoprotein, gRNA = single guide RNA, ssODN = single-stranded oligodesoxynucleotide, NGS = Next 
Generation Sequencing. 
 
2.4.2. Sib-selection and allele quantification with dPCR 
As previously described, the fractionation of a heterogenous population of genome-edited stem 
cells can randomly enrich desired sub-populations, such as isogenic cells.102 A population of cells 
containing a small number of cells of interest is subdivided into small pools (‘sib-selection’). From 
these, the one with the highest percentage of target cells is selected and subjected to a new round 
of subdivision. After the enrichment of target cells to a reasonable amount, single-cell cloning can 
be performed to achieve a pure cell population. It was hypothesized that - by quantifying the ratio 
of WT and Mut alleles in these sib-selections – cells which had precisely corrected the heterozygous 
mutation would be detectable. A present sub-population of isogenic cells contributes two WT 
alleles to the DNA pool leading to a shift in the WT/Mut allele ratio. Sib-selections with an over-
average abundance of WT alleles potentially contain enriched amounts of isogenic cells and can 
therefore be selected for further analysis and single-cell cloning. 
The massive sample partitioning in a digital PCR system (such as ddPCR™), which allows tens of 
thousands of individual PCR reactions from single molecule templates, makes this method suitable 
for precise quantification and identification of DNA strands. Utilizing this property, it has been 
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successfully applied in low gene expression quantification, copy number variation (CNV) analysis 
and detection of rare genome editing events.102,129,130 Here, it was utilized to compare WT/Mut allele 
ratios within individual sib-selections. Primers and TaqMan probes specific for the respective WT 
alleles (SHOX2 c.849C and SHOX2 c.*28T, labelled with HEX fluorophore) and Mut (SHOX2 
c.849C and SHOX2 c.*28C labelled with FAM fluorophore) alleles were designed to be used in the 
dPCR reaction (Figure 9A). 
For a reliable quantification, the sensitivity and specificity of probes and primers had to be tested. 
The TaqMan probe specificity for their respective alleles was confirmed with plasmids containing 
a mutated or unmutated SHOX2 gene (Figure 9B). The sensitivity and specificity of the system was 
analyzed by mixing different ratios of genomic DNA from healthy donors with DNA from patient-
specific iPSCs and comparing detected allele ratios to actual ratios. The strong correlation between 
calculated and measured Mut alleles indicated a high precision of allelic quantification as well as a 
specificity of WT and Mut TaqMan probes for their respective alleles (Figure 9C). 
Results 
60 
 
Figure 10 P retests for al lele quan tifica tion via dPCR  
Figure 10 Pretests for allele quantification via dPCR. (A) Primer/probe design for detection of WT and Mut alleles with specific 
probes. The mutation-spanning oligonucleotide donor is depicted above the mutant allele. (B) dPCR result for different ratios of control 
and patient genomic DNA represented as HEX channel 1D amplitude (upper panel) and plotted against the expected percentage (lower 
panel); n=3, error bars represent ± SD of the mean. (C) Probe specificity test with plasmids containing WT (SHOX2 c.849C, SHOX2 
c.*28T) and Mut (SHOX2 c.849A, SHOX2 c.*28C) alleles. (Sumer et al., under revision) 
Abbreviations: dPCR = digital PCR, WT = wildtype, Mut = mutant, gDNA = genomic DNA, FAM = 6-Carboxyfluorescein, HEX = 
Hexachloro-fluorescein, BHQ = black hole quencher. 
 
Cas9 RNP/gRNA/ssODN-transfected iPSCs were seeded into small cell pools of 200 cells per well 
on a 96-well plate, 48 hours after transfection and grown until confluency (~8-10 days) (Figure 
11A). From each well, 50% of the cells were cryopreserved while the other 50% were subjected to 
DNA extraction for subsequent allele quantification with dPCR (Figure 11B). While most sib-
selections still showed a nearly equal allele distribution of 50:50 (dotted line), which is 
characteristic for a heterozygous mutation and indicates no enrichment of isogenic cells, a higher 
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abundance of WT alleles was seen in some of them. These cell pools were therefore selected for 
further analysis. 
The major limitation of allele quantification via dPCR is its dependence on a functional PCR 
reaction. Mutations or the complete loss of primer/probe binding sites in alleles can prevent a 
successful amplification of the DNA strands and therefore their identification. If large populations 
of iPSCs in a sib-selection contain WT alleles and non-detectable mutant alleles, it will generally 
lead to a shift in the WT/Mut allele ratio similar to what is caused by isogenic cells (Figure 11C). 
Consequently, sequences had to be analyzed in detail via NGS to confirm the presence of isogenic 
cells in the chosen sib-selections. 
 
 
Figure 11 A llele quan tif ication  in s ib-selections  via dP CR and NGS  
Figure 11 Allele quantification in sib-selections via dPCR and NGS. (A) Experimental scheme of gene-editing approach. (B) WT 
and Mut alleles were quantified in each sib-selection 10 days after transfection via dPCR. Each dot represents the result for one sib-
selection. The dotted line marks the 50% WT allele percentage expected in unedited hiPSCs. Sib-selections with the highest abundance 
of WT alleles were thawed and re-analyzed. (C) Limitations of dPCR in allele quantification: Due to the PCR-based allele detection, 
non-amplifiable Mut alleles can lead to shifts in the WT:Mut ratio similar to what is caused by isogenic subpopulations. (Sumer et al., 
under revision) 
Abbreviations: Indel = Insertions/Deletions 
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2.4.3. Allele quantification in sib-selections via NGS 
For SHOX2 c.849C>A, three cell pools transfected with gRNA-1 and four cell pools transfected 
with gRNA-2 were subjected to NGS, for SHOX2 c.*28T>C, DNA of two cell pools transfected 
with gRNA-1 or gRNA-2 were deep-sequenced. To determine the percentage of targeted cells from 
WT:Mut allele ratios, two assumptions were made: First, the probability for SHOX2 CNVs, for 
example due to a trisomy or gene duplications, was considered to be very small. CNVs could lead 
to changes in allele ratios that are also not caused by isogenic subpopulations. Second, the 
probability of an imprecise correction of the SHOX2 mutations (mutation lost, but other mutations 
introduced) was neglected for that moment. Under normal circumstances, HDR leads to a complete 
restoration of the sequence. With these prerequisites, the percentage of isogenic subpopulations 
could be directly calculated from the WT and Mut alleles. 
NGS reads were classified into three categories: WT alleles (reads with SHOX2 c.849C or SHOX2 
c.*28T), Mut alleles (reads with SHOX2 c.849A or SHOX2 c.*28C) and non-assignable (N/A) 
alleles (reads with SHOX2 c.849 or SHOX2 c.*28 base-spanning deletions). This classification was 
carried out independently of additional mutations in the respective alleles. N/A alleles caused 
uncertainty in allele quantification, as their origin from either WT or Mut alleles could not be 
determined. This uncertainty was addressed by defining all N/A alleles as either WT or Mut alleles 
when calculating the WT/Mut allele ratio. The result was a range of possible ratios, spanning from 
the two extreme scenarios where N/A alleles were counted as either all WT or all Mut (Figure 12). 
Using gRNA-1 to correct the SHOX2 c.849C>A mutation, led to a high percentage of reads with 
deletions spanning the mutation of interest, which made the precise quantification of isogenic sib-
selections impossible (Figure 12A). For the SHOX2 c.849C>A sib-selections gRNA-2 #2-4, a large 
fraction of N/A alleles led to a wide range of potential allele ratios. As this included a scenario, in 
which the higher percentage of WT alleles could solely be explained by a loss of detectable Mut 
alleles, a sub-population of isogenic cells was possible, but not guaranteed. On the other hand, sib-
selection SHOX2 c.849C>A gRNA-2 #1 had a strong and robust increase of WT alleles, indicating 
a large fraction of isogenic clones (Figure 12B). For SHOX2 c.*28T>C sib-selections gRNA-1 #1 
and gRNA-2 #1 showed a similar shift and were therefore selected for single-cell cloning together 
with SHOX2 c.849C>A gRNA-2 #1. Allelic distributions were used to calculate the percentage of 
isogenic cells in these cell pools, estimating frequencies of 20-26% for SHOX2 c.849C>A gRNA-
2 #1 as well as 7-9% and 5-9% in sib-selection gRNA-1 #2 and gRNA-1 #1, respectively (Figure 
12B, red arrows). With a supposed initial efficiency of ~1% for precise genome-editing, the sib-
selection process led to a significant enrichment of target cells. 
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Figure 12 A llele quan tif ication  via NG S  
Figure 13 A llele quan tif ication  via NG S  
Figure 12 Allele quantification via NGS. Alleles with SHOX2 c.849- and SHOX2 c.*28-spanning deletions cause an uncertainty in 
allele quantification that is addressed by defining those alleles as all WT or all Mut. The resulting span of possible allele ratios is 
represented as error bars. (A) Alleles with SHOX2 c.849-spanning deletions cause an uncertainty in allele quantification that is addressed 
by defining those alleles as all WT or all Mut. The resulting span of possible allele ratios is represented as error bars. However, due to 
the high numbers of reads containing large deletions, the ratios cannot be determined precisely enough. (B) Sib-selections in which an 
increased WT:Mut allele ratio is not solely explicable by a loss of detectable Mut alleles were chosen for single-cell cloning. The 
percentage of isogenic cells was calculated with the given formula. (Sumer et al., under revision) 
Abbreviations: Indel = Insertions/Deletions, N/A = non-assignable. 
 
2.4.4. Single cell-cloning and screening 
The number of cells that had to be screened to find at least one isogenic/corrected clone with a 
given probability was determined by negative binominal distribution. The applied parameters were 
the calculated frequency of target cells (~23% or ~8%), the desired number of positive clones to be 
found (≥ one clone) and a self-defined chance of success to find one (95%) (Figure 13A). Twelve 
clones for sib-selection SHOX2 c.849C>A gRNA-2 #1 and 35-40 clones for SHOX2 c.*28T>C sib-
selections had to be generated to find at least one clone of interest with a 95% probability. Compared 
to the nearly 300 cells that would have to be screened for the same chances of success - if the target 
cell population was only ~1% - this option represented a substantial reduction of screening 
workload. 
Monoclonal cell populations were obtained via limiting dilution cloning (Figure 13B). The 
clonability, which is defined as the success rate for obtaining a single cell-derived iPSC clone from 
every well seeded, was determined to be 10-20%. Using three 96-well plates per cell line resulted 
in 24, 33 and 57 analyzable clones for sib-selection SHOX2 c.849C>A gRNA-2, SHOX2 c.*28T>C 
gRNA-1 #2, and SHOX2 c.*28T>C gRNA-2 #2, respectively (Figure 13C). From each well, 50% 
of the cells were cryopreserved while the other 50% were subjected to DNA extraction for 
subsequent genotyping. 
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Figure 13 Single cell-cloning of iPSCs (A) Coating free method for single-cell cloning via limited dilution. A single-cell suspension is 
generated from the chosen sib-selection and diluted to 10 cells/ml. The extracellular matrix is added to the cell suspension and 1 cell/well 
is seeded on 96-well plates (100 μl). (B) Single-cell derived hiPSC colony after 72h (upper row; scale bar, 50 μm) and 8 days (lower 
row; scale bar, 200 μm). (Sumer et al., under revision) 
 
Both digital PCR primers and probes were reused for TaqMan SNP genotyping of SHOX2 
c.849C>A and SHOX2 c.*28T>C to pre-select potentially homozygous WT clones. DNA extracted 
from an unrelated control line (control_1) was used as a positive control for homozygous WT and 
patient-derived DNA as positive control for heterozygous WT. All annotated homozygous WT 
clones were identified from the allele discrimination plot. The automated classification could not 
precisely annotate the different allele combinations due to the lack of a positive control for a 
homozygous mutation. The melting curves of single-cell clones were therefore manually compared 
to the WT positive controls (Figure 14A). Subsequent sequencing confirmed the precise correction 
of the heterozygous SHOX2 c.849C>A or SHOX2 c.*28T>C mutation and to screen for additional 
mutations up- and downstream of the Cas9 target site. For SHOX2 c.849C>A, 5 out of 24 sequenced 
clones (~21%) were confirmed to have lost the patient mutation, matching the expected frequency 
of 20-26%. However, in two of them, additional mutations were introduced during the editing 
process. For SHOX2 c.*28T, 5 of the genotyped WT clones (1x from sib-selection gRNA-1 #1 and 
4x gRNA-2 #1) were confirmed to be isogenic with no additional detectable mutations, neither 
~600 bp upstream nor ~260 bp downstream of the Cas9 cut site. For the rest of the clones that were 
predicted to be homozygous WT via genotyping, a loss of primer/probe binding sites on the mutant 
allele explained the false annotation (Figure 14B). 
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Figure 14 S ingle cell-clon ing with sib-selections and screening fo r isogenic clones  
Figure 14 Single cell-cloning with sib-selections and screening for isogenic clones. (A) Experimental scheme for single-cell cloning 
and screening: The number of clones needed to be analyzed was calculated with binomial distribution function. Sib-selections with 
isogenic subpopulations were thawed for single-cell cloning via limited dilution. Clones were screened via TaqMan Probe-based SNP 
genotyping and potential homozygous WT clones were confirmed with Sanger Sequencing. (B) Screening for isogenic clones derived 
from heterozygousSHOX2 c.849C>A cells: 24 single-cell clones were genotyped and sequenced. In 5/24 clones (21%) the mutation was 
corrected back to wildtype, with 3 clones showing no additional mutations several hundred nucleotides up- and downstream. (C) 
Screening for isogenic clones derived from heterozygous SHOX2 c.*28T>C cells: Single-cell derived clones were genotyped. 10 
annotated homozygous WT clones were sequenced to confirm the loss of the SHOX2 c.*28T>C mutation. In 5/10 clones the mutation 
was repaired precisely back to WT, in the other 5/10 clones, deletions on the Mut allele explained the false annotation. (Sumer et al., 
under revision) 
Abbreviations: SNP = Single nucleotide polymorphism, here: SHOX2 c.849C>A and SHOX2 c.*28T>C, Indel = Insertions/deletions. 
 
2.4.5. Re-characterization of isogenic control lines for SHOX2 c.849C>A and 
SHOX2 c.*28T>C 
For subsequent detailed re-characterization, one isogenic clone for SHOX2 c.*28T>C isoWT and 
SHOX2 c.849C>A isoWT were selected. Both clones had maintained their stem-cell like 
morphology and pluripotent capacity and also exhibited high ALP activity, expression of 
pluripotency markers on RNA/protein level and spontaneously differentiated into derivates from 
all three germ layers (Figure 14A-D) (work performed by Viktoria Frajs under supervision, also 
see Master Thesis Viktoria Frajs SHOX2 in atrial fibrillation disease modelling using induced 
pluripotent stem cells). Classical cytogenetic analysis on Giemsa stained chromosomes revealed in 
each of the 30 investigated metaphases (Figure 14E). Cell line authentication confirmed their 
patient-specific origin and excluded a cross-contamination with the control line (Figure 13I). 
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Twelve and eleven highly scored off-targets for SHOX2 c.849C>A gRNA-2 and SHOX2 c.*28T>C 
gRNA-1 consisting of exonic regions as well as intronic and intergenic regions with potential 
regulatory relevance were sequenced, but no additional mutations were found to be introduced in 
these sites (Figure 14F). 
 
 
Figure 15 Re-characterizat ion of SHOX2 c.849C>A_isoW T and SHOX2 c.*28T>C_isoW T 
Figure 15 Re-characterization of SHOX2 c.849C>A_isoWT and SHOX2 c.*28T>C_isoWT. Isogenic control lines were generated 
as described above and re-characterized to confirm the preservation of pluripotency capacity and karyotype. (A) Loss of heterozygous 
SHOX2 c.849C>A (= SHOX2 p.H283Q) and SHOX2 c.*28T>C mutations in isogenic control clones. (B) Detection of alkaline 
phosphatase activity in isogenic hiPSCs as a pluripotency marker. (C) Immunofluorescence detection of the endogenous pluripotency 
markers OCT4 and SOX2 in isogenic hiPSCs; scale bar, 100 μm. (D) qRT-PCR analysis of pluripotency genes at d0 and germ layer 
markers after 21 days of EB differentiation (see the schematic above). (E) Giemsa banding of isogenic control lines revealing no 
chromosomal aberrations. (Sumer et al., under revision) 
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2.4.6. Estimation of the HDR frequency via reverse genome-editing 
When calculating the enrichment of homozygous wildtype cells and the reduction in workload, the 
reported HDR frequency of ~1% was assumed.66,101,131 To determine if the sib-selection process 
indeed enriched targeted cells, the initial HDR efficiency had to be quantified. For an approximation 
of the real HDR efficiency in these specific settings, the SHOX2 c.849C>A and SHOX2 c.*28T>C 
mutations were re-introduced into the isogenic clones using the same Cas9 enzyme batch and 
gRNAs but replacing the ssODN by analogous versions, which led to the insertion of the point 
mutation rather than to its repair. Seventy-two hours after transfection, the frequency of HDR events 
was determined by NGS (Figure 15A). The SHOX2 c.849C>A mutation was detected in 0.70% of 
the reads about half of them with additional mutations such as deletions introduced (Figure 15B). 
The SHOX2 c.*28T>C mutation was found in 0.85% of the reads, but in nearly all cases the base 
substitution had happened scarlessly (Figure 15C). 
In conclusion, the HDR events had happened in a frequency of ~1% correlating with previous 
reports, and the sib-selection process with the detection via allele quantification led to an 8-20-fold 
enrichment of isogenic cells. 
 
 
Figure 16 Reverse genome-editing  to determ ine the in itia l HDR eff iciency 
Figure 16 Reverse genome-editing to determine the initial HDR efficiency. (A) Experimental scheme for reverse gene-editing. The 
newly generated isogenic clones were used to determine the initial HDR efficiency. For this, the same Cas9 RNP and gRNA were used 
in combination with an oligonucleotide donor differing only in the one base analogous to SHOX2 c.849 (B) or SHOX2 c.*28 (C). In 
consequence, HDR events would lead to the introduction of the SHOX2 c.849C>A or SHOX2 c.*28T>C mutation. The frequency of 
HDR was determined by NGS 72h after isogenic cells were transfected with Cas9/gRNA/ssODNs. (Sumer et al., under revision) 
Abbreviations: HDR = homology-directed repair 
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3. Discussion 
3.1. Functional characterization of rare variants in the SHOX2 gene 
identified in SND and AF 
The proper function of the cardiac conduction system is mediated by a highly conserved and 
complex network of transcriptional regulators.2,9 Arrhythmias and other cardiac conduction defects 
are often polygenic with thousands of common risk alleles underlying the disease onset, but they 
can also be caused by haploinsufficiency of single cardiac transcription factors.132,133 AF, the most 
prevalent cardiac rhythm disorder, has a strong genetic component as seen by a significant familial 
aggregation of disease cases. Research into the genetic basis of AF has led to the discovery of 
several transcription factors as potential contributors to arrhythmia susceptibility. These include 
TBX5, an activator of SHOX229, NKX2.5, an antagonist of SHOX2,30 and PITX2, a repressor of 
SHOX2.17 Further evidence to support the role of transcription factors in the manifestation of AF 
has come from transgenic and pacing-induced AF animal models.132 In addition, mutations in 
several SHOX2 regulated genes have been causally linked to AF, including the CCS-specific gene 
HCN4 or the suppressed working myocard genes GJA5 (CX40) and GJA1 (CX43).134-136 SND is 
often the consequence of structural degeneration or remodeling processes due to ageing or 
pathological conditions such as AF, infarction or heart failure. Additionally, idiopathic 
degeneration of the SAN with familial inheritance has been described.137 AF and SND often coexist 
in a clinical context, but the causality between the two conditions and shared molecular mechanisms 
are poorly understood.35,43 Yet,, there is a proposed substantial overlap between candidate genes for 
SND and AF.137 
Genome-wide association studies did not provide evidence for a link between SHOX2 and AF or 
SND so far.27 More recent data, however, has given first clues that certain variants in this gene were 
linked to AF.28,50 In the present study, the mutational analysis has been expanded to investigate if 
SHOX2 also represents a common susceptibility gene for SND and general AF, and to unravel a 
putative shared genetic etiology that underlies both conditions. A total of four heterozygous variants 
were detected in a cohort of 450 AF patients comprising two synonymous (p.L192=; p.A293=) and 
two non-synonymous (p.G77D; p.L130F) variants. In the cohort of 98 SND patients, one 
heterozygous missense mutation (p.P33R) was identified. All variants resided outside the DNA-
binding homeodomain. For a first estimation of the pathogenic potential, several prediction tools 
based on machine learning approaches or empirical scoring systems and CADD scoring was used. 
CADD combines diverse genomic features, such as derived evolutionary constraint, functional 
predictions, epigenetic measurements, surrounding sequence context and gene model annotations. 
All of these annotations are integrated into a single CADD or C-score for any given variant.123,124 
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The C-scores of the identified variants ranged from 9.02 to 25.8. A scaled C-score ≥20 of a variant 
indicates it to be within the 1% most deleterious substitutions in the human genome. None of the 
variants with a CADD score above 20 (p.G77D, p.A293=, p.P33R) were present in the European 
Non-Finnish population of the 1,000 genomes project or the DZHKomics database, indicating very 
rare events, and only p.P33R (1/50770) and p.A293= (55/60141) were reported in the gnomAD 
database. However, late-onset cardiovascular traits cannot be entirely excluded in the gnomAD 
database even though participants from the National Heart, Lung, and Blood Institute Trans-Omics 
for Precision Medicine program (www.nhlbiwgs.org), were excluded in this analysis. 
Subsequent in vivo studies in the zebrafish revealed a functional consequence only for p.G77D. 
Upon cardiac-specific overexpression of this missense mutation, pericardial edema and 
significantly reduced heart rates could be observed. No phenotype resulted from the overexpression 
of the synonymous variant p.A293=, which had the lowest C-score (20.6) and highest allele 
frequency in the control population. The SND missense variant p.P33R with the highest C-score 
(25.8) and a consistent classification as deleterious variant had a relatively low allele frequency in 
the control population but did not show obvious phenotypic effects in the zebrafish model. 
However, in vitro reporter assays demonstrated an impaired transactivation activity for this variant 
as well as for the variant p.G77D. The result for p.P33R could also be confirmed in zebrafish, were 
molecular changes resulting in an altered target gene expression of Bmp4. 
In the first study that linked SHOX2 variants to AF, mutated Shox2 was ectopically expressed in 
embryonic zebrafish hearts after morpholino-induced knockdown of endogenous Shox2.28 Here, the 
variants were tested with human SHOX2 and without alternating the intrinsic Shox2 expression. 
p.G77D and p.P33R therefore have a dominant negative effect on SHOX2 function. SHOX2, like 
its paralog SHOX, is capable of forming homo- and hetero-dimers. Given that cooperative 
dimerization of paired-related homeodomains to DNA increases the transactivation efficiency,138 it 
is possible that these variants negatively affect the DNA binding capacity of dimers if one of the 
SHOX2 proteins is mutated. 
SHOX2 is a key transcription factor in the development of the SAN and could contribute to an 
increased susceptibility to SND and AF in different direct and indirect ways: 
Impaired expression within the SAN has been shown in Shox2-/- mice, who die from severe SV and 
SAN hypoplasia between E11.5 and E17.5 due to reduced pacemaker cell proliferation and a switch 
to the genetic program of a working myocard.48,49 The replacement of Shox2 with human SHOX 
plus a PGK-neo cassette (Shox2KI+Neo/KI+Neo) in the mouse heart results in a hypomorphic allele with 
reduced gene expression. Shox2KI+Neo/KI+Neo mice exhibit arrhythmias and severe bradycardia 
leading to death within days after birth, which supports the hypothesis of a genetically compromised 
SHOX2 copy in patients resulting in AF.139 Similarly, the deregulation of Shox2 antagonists and 
repressors for example due to mutations in gene expression regulation sites, could have the same 
impact. When the antagonist Nkx2.5 is overexpressed, it causes the same SAN and sinus valve 
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hypoplasia and dysregulation of the SAN genetic network that is observed upon Shox2 knockout. 
This indicates that Nkx2.5 activity is detrimental to SAN development by de-repressing the atrial 
myocardium development.140 Physiologically, the loss of functional SHOX2 can lead to the reduced 
expression of crucial ion channels and electrical conductors such as HCN4, CX30.2 and CX45 
impeding the role of the SAN as the dominant pacemaker. While it might still be a functional tissue 
under normal conditions, it could facilitate the stabilization of ectopic re-entry points in the atrium 
making the carriers of SHOX2 mutations prone to the manifestation of AF. 
Another potential mechanism of how SHOX2 could influence the development of AF, is the 
abnormal expression of this gene outside the SAN. Unlike SHOX2, PITX2 has been strongly 
associated with AF in GWAS studies.141,142 In mice, this gene suppresses Shox2 by direct interaction 
with its promotor and indirect regulation through the inhibitory effects of miRNA miR-1792 and 
miR-106-25.143 Pitx+/- mice develop atrial arrhythmias upon pacing and show increased expression 
of SAN related genes, including Shox2 and Tbx3, as well as other AF-related genes such as the 
potassium-channel Kcnq1. It was hypothesized that this generated an arrhythmogenic substrate due 
to dysregulated gene expression, which would enhance other pathological triggers for AF.17 
Similarly, reduced activity of the SHOX2 antagonist NKX2.5 could lead to the same effect. In the 
past, several mutations in the transcriptional activation domain or the homeodomain of NKX2.5 
have been described in patients suffering from lone and familial forms of AF, which lead to a loss-
of-function of the protein.30,144,145 Considering that the mutually exclusive expression patterns of 
SHOX2 and NKX2.5 are mediated through binding of the transcription factors on regulatory 
elements of the antagonist, the detrimental effects of these mutations could be caused by ectopic 
expression of SHOX2. Especially pulmonary veins, which have been implicated in the initiation 
and maintenance of AF, are prone to develop pacemaker-like structures. In a Nkx2.5 hypomorphic 
model, pulmonary cardiomyocytes developed pacemaker activity by upregulation of Hcn4 and 
downregulation of Cx40.16 In reverse, an impaired regulation of SHOX2 due to pathogenic cis-
regulatory variants in enhancer regions could lead to the same effect. However, to date no mutations 
in enhancer regions of SHOX2 in the context of cardiovascular diseases have been described and 
previous studies showed that the ectopic expression of Shox2 alone did not induce SAN-like foci 
in atria and ventricles in mice, indicating that additional factors would have to play a role.140 
The interpretation of variants is a major challenge in clinical genetics. Here it could be demonstrated 
that in silico prediction tools alone are not sufficient to determine the pathogenicity of a genomic 
variant; further assays are needed to determine functionality. The SND cohort size (n=98) may have 
been too small to detect rare SHOX2 variants with strong functional consequences. Assuming 
similar frequencies for rare pathogenic SHOX2 variants in AF and SND (3/990; 0.3%) larger 
cohorts are required to detect further SHOX2 variants and decipher SHOX2 deficiency in SND. As 
sequencing was restricted to exonic parts of SHOX2, noncoding variants affecting regulatory 
elements could also be addressed. 
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It will be interesting to complement these findings with more functional investigations in vitro and 
in vivo to distinguish pathogenic from nonpathogenic variants. The species-specific 
electrophysiological differences, the poorly understood mechanisms of atrial remodeling that 
maintain AF and the complex genetic causes that contribute to this disease make the development 
of a human AF model crucial. AF has been simulated in artificial tissue consisting of hESC-derived 
atrial-like cardiomyocytes that reacts to anti-arrhythmic drugs.64 Recently, the first iPSC-based 
model for familial AF has been established where iPSC-CMs from patients showed abnormal ion 
currents and prolonged APDs compared to unrelated controls.65 However, the genetic cause of the 
AF was not determined in this study and immature types of CMs were used rather than generating 
atrial tissue through subtype-specific differentiation. In addition, the analysis of patient-derived 
SAN-like CMs has not been done yet despite recent advances in differentiation approaches. 
Establishing an in vitro AF model with a clear genetic background opens exciting new possibilities 
for direct phenotype to genotype comparisons. 
 
3.2. Generation and correction of SHOX2 c.849C>A and SHOX2 
c.*28T>C iPSC lines 
 
The SHOX2 c.849C>A or SHOX2 c.28T>C mutations were the first variants in this gene to be 
associated with AF. They were demonstrated to have a negative impact on the function of SHOX2 
as seen in in vitro and in vivo studies.28 However, the molecular basis for these findings can only 
be insufficiently addressed in non-human model organisms or reporter assays due to the lack of a 
complete genetic network. The newly generated patient-specific iPSC lines offer unprecedented 
opportunities to investigate the role of SHOX2 in the genetic network of the SAN and its influence 
on the onset and progression of AF. Nevertheless, it should be noted that the genetic analysis of the 
patients should be expanded as especially patient II (SHOX2 c.*28T>C) presented with substantial 
comorbidities that most likely confounded the emergence of arrhythmias. The unusually young age 
of 37 years at onset, however, suggests a genetic predisposition that could be explained by SHOX2 
c.*28T>C. To address this question and to generate an optimal control for the disease model, these 
variants were corrected precisely and scarlessly in patient-derived iPSCs with a novel approach. 
The concept of using stochastic enrichment of cells by sib-selection to introduce precise mutations 
into iPSCs, derived from a healthy donor, has been proposed before.102 The insertion of disease-
linked variants into a wildtype background helps to interrogate the influence of these mutations on 
the onset and progression of a disease by direct comparison of mutated and wildtype cells. Yet, this 
approach is limited to monogenic diseases or variances with a high impact on the phenotype. Here, 
it was demonstrated that this approach can be used to correct heterozygous mutations as well. This 
is of particular interest when using patient-derived iPSCs that already harbor putative disease-
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causing variants. Recent and future optimizations in iPSC technology and commercially available 
tools will further facilitate iPSC derivation, thus making the generation of patient-specific iPSCs 
more accessible.67 These patient models play a central role in the investigation of sporadic or 
idiopathic diseases, where a combination of multiple risk alleles with low effect size is thought to 
be the genetic base and individual risk variants might not be sufficient to cause a disease-associated 
phenotype. 
AF is a multifactorial disease with a strong genetic component and a complex heritability.146 
Multiple genetic loci have been associated with this disease 27 and mutations in potassium and 
sodium channels as well as mutations in transcription factors and structural proteins have been 
identified.26 However, linking specific mutations to an AF phenotype in iPSC-CMs has not been 
achieved yet. The correction of putative disease-contributing variants in iPSCs could unravel subtle 
phenotypic changes when comparing patient cells to their isogenic controls, even if the disease 
phenotype overall persisted. 
Genome-editing also holds potential for human gene therapy approaches, in which somatic cells 
are reprogrammed to iPSCs and the detrimental mutation is corrected before the cells are 
differentiated to the desired cell type and re-transplanted into the patient for a beneficial effect.98 
The proposed strategy can be applied to a precise repair of heterozygous mutations that does not 
require the use of selection marker integration, its transient expression or an enrichment of nuclease-
expressing cells by fluorescence-activated cell sorting.147-149 This does not only abolish the need to 
optimize the selection or sorting process, but also allows the use of unlabeled nuclease proteins or 
gene constructs. The enrichment of cells with a high expression of Cas9 via puromycin or cell 
sorting has led to concerns regarding off-targeting, as prolonged expression or high concentrations 
of nucleases tend to increase the probability of unwanted DSBs.150,151 This can be countered by the 
use of Cas9 RNPs, which reportedly show less off-targeting due to the shorted activity span by 
immediate DNA cleavage after delivery into cells, followed by a rapid degradation.152,153 In this 
study, gene-editing was analyzed via NGS 48h after transfection unravelling substantial targeting 
efficiencies for some gRNAs. Despite that, no additional mutations were found to be introduced in 
highly scoring off-target regions. 
Avoiding delivery vectors with a potential to integrate into the genome also opens possibilities for 
gene-editing in clinical settings under good manufacturing practice conditions. In addition, high-
fidelity gRNAs with few predicted off-targets should be preferentially chosen.154 However, to 
increase the frequency of HDR events, gRNAs must be selected according to the distance between 
the induced DSB to the HDR-targeted DNA section, rather than off-target scores or predicted 
efficiency. This is mainly because of a decrease in HDR frequency with increasing distances 
between Cas9 cut site to the targeted nucleotides, presumably due to short gene conversion tracts 
in mammalians.127 Nevertheless, to completely rule out additional editing, a genome-wide analysis 
via whole genome sequencing would be required. Enriching cells of interest before single-cell 
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seeding is especially beneficial for cell lines that behave poorly during clonal expansion. Keeping 
cells even in small pools of 200 cells per well of a 96-well plate greatly enhances survival rates 
upon splitting. This avoids the selective enrichment of cell populations with abnormal survival 
advantages or growth rates caused by chromosomal aberrations. Subsequently, low clonability rates 
(defined as the success chance to isolate a single-cell derived population from each well seeded) do 
not lead to an immense increase in time and material consumption due to large scale cloning efforts 
as only a handful of clones have to be analyzed to find an isogenic one. In fact, even with the low 
clonability rates of 10-20% achieved with the patient lines, only two to three 96-well plates per line 
were sufficient to find several isogenic populations. 
In regions that are difficult to target, one might find the initial HDR efficiency to still be low even 
after incorporation of improvement strategies such as optimizing the DNA template108-110, 
modifying the Cas9 enzyme itself112,113 or applying small molecules to increase HDR.103 The 
proposed strategy can be combined with any of these approaches, as it is locus-independent and 
solely relies on a stochastic enrichment rather than the modulation of biological processes. 
Especially emerging techniques like base-editing155 and prime editing113 can profit from this 
approach by complementing their increased efficiency in targeted editing with an additional 
enrichment of correctly edited cells. Quantifying isogenic subpopulations with NGS enabled 
predictions for the single cell cloning workload with relative precision. While only one round of 
sib-selection was used to enrich the cells of interest, several subsequent sib-selections are also 
possible to further increase the fraction of precisely edited cells and to decrease the required cloning 
effort. The insertion of blocking mutations together with the mutation correction in the ssODN 
sequence was purposely avoided. These (silent) mutations are introduced to prevent re-cutting by 
Cas9 after HDR-mediated editing and reportedly increase the efficiency of precise DNA 
modifications.108,156 Yet, their application should be restricted to coding mutations, as unwanted 
side-effects in UTRs or non-coding regulatory regions by altered posttranscriptional regulation or 
transcription factor binding cannot be completely ruled out. An example for this is the SHOX2 
c.*28T>C mutation which resides within the 3’UTR and presumably mediates its detrimental effect 
by the generation of a novel miRNA binding site.28 A thorough analysis before additional mutations 
are introduced is highly recommended by examining evolutionary sequence conservation or using 
prediction tools for miRNA and transcription factor binding. 
However, despite the clear advantages of this method, several limitations remain. Laboratories are 
required to have fast and easy access to NGS and potentially dPCR. dPCR was used to preselect 
sib-selections with potentially high fractions of isogenic cells despite the stated limitations of this 
method to quantify such subpopulations. This allowed the sending of single samples for NGS that 
could be analyzed with freely available online tools such as Cas-analyzer.120 Nevertheless, a more 
straightforward approach would be to quantify alleles in all sib-selections at once with deep-
sequencing. Although this is more cost-intense and requires amplicon-NGS analysis knowledge due 
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to sample multiplexing, it would speed up the process significantly and allow to find the one sib-
selection that truly has the highest percentage of isogenic cells. With recent and future advances in 
NGS, this method can be expected to become more feasible and affordable.157,158 The additional 
passaging and cryopreservation required in the sib-selection process is a potential source for 
acquiring mutations and chromosomal translocations in the extended culturing periods.159,160 On the 
other hand, and as mentioned before, stressful processes like cell sorting and antibiotic selection 
are not required. Yet, its applicability to primary cells and cell types that cannot be extensively 
passaged is limited. Furthermore, the additional culturing periods are time-consuming. Even under 
ideal circumstances, the isolation of isogenic clones takes several weeks to months. However, most 
of the time is spent waiting for the cells to grow and during allele quantification procedures, sib-
selections are cryopreserved, thus making the process easily interruptible. The quantification of 
HDR events after each sib-selection allows precise workload calculations for the next step and 
prevents tedious single-cell cloning even if no isogenic cells are present. 
In conclusion, this represents a novel strategy for the scarless correction of heterozygous mutations 
by random enrichment of precisely edited cells and their detection via allele quantification. It was 
proposed that the frequency of isogenic cells can be determined by comparing WT:Mut allele ratios 
with two assumptions: no copy number variation and an error-free correction of the mutation via 
HDR. This approach can facilitate the generation of isogenic control cells, which represent the gold 
standard of controls when investigating the influence of putative disease-causing variants on the 
disease phenotype. Finally, a cardiac disease model for AF with isogenic controls was established, 
which will allow direct genotype-phenotype comparison to further elucidate the role of SHOX2 in 
the genetic network of atrial and sinoatrial cardiomyocytes and in the development of the disease. 
Compared to already existing AF models 65,161, this would be the first one using patient-specific and 
gene-corrected iPSCs. 
 
4. Outlook 
Detailed analyses of the generated cell lines are currently ongoing. A strategy to generate pure 
SAN- and atrial-like cardiomyocyte populations is the use of fluorescent proteins with subtype-
specific expression to identify and sort out cells of interest (Figure 17A). For this, lentiviral 
constructs were cloned and validated in this project; however, spontaneous or directed cardiac 
differentiation mainly produced ventricular-like cells and did not yield enough cardiomyocytes of 
the right subtype for molecular analysis. Yet, this approach can still be used to purify cells that are 
generated in other ways. 
The central role in the SAN genetic network has also established SHOX2 as a candidate for 
heterologous expression in transgene-based differentiation strategies. SHOX2 overexpression in 
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embryonic stem cells reportedly favors the differentiation into cardiac pacemaker cells and can 
influence mesenchymal stem cell fate in co-culturing models with neonatal rat 
cardiomyocytes.162,163 A newer approach uses combinations of key transcription factors (e.g. 
SHOX2, HCN2, TBX5) to drive the differentiation of cardiac progenitor cells into pacemaker-like 
cells with functional characteristics.164 However, detrimental effects of the SHOX2 mutations would 
most likely be mediated by disturbances in development or specification of cardiac cells. Therefore, 
manipulation of the genetic network by transgene expression during in vitro differentiation could 
mask a phenotype through bypassing or overcoming an impaired SHOX2 function. In fact, the 
original plan of using reporter constructs to isolate SAN- and atrial-like cardiomyocytes from 
spontaneous differentiation was based on the idea of deriving cells that had not been substantially 
manipulated during their specification. 
Monolayer-based cardiomyocyte differentiation by modulating Wnt/β-Catenin signaling yields 
mainly ventricular-like cells for disease-modelling (Figure 17B). Substantial effort has been 
undertaken in recent years to develop subtype-specific differentiation protocols for stem cells by 
investigating embryonic developmental pathways. A key finding towards generating atrial-like 
cardiomyocytes was the fact that retinoic acid signaling is essential for the specification into heart 
cells with high expression of atrial markers (COUPTFII, NPPA, SLN, PITX2) and characteristic 
action potentials.165 An advanced version of this differentiation protocol 166 was recently optimized 
for these lines and yielded first insights into a dysregulated expression of SHOX2 c.*28T>C and its 
target genes (Figure 17C) (for details see Master Thesis Viktoria Frajs, SHOX2 in atrial fibrillation 
disease modelling using induced pluripotent stem cells). More detailed molecular analyses are 
pending and electrophysiological profiling using voltage-sensitive fluorescent proteins will be 
performed. Regarding SAN morphogenesis, several signaling pathways including RA and BMP 
have been implicated in this process.96 However, recent insights through lineage tracing in zebrafish 
provide a refined paradigm as to how canonical Wnt signaling can establish/influence pacemaker 
cell fate.14,167 These findings have been successfully translated into modified differentiation 
approaches where mesoderm induction is achieved by Wnt signaling activation without subsequent 
strong Wnt inhibition, which normally defines the cardiac cell fate (Figure 17D). The resulting 
cardiomyocytes show increased expression of pacemaker marker genes (Hcn4, Tbx18, Shox2), as 
well as electrophysiological features and an intrinsic automaticity typical for SAN cells.168 
Currently ongoing pilot experiments with patient and control lines have yielded promising results 
showing the same impaired SHOX2 c.*28T>C that had been observed in atrial-like cells. The 
combination of subtype-specific differentiation protocols with lentiviral reporter constructs is likely 
to produce pure cardiomyocyte populations for electrophysiological and molecular investigations. 
A detailed analysis of this in vitro disease model will aid in refining the paradigm of how SHOX2 
mutations influence the onset and progression of AF and even has the potential to serve as a 
platform for novel drug discovery and personalized medicine. 
Outlook 
76 
 
Figure 17 Generation o f sub type-specific cardiomyocytes fo r molecula r and electrophysiological analysis  
Figure 17 Generation of subtype-specific cardiomyocytes for molecular and electrophysiological analysis. (A) Labelling of CM 
subtypes with lentiviral constructs. iPSCs are differentiated spontaneously or with directed differentiation protocols to generate mixed 
populations with different CM subtypes. These cells are subsequently transduced with lentiviral constructs consisting of different 
fluorescent proteins (miRFP670, eGFP, dsRED) under the control of a subtype-specific promotors (SHOX2 = CSS-specific promotor, 
SLN = atrial-specific promotor, MLC2v = ventricular-specific promotor). For electrophysiological analysis, voltage-sensitive fluorescent 
proteins can be used. Certain CM subtypes can be sorted by FACS to generate pure cell populations. This strategy is based on Chen et 
al., 2016. (B) Mesoderm induction by Wnt signaling activation followed by Wnt signaling inhibition for cardiac determination leads to 
mainly ventricular-like cardiomyocytes. (C) Pure atrial-like cardiomyocyte populations can be generated by Wnt signaling alteration 
and retinoic acid. This approach is based on Zhang et al. 2015, scheme modified from Frajs V, master thesis. (D) CMs with pacemaker 
properties can be generated by activating Wnt signaling to induce mesoderm differentiation, followed by weak inactivation of Wnt 
signaling to induce cardiac differentiation. This strategy is based on Liang et al. 2019 
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6. Appendix 
Variable All (450) Male (311) Female (139) 
Sex (Female)  30.9% (139/450)  0% (0/311)  100.0% (139/139)  
Age at study 
enrollment [y]  64.4 (8.4)  64.5 (8.4)  64.2 (8.7)  
        
CVRFs:        
Diabetes (yes)  22.4% (101/450)  23.5% (73/311)  20.1% (28/139)  
Obesity (yes)  37.1% (167/450)  35.0% (109/311)  41.7% (58/139)  
Smoking (yes)  13.6% (61/448)  13.9% (43/310)  13.0% (18/138)  
Hypertension (yes)  71.6% (322/450)  71.7% (223/311)  71.2% (99/139)  
Dyslipidemia (yes)  69.8% (314/450)  73.6% (229/311)  61.2% (85/139)  
FH of MI/Stroke (yes)  24.9% (112/450)  23.5% (73/311)  28.1% (39/139)  
        
Comorbidities:        
MI (yes)  15.1% (67/443)  16.3% (50/306)  12.4% (17/137)  
CAD (yes)  23.0% (99/430)  24.9% (75/301)  18.6% (24/129)  
Stroke (yes)  8.5% (38/446)  9.8% (30/307)  5.8% (8/139)  
AF (yes)  100.0% (450/450) 100.0% (311/311) 100.0% (139/139) 
PAD (yes)  8.1% (36/443)  8.2% (25/306)  8.0% (11/137)  
CHF (yes)  12.4% (56/450)  10.0% (31/311)  18.0% (25/139)  
        
Echo:        
LA Volume (Biplane) 
[cm³]  89.2 (34.1)  95.3 (34.8)  76.1 (28.5)  
EF [%]  60.3 (8.6)  59.9 (8.7)  61.3 (8.4)  
E/E´  8.95 (3.96)  8.65 (3.93)  9.62 (3.94)  
        
ECG:        
RR Interval [ms]  936 (220)  926 (229)  957 (197)  
PQ Interval [ms]  170 (28)  172 (29)  165 (27)  
QRS Duration  102.6 (20.3)  104.6 (20.3)  98.0 (19.6)  
QT Interval  417 (46)  414 (46)  424 (43)  
Table S1 Clinical characteristics of AF cohort. Data are presented as mean ±SD. Table and 
legend taken from Hoffmann et al., 2019.1 
Supplementary Table 1 Clinical characteris tics of  AF cohor t  
  
 
 
 
Variable All (98) Male (62) Female (36) 
Sex (Female)  37% (36/98) 0% (0/62) 100% (36/36) 
Age at study enrollment [y]  75.7 (10.9) 76.1 (9.6) 75.0 (12.9) 
Age at diagnosis [y] 71.0 (13.4) 71.3 (10.9) 70.5 (16.4) 
        
CVRFs:        
Diabetes (yes)  27.6% (27/98) 25.8% (16/62) 30.6% (11/36) 
Obesity (yes)  n.a. n.a. n.a. 
Smoking (yes)  20.4% (20/98) 29.0% (18/62) 5.6% (2/36) 
Hypertension (yes)  94.9 % (93/98) 96.8% (60/62) 91.7% (33/36) 
Dyslipidemia (yes)  56.1% (55/98) 64.5% (40/62) 41.7% (15/36) 
FH of MI/Stroke (yes)  15.3% (15/98) 19.4% (12/62) 8.3% (3/36) 
        
Comorbidities:        
MI (yes)  21.4% (21/98) 24.2% (15/62) 16.7% (6/36) 
CAD (yes)  54.1% (53/98) 62.9% (39/62) 38.9% (14/36) 
Stroke (yes)  14.3% (14/98) 12.9% (8/62) 16.7% (6/36) 
AF (yes)  68.4% (67/98) 59.7% (37/62) 83.3% (30/36) 
PAD (yes)  14.3% (14/98) 19.4% (12/62) 5.6% (2/36) 
CHF (yes)  33.7% (33/98) 38.7% (24/62) 25.0% (9/36) 
AF (yes)  61.2% (60/98) 54.8% (34/62) 72.2% (26/36) 
        
Echo:        
LA Diameter [mm]  45.3 (10.7) 46.0 (10.7) 44.3 (10.9) 
EF [%]  54.6% (13.7) 54.3% (15.0) 55.0% (11.0) 
E/E´  n.a. n.a. n.a. 
        
ECG:        
RR Interval [ms]  919.4 (215.1) 928.2 (194.6) 903.8 (249.6) 
PQ Interval [ms]  190.0 (44.4) 190.4 (47.5) 189.1 (38.0) 
QRS Duration  122.4 (38.5) 124.4 (37.5) 118.9 (40.6) 
QTc Interval  438.3 (46.7) 440.3 (46.1) 434.9 (48.5) 
Table S2 Clinical characteristics of SND cohort. Data are presented as mean ±SD. n.a. = not 
available. Table and legend taken from Hoffmann et al., 2019.1 
Supplementary Table 2 Clinical characteris tics of  SND cohort
 
 
SHOX2 
variant Sex Age [y] 
LA Volume 
(Biplane) [cm³] EF [%] E/E´ 
RR Interval 
[ms] 
PQ Interval 
[ms] QRS Duration 
QTc 
Interval 
Patient 
cohort 
G77D Male  52 89 58 6 490 n.a. 100 376 AF 
L129= Male  67 102 47 7 682 n.a. 138 398 AF 
L129=  Female  70 96 65 5 1088 140 80 424 AF 
L129=  Male  74 78 56 11 640 n.a. 86 330 AF 
L130F  Male  60 76 68 5 872 138 90 408 AF 
A293=  Male  72 104 67 6 880 190 102 422 AF 
P33R Female 88 n.a. 65 n.a. 968 n.a. 78 405 SND 
G81E Female  51 n.a. n.a. n.a. n.a. n.a. n.a. n.a. AF 
H283Q Male  56 43 n.a. n.a. 400 n.a. n.a. 480 AF 
R194X Male  41 n.a. 62 n.a. n.a. >200 100 447 AF 
R194X Female  43 n.a. 60 n.a. n.a. >200 116 528 AF 
R194X Male  39 n.a. 63 n.a. n.a. >200 102 450 AF 
R194X Female  20 n.a. 65 n.a. n.a. >200 96 435 AF 
Table S3 Summary of all identified SHOX2 variants in SND and AF patients. Novel identified variants and phenotypic features are highlighted in blue, 
the previously identified variants are highlighted in grey. n.a. = not available. Data are presented as mean ±SD. Blue: age at study enrollment; light blue: age 
at diagnosis; grey: age at diagnosis. Table and legend taken from Hoffmann et al., 2019.1 
 
Supplementary Table 3 Summary of  all identi fied SHOX2  varian ts in SND and AF pa tients  
  
 
 
Supplementary Table 4 NGS sequences SHOX 2 c.849C>A gRNA-2 #1  
  
#ID RGEN Treated Sequence Count Type Allele 
1 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCTGCATCCGCACCTGGCC 3225 WT WT 
2 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCACCTGCATCCGCACCTGGCC 2559 Mut Mut 
3 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCAC------------CACCTGGCC 1206 del WT 
4 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCATGTGGCGCATCCGCACCTGGCC 340 Ins WT 
5 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCTGCATCCGCACCTGGCC 323 Sub WT 
6 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCG---CACCACCTGCATCCGCACCTGGCC 307 del Mut 
7 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCACCTGCATCCGCACCTGGCC 272 Sub Mut 
8 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCTGCATCCGCACCTGGCC 171 Ins WT 
9 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCAC-------------------CC 136 del Mut 
10 GCTGCAGCTGGACAGCGCTG-------------------CCTGCATCCGCACCTGGCC 109 del N/A 
11 GCTGCAGCTGGACAGCGCTGTGG-----------------------CCGCACCTGGCC 100 del N/A 
12 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCTGCATCCGCACCTGGCC 96 Sub WT 
13 GCTGCAGCTGGACAGCGCTGTGGCGCACGCG------CACCTGCATCCGCACCTGGCC 86 del WT 
14 GCTGCAGCTGGACAGCGCTGTGGCG------------CACCTGCATCCGCACCTGGCC 81 del N/A 
15 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCTGCATCCGCACCTGGCC 77 Sub WT 
16 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACC-----CATCCGCACCTGGCC 69 del WT 
17 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCACCTGCATCCGCACCTGGCC 63 Sub Mut 
18 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCACCTGCATCCGCACCTGGCC 62 Sub Mut 
19 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCTGCATCCGCACCTGGCC 54 Sub WT 
20 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCACCTGCATCCGCACCTGGCC 54 Sub Mut 
21 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCG---CACCACCTGCATCCGCACCTGGCC 33 del Mut 
Table S4. Sequences of allele-quantification in sib-selection SHOX2 c.849C>A gRNA-2 #1 
 
 
#ID RGEN Treated Sequence Count Type Allele 
1 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCACCTGCATCCGCACCTGGCC 1118 Mut Mut 
2 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCTGCATCCGCACCTGGCC 1014 WT WT 
3 GCTGCAGCTGGACAGCGCTGTGGCGCAAG------------------CGCACCTGGCC 616 del Mut 
4 GCTGCAGCTGGACAGCGCTGTGGCGCACGCG--------CCTGCATCCGCACCTGGCC 387 del WT 
5 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACC----------------------- 342 del WT 
6 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCG------CACCTGCATCCGCACCTGGCC 260 del Mut 
7 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCAC---------------CACCTGGCC 255 del WT 
8 GCT---------------------------------------------GCACCTGGCC 217 del N/A 
9 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCAC------CATCCGCACCTGGCC 166 del Mut 
10 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCA----CATCCGCACCTGGCC 158 del Mut 
11 GCTGCAGCTGGACAGCGCTGTGGCGCACGCG------CACCTGCATCCGCACCTGGCC 128 del WT 
12 GCTGCAGCTGGACAGCGCTGTGGCGCA----------------------CACCTGGCC 70 del N/A 
13 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCACCCTGCATCCGCACCTGGCC 46 Ins Mut 
14 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCATGCACCTGCATCCGCACCTGGC 41 Ins WT 
15 GCTGCAGCTGGACAGCGCTGTGGCG------------CACCTGCATCCGCACCTGGCC 40 del N/A 
16 GCTGCAGCTGGACAGCGCTGTGG----------------------------------- 38 del N/A 
17 GCTGCAGCTGGACAGCGCTGT-GCG----------------------CGCACCTGGCC 37 del N/A 
18 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCTACATCCTGCATCCGCACCTACACCT 33 Ins WT 
19 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCA-CAC-----------CCTGGCC 31 del Mut 
20 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCATCCGCACCTGCACCTGGCC 30 Sub Mut 
21 GCTGCAGCTGGACAGCG--------------------CACCTGCATCCGCACCTGGCC 27 del N/A 
22  ---------------------------------------------------CCTGGCC 27 del N/A 
23 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCAC--------------------- 19 del Mut 
24 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCA--TG-AT--GGGTCTGGCC 18 del WT 
Table S5. Sequences of allele-quantification in sib-selection SHOX2 c.849C>A gRNA-2 #2 
Supplementary Table 5 NGS sequences SHOX 2 c.849C>A gRNA-2 #2  
  
 
 
#ID RGEN Treated Sequence Count Type Allele 
1 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCTGCATCCGCACCTGGCC 1122 WT WT 
2 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCACCTGCATCCGCACCTGGCC 795 Mut Mut 
3 GCTGCAGCTGGACAGCGCTGTGGCGCACGCG---CACCACCTGCATCCGCACCTGGCC 540 del WT 
4 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACC----CCTGCATCCGCACCTGGCC 280 del WT 
5 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCAC------------CACCTGGCC 273 del WT 
6 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCG------CACCTGCATCCGCACCTGGCC 234 del Mut 
7 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCAC------CATCCGCACCTGGCC 215 del Mut 
8 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCAACCTGCATCCGCACCTGGCC 211 Ins Mut 
9 GCTGCAGCTGGACAGCGCTG---------------------------------TGGCC 211 del N/A 
10 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCAC-----------------CCTGGCC 183 del WT 
11 GCTGCAGCTG-----------------------------CCTGCATCCGCACCTGGCC 158 del WT 
12 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCG---CACCACCTGCATCCGCACCTGGCC 139 del Mut 
13 GCTGCAGCTGGACAGCGCTGTGGCGCA--------------AGCATCCGCACCTGGCC 137 del N/A 
14 GCTGCAGCTGGACAGCGCTGTGGCG--------------------------------- 121 del N/A 
15 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCAC---------------CACCTGGCC 114 del WT 
16 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCAAGCGCACCTGCATCCGCACCT 106 Ins Mut 
17 GCTGCAGCTGGA-------------------------------CATCCGCACCTGGCC 104 del N/A 
18 GCTGCAGCTGGACAGCGCTGT------------------CCTGCATCCGCACCTGGCC 98 del N/A 
19 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCA-------------CACCTGGCC 96 del Mut 
20 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCAC---------------CACCTGGCC 96 del Mut 
21 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACC-CCTGCATCCGCACCTGGCC 94 del Mut 
22 GCTGCAGCTGGACAGCGCTGTGGC------------------GCATCCGCACCTGGCC 86 del N/A 
23 GCTGCAG---------------------------------------------CTGGCC 62 del N/A 
24 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCAC------CATCCGCACCTGGCC 57 del WT 
25 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCATGCAGGTGCCTGCATCCGCAC 44 Ins Mut 
26 GCTGCAGCTGGACAGCGCTGTGGCGCACGCG------CACCTGCATCCGCACCTGGCC 32 del WT 
27 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCATCCGCACCTGCATCCGCACCTG 31 Ins WT 
28 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCA---------GCACCTGGCC 29 del Mut 
29 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCCTGCATCCGCACCTGGCC 28 Ins WT 
30 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCAGGCGCATCCGCACCTGGCC 27 Sub WT 
31 GCTGCAGCTGG---------------------------ACCTGCATCCGCACCTGGCC 19 del Mut 
Table S6. Sequences of allele-quantification in sib-selection SHOX2 c.849C>A gRNA-2 #3 
Supplementary Table 6 NGS sequences SHOX 2 c.849C>A gRNA-2 #3  
  
 
 
#ID RGEN Treated Sequence Count Type Allele 
1 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCACCTGCATCCGCACCTGGCC 730 Mut Mut 
2 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCTGCATCCGCACCTGGCC 630 WT WT 
3 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCAC------CATCCGCACCTGGCC 197 del Mut 
4 GCTGCAGCTGGACAGCGCTGTGGCGCACGCG---CACCACCTGCATCCGCACCTGGCC 175 del WT 
5 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCG---CACCACCTGCATCCGCACCTGGCC 172 del Mut 
6 GCTGCAGCTGGACA----------------------------------------GGCC 155 del N/A 
7 GCTGCAGCTGGACAGCGCTGTGGC------------------GCATCCGCACCTGGCC 153 del N/A 
8 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACC-CCTGCATCCGCACCTGGCC 137 del WT 
9 GCTGCAGCTGGACAGCGCTG---------------------------------TGGCC 126 del N/A 
10 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCA---GCATCCGCACCTGGCC 86 del Mut 
11 GCTGCAGCTGGACAGCGCTGTGGCGCACGCG------CACCTGCATCCGCACCTGGCC 80 del WT 
12 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCCTGCATCCGCACCTGGCC 72 Ins WT 
13 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCACCTGCATCCGCACCTGGCC 56 Mut Mut 
14 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCAC------CATCCGCACCTGGCC 50 del WT 
15 GCTGCAGCTGGACAGCGCTGT------------------CCTGCATCCGCACCTGGCC 48 del N/A 
16 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCAC---------------CACCTGGCC 47 del WT 
17 GCTGCAGCTGGACAGCGCTGTGGCGCA-------------------CCGCACCTGGCC 40 del N/A 
18 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCA----AATCCGCACCTGGCC 39 del WT 
19 GCTGCAGCTGGACAGCGCTGTGGCGCACG------------------CGCACCTGGCC 36 del WT 
20 GCTGCAGCTGGACAGCGCTGTGGCGCAAG------------------CGCACCTGGCC 34 del Mut 
21 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCTGCATCCGCCTGCATCCGCACCTGGCC 33 Ins WT 
22 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCACCTGCATCCGCACCTGGCC 32 Mut Mut 
23 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCACCTGCATCCGCACCTGGCC 31 Mut Mut 
24 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCTGCATCCGCACCTGGCC 30 WT WT 
25 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCTGCATCCGCACCTGGCC 29 WT WT 
26 GCTGCAGCTGGACAGCGCTGTG------------------------------------GCGCACGCGCC 27 del Mut 
27 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCAC---------------CACCTGGCC 25 del Mut 
28 GATAGTCATTGCAACGTGACGCCCTTTTCCTTTCAGGTTCAGGCGCAGCTGCAGCTGGA 22 Sub N/A 
29 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACATGATGCATCCGCACCTGGCC 22 WT WT 
30 GCTGCAGCTGGACAGCGCTGTGGCG---------------------------CTGGCC 22 del N/A 
31 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCAC------------CACCTGGCC 21 del Mut 
32 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCA-----------CGCACCTGGCC 21 del Mut 
33 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCACCACCTGCATCCGCACCTGGCC 20 Mut Mut 
 
 
34 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCTGCATCCGCACCTGGCC 19 WT WT 
35 GCTGCAGCTGGACAGCGCTGTGGCGCACGCGCACCACCACCTGCATCCGCACCTGGCC 19 WT WT 
36 GCTGCAGCTGGACAGCGCTGTGGCGCACGCG---CACCACCTGCATCCGCACCTGGCC 19 del WT 
37 GCTGCAGCTGGACAGCGCTGTGGCGCA----------------------CACCTGGCC 16 del N/A 
38 GCT---------------------------------------------GCACCTGGCC 16 del N/A 
39 GCTGCAGCTGGACAGCGCTGTGGCGCAAGCGCACCA-CAC---CATCCGCACCTGGCC 15 del Mut 
40 GCTGCAGCTGGACAGCGCTGTGG------------------------CGCACCTGGCC 14 del N/A 
Table S7. Sequences of allele-quantification in sib-selection SHOX2 c.849C>A gRNA-2 #4 
Supplementary Table 7 NGS sequences SHOX 2 c.849C>A gRNA-2 #4  
  
 
 
Supplementary Table 8 NGS sequences SHOX 2 c.*28T>C gR NA-1 #1  
  
#ID RGEN Treated Sequence Counts Type Allele 
1 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGGCACTCAGCCTGCACGCCCTCCGC 55614 WT WT 
2 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGGCACTCAGCCTGCACGCCCTCCGC 48571 Mut Mut 
3 CCAACGCCAGCACCAATGTCGCGCCTGTCCC---GCACTCAGCCTGCACGCCCTCCGC 3043 del WT 
4 CCAACGCCAGCACCAATGTCGCGCCCGTC-------------CCTGCACGCCCTCCGC 1533 del Mut 
5 CCAACGCCAGCACCAATGTCGCGCCCGTCCC---GCACTCAGCCTGCACGCCCTCCGC 1507 del Mut 
6 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGC-GCACTCAGCCTGCACGCCCTCCGC 1239 del WT 
7 CCAACGCCAG-----------------------------CAGCCTGCACGCCCTCCGC 1124 del N/A 
8 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCG----------TGCACGCCCTCCGC 1014 del WT 
9 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCG-----CAGCCTGCACGCCCTCCGC 694 del Mut 
10 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGTGCACTCAGCCTGCACGCCCTCCGC 613 Ins WT 
Supplementary Table 8. Sequence of allele-quantification in sib-selection SHOX2 c.*28T>C gRNA-1 #1 
 
 
Supplementary Table 9 NGS sequences SHOX 2 c.*28T>C gR NA-1 #2  
  #ID RGEN Treated Sequence Counts Type Allele 
1 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGGCACTCAGCCTGCACGCCCTCCGC 47314 WT WT 
2 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGGCACTCAGCCTGCACGCCCTCCGC 42198 Mut Mut 
3 CCAACGCCAGCAC---------------------------------CACGCCCTCCGC 4312 del N/A 
4 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCCTGCACTCAGCCTGCACGCCCTCCGC 2618 Ins WT 
5 CCAACGCCAGCACCAATGTCGC-------------------GCCTGCACGCCCTCCGC 2227 del N/A 
6 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCG---CTCAGCCTGCACTGCACGCCCTCCGC 2036 Ins Mut 
7 CCAACGCCAGCACCAATGTCGCGCCCGTCC------------------CGCCCTCCGC 1953 del Mut 
8 CCAACGCCAGCACCAATGTCGCGCCTGTCC-------CTCAGCCTGCACGCCCTCCGC 1898 del WT 
9 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGACAGGCACTCAGCCTGCACGCCCTCCGC 1702 Ins WT 
10 CCAACGCCAGCACCAATGTCGC-----------------------GCACGCCCTCCGC 1649 del N/A 
11 CCAACGCCAGCACCAATGTCGC------------GCACTCAGCCTGCACGCCCTCCGC 1577 del N/A 
12 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGGGCACTCAGCCTGCACGCCCTCCGC 1218 Ins Mut 
13 CCAACGCCAGCACCAATGTCGCGCCTGTCCC---GCACTCAGCCTGCACGCCCTCCGC 818 del WT 
14 CCAACGCCAGCACCAATGTCGCGCCCGTCCC---GCACTCAGCCTGCACGCCCTCCGC 589 del Mut 
15 CCAACGCCAGCACCAATGTCGCGCCTGTCC------------------CGCCCTCCGC 64 del WT 
16 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGGCACTCAGCCTGCACGCCCTCCGC 45 del Mut 
17 CCAACGCCAGCACCAATGT------------------------------------CGC 45 del N/A 
18 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGGCACTCAGCCTGCACGCCCTCCGC 41 del WT 
19 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGC-GCACTCAGCCTGCACGCCCTCCGC 35 del WT 
Supplementary Table 9. Sequences of allele-quantification in sib-selection SHOX2 c.*28T>C gRNA-1 #2 
 
 
Supplementary Table 10  NGS sequences SHOX2 c.*28T>C gR NA-2 #1  
  #ID RGEN Treated Sequence Counts Type Allele 
1 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGGCACTCAGCCTGCACGCCCTCCGC 49134 WT WT 
2 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGGCACTCAGCCTGCACGCCCTCCGC 40933 Mut Mut 
3 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGACTCAGCCTGCACTCAGCCTGCACGC 3056 Ins WT 
4 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGGCCTGCACTCAGCCTGCACGCCCTCCGC 2408 Ins WT 
5 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGGGCTGCACTCAGCCTGCACGCCCTCCGC 2363 Ins Mut 
6 CCAACGCCAGCACCAATGT------------------CTCAGCCTGCACGCCCTCCGC 1916 del N/A 
7 CCAACGCCAGCACCAATGTCGCGCCCG----------------CTGCACGCCCTCCGC 1554 del Mut 
8 CCAACGCCAGCACCAATGTCGCGCCCGTCC-----CACTCAGCCTGCACGCCCTCCGC 1487 del Mut 
9 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCG-------GCCTGCACGCCCTCCGC 1344 del Mut 
10 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCG--ACTCAGCCTGCACGCCCTCCGC 948 del WT 
11 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGGGCACTCAGCCTGCACGCCCTCCGC 761 Ins Mut 
12 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGC-GCACTCAGCCTGCACGCCCTCCGC 682 del WT 
13 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGG------GCCCTGCACGCCCTCCGC 371 del Mut 
14 C------------------------------------------GCCTGCACGCCCTCCGC 363 del N/A 
15 CCAACGCCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGG------GCCTGCACGCCCTCCGC 177 del Mut 
16 CCAACGCCAGCACCAATGTCGCGCCCGTCCC--------------GCACGCCCTCCGC 144 del Mut 
17 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGG------------GCGCCCTCCGC 125 del Mut 
18 CCAACGCCAGCACCAATGTCGCGCCTGTCCC---GCACTCAGCCTGCACGCCCTCCGC 74 del WT 
19 G--------------------------------------------------------- 53 del N/A 
20 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGACTCAGCCTGCACTCAGCCTGCACGC 38 Ins Mut 
21 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGTGCACTCAGCCTGCACGCCCTCCGC 38 Ins WT 
22 CCAACGCCAGCACCAATGTCGCGCC---CC-----CACTCAGCCTGCACGCCCTCCGC 37 del N/A 
23 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGG------GCCTGCACGCCCTCCGC 36 del Mut 
24 CCAACGCCAGCACCAATGTCGC-------------------GCCTGCACGCCCTCCGC 34 del N/A 
25 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCG-------GCCTGCACGCCCTCCGC 34 del WT 
26 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGGCACTCAGCCTGCACGCCCTCCGC 33 del WT 
27 CCAACGCCAGCACCAATGTCGCGCCT-------------------------------- 32 del WT 
28 CCAACGCCAGCACCAATGTCGCGCCCGTCCC---GCACTCAGCCTGCACGCCCTCCGC 31 del Mut 
29 CCAACGCCAGCACCAATGTCGCGCCTGTCC-----CACTCAGCCTGCACGCCCTCCGC 31 del WT 
Supplementary Table 10. Sequences of allele-quantification in sib-selection SHOX2 c.*28T>C gRNA-2 #1 
 
 
Supplementary Table 11  NGS sequences SHOX2 c.*28T>C gR NA-2 #2  
#ID RGEN Treated Sequence Counts Type Allele 
1 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGGCACTCAGCCTGCACGCCCTCCGC 51685 WT WT 
2 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGGCACTCAGCCTGCACGCCCTCCGC 42258 Mut Mut 
3 CCAACGCCAGCACCAATGTC--------------GCACTCAGCCTGCACGCCCTCCGC 2985 del N/A 
4 CCAACGCCAGCACCAATGTCGCGCCCGTCCCG-------------------------- 2679 del Mut 
5 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGG------------ACGCCCTCCGC 1855 del Mut 
6 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGTGCAGGCATTCTCAGCCTGCACGCCCTCCGC 1532 Ins Mut 
7 CCAACGCCAGCACCAATGTCGCG------ACGCCAGCACTCAGCCTGCACGCCCTCCGC 1083 del N/A 
8 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGGCGCTCAGCCTGCACGCCCTCCGC 1071 Ins Mut 
9 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCACGACACTCAGCCTGCACGCCCTCCGC 1016 Ins Mut 
10 CCAACGC--------------------------------CAGCCTGCACGCCCTCCGC 920 del N/A 
11 CCAACGCCAGCACCAAT-------------------------CCTGCACGCCCTCCGC 899 del N/A 
12 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGGCA--CAGCCTGCACGCCCTCCGC 710 del WT 
13 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGGGCGCCACTCAGCCTGCACGCCCTCCGC 540 Ins Mut 
14 CCAACGCCAGCACCAATGTCGCGCCCGTCCGCGCGACACTCAGCCTGCACGCCCTCCGC 533 Ins Mut 
15 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGGGGTGCACTCAGCCTGCACGCCCTCCGC 432 Ins Mut 
16 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGTCCCG--TCTCAGCCTGCACGCCCTCCGC 344 Ins Mut 
17 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGCCCGTGCACTCAGCCTGCACGCCCTCCGC 330 Ins Mut 
18 CCAACGCCAGCACCAATGTCGCGCCTGTCCCG-------------------------- 139 del WT 
19 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGGCATTGCACTCAGCCTGCACGCCCTCCGC 110 Ins WT 
20 CTAACGCCACCACCAATGTCGCGCCTG------------------------------- 79 del WT 
21 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGG--------CTGCACGCCCTCCGC 78 del WT 
22 CCAACGCCAGCACCAATGTCGCGCCT-------------------------------- 55 del WT 
23 CCAACGCCAGCACCAATG---------------------------------------- 40 del N/A 
24 CCAACGCCAGCACCAATGTCGCGCCCGTCCCGCGGCACTCAGCCTGCACGCCCTCCGC 37 del Mut 
25 CCAACGCCAGCACCAATGTCGCGCCTG------------------------------- 37 del WT 
26 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGG------------ACGCCCTCCGC 35 del WT 
27 CCAACGCCAGCACCAATGTCGCGCCTGTCCCGCGGCACTCAGCCTGCACGCCCTCCGC 33 del WT 
Supplementary Table 11. Sequences of allele-quantification in sib-selection SHOX2 c.*28T>C gRNA-2 #2 
